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ABSTRACT 
The renin-angiotensin system (RAS) is an enzymatic cascade that plays a critical role in the 
control of blood pressure and the pathophysiology of heart failure. The primary end product 
of the cascade is the vasoconstrictor peptide angiotensin II (Ang II), produced by the 
proteolytic activity of angiotensin-converting enzyme (ACE). The ACE protein is a zinc-
dependent dipeptidyl carboxypeptidase comprised of two homologous domains termed the 
C- and N-domain. The C-domain is primarily responsible for the catalytic production of Ang 
II, while the tetrapeptide acetyl-seryl-aspartyl- lysyl-proline (AcSDKP) is predominantly 
cleaved by the N-domain, and both domains play a role in the metabolism of vasodilatory 
peptide bradykinin. In the event of myocardial infarction (MI), cardiac output and blood 
pressure decreases, resulting in activation of the RAS and an increase in both Ang II 
production and bradykinin metabolism.   While initially compensatory, prolonged RAS 
activation has been shown to have long-term detrimental effects, and pharmaceutical 
intervention in the form of ACE inhibition is the first line treatment following an MI event.  
The ACE inhibitors currently in clinical use target both domains equally, and it has been 
suggested that the major side-effects of this drug class are largely attributable to the 
inhibition of bradykinin breakdown. A novel C-domain selective ACE inhibitor lisinopril-Trp 
(lisW-S) incorporates a tryptophan moiety into the P2' position of the clinically available ACE 
inhibitor lisinopril. In the present pre-clinical study, the in vivo efficacy of LisW-S was 
characterised in a rat model. Initially, ex vivo inhibition assays were established to determine 
an effective dosage in rat plasma and a plasma concentration of 100 nM was found to be 
effective for 70% ACE inhibition. Additionally, these assays gave strong evidence of C-
domain selective inhibition of rat ACE by LisW-S.  Pharmacokinetic studies were then 
carried out to assess the bioavailability of LisW-S in the rat, and also to determine optimal 
delivery methods for achieving required dosages. The bioavailability of lisW-S was found to 
be 3.1%, and an effective dosage was achieved by continuous infusion at a concentration of 
30 mg/ml LisW-S. As one primary therapeutic target of a C-domain selective inhibitor would 
be MI induced heart failure, the effect of LisW-S on RAS peptides was assessed in a rat MI 
model. Domain-selectivity of LisW-S in vivo was investigated by enzyme-linked 
immunosorbent assay quantification of AcSDKP. Treatment with LisW-S elicited no increase 
in AcSDKP levels, whilst lisinopril caused a significant increase in serum AcSDKP confirming 
the in vivo domain-selective action of LisW-S. . Quantification of ten Ang peptides in the RAS 
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LC-MS methodology at 1 and 7 days following MI induction in a rat model. Analysis of 
plasma peptide concentrations and ACE-mediated peptide generation verified the inhibitory 
potential of lisW-S. A significant 3.4-fold decrease in the Ang II/Ang I ratio relative to that in 
MI was observed with administration of lisW-S. Interestingly, reduced levels of AngII as a 
result of LisW-S administration were only observed at day 1, but significantly elevated levels 
of AngI were observed at both time points.  
It should be noted that the limitations of this study include a low product yield of lisW-S as a 
result of the synthesis process as well as a low bioavailability in vivo as established in the 
pharmacokinetic studies. 
The detailed in vivo characterisation of the C-domain selective ACE inhibitor LisW-S 
reported here establishes it as a promising alternative to current ACE inhibitor therapy and 
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AFU	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Ang	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   Atrial	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B2	   Bradykinin	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cGMP	   Cyclic	  guanosine	  monophosphate	  
CHF	   Congestive	  heart	  failure	  
CNS	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COX	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CVD	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DAP	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DMSO	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DRI	   Direct	  renin	  inhibitor	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   Extracellular	  matrix	  
EIA	   Enzyme-­‐linked	  immunosorbent	  assay	  
FRET	   Fluorescent	  resonance	  energy	  transfer	  
HCl	   Hydrochloric	  acid	  
HEPES	   N-­‐2-­‐hydroxyethylpiperazine-­‐N’-­‐2-­‐ethanesulphonic	  
Acid	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IV	   Intravenous	  
JG	   Juxtaglomerular	  
KCl	   Potassium	  chloride	  
KKS	   Kallikrein-­‐kinin	  system	  
KO	   Knockout	  
LAD	   Left	  anterior	  descending	  artery	  
LC-­‐MS	   Liquid	  chromatography	  -­‐	  mass	  spectrometry	  
LisW-­‐S	   The	  novel	  ACE	  inhibitor	  lisinopril-­‐tryptophan	  
LV	   Left	  ventricle	  
Mca-­‐Ala	   N-­‐domain	  selective	  substrate	  (human	  ACE)	  
Mca-­‐BK(1-­‐8)	   C-­‐domain	  selective	  substrate	  (human/	  rat	  ACE)	  
MI	   Myocardial	  Infarction	  
mRNA	   Messenger	  ribose	  nucleid	  acid	  
MS	   Maleate	  salt	  
NaCl	   Sodium	  chloride	  
NEP	   Neutral	  aminopeptidase	  
NO	   Nitric	  oxide	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   Nitric	  oxide	  synthase	  
NSB	   Non-­‐specific	  binding	  
PGE2	   Prostagalndin	  E2	  
PGI1	   Prostaglandin	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PK	   Pharmacokinetics	  
PRR	   (Pro)renin	  receptor	  
RAAS	   Renin-­‐Angiotensin-­‐Aldosterone	  system	  
RAS	   Renin-­‐Angiotensin	  system	  
ROS	   Reactive	  oxygen	  species	  
RXP	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   N-­‐domain	  specific	  ACE	  inhibitor	  
RXPA380	   C-­‐domain	  specific	  ACE	  inhibitor	  
sACE	   Somatic	  ACE	  
ST	  DEV	   Standard	  deviation	  
tACE	   Testis	  ACE	  
TFA	   Trifluoroacetic	  acid	  
TGF	   Transforming	  growth	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Tris	   Tris(hydroxymethyl)aminomethane	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Chapter 1 REVIEW OF THE LITERATURE 
1.1 THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND MYOCARDIAL 
INFARCTION 
The Renin-Angiotensin-Aldosterone system (RAAS) – often referred to as the Renin-
Angiotensin system (RAS) - is an enzymatic cascade that plays a critical role in the control of 
blood pressure, tissue perfusion and volume homeostasis. It is stimulated primarily in 
response to a systemic loss of blood pressure (hypotension) or volume (hypovolemia) (Reid 
et al. 1978).  
The basic RAS pathway is presented in figure 1.1 and is now textbook knowledge. It is 
initiated by the release of the enzyme renin from the kidneys. The discovery that renal 
extracts contained a pressor compound occurred more than 100 years ago, and so renin 
was named for its origin (Tigerstedt et al.1898). By 1957, the nature of renin’s ability to 
induce hypertension had been successfully clarified by a number of research groups, and 
the major peptides involved in the mechanism isolated and identified (Basso et al. 2001). It is 
now known that renin acts proteolytically on the hepatically-derived circulating substrate 
Angiotensinogen, resulting in the formation of the inactive precursor Angiotensin I (Ang I). 
Ang I is in turn hydrolysed by Angiotensin Converting Enzyme (ACE) to form the potent 
vasoconstrictor Angiotensin II (Ang II) (Erdos et al. 1967). The actions of Ang II counteract 
the stimuli for renin secretion in the first place - namely hypotension and hypovolemia – 
primarily by causing constriction of the peripheral vascular system. Additionally, secretion of 
aldosterone is stimulated to increase sodium reabsorption and water retention (Bartter et al. 
1956). The system is controlled by a central negative feedback mechanism. Ang II 
suppresses renin secretion both directly (by its action on renin-producing cells in the kidney) 
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Figure 1.1 The renin angiotensin system pathway 
However, it has recently come to light that this classic view of the RAS is overly simplified 
and incomplete. It has also been found that the RAS is active not only at a systemic level,  
but also at both tissue (Paul et al. 2006) and intracellular (Kumar et al. 2007) levels. The 
classic RAS pathway has thus been modified to include all presently known peptides, 
pathways and feedback mechanisms. While Ang II is still recognised as the main effector 
peptide of the RAS cascade, it is by no means exclusively responsible for the physiological 
effects of RAS activation. The more complete view of the RAS is presented later in figure 
1.10.  
As a consequence of its primary regulatory role of systemic haemodynamics, the RAS 
cascade plays a critical role in the pathophysiology of cardiovascular disease (Cohn 2010). 
Cardiovascular diseases (CVDs) include a number of blood vessel and heart disorders, of 
which coronary heart disease is one of the most prevalent. According to the World Health 
Organisation (WHO), approximately one third of deaths globally result from CVDs, and so 
heart disease is now recognised as one of the leading health problems in the world (WHO 
2011). In 2001 an estimated 16 million deaths worldwide were attributed to CVDs, and most 
alarmingly - and contrary - to previously held views on the prevalence of CVDs, some 13 
million of these were estimated to have occurred in low- to middle-income countries, as 
opposed to just 3 million in higher-income developed countries (Mathers et al. 2006). Indeed, 
the burden of CVDs has now spread to regions such as China, India and many Sub-Saharan 
African countries, where the estimates of CVD-related deaths are known to be drastically 
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Saharan Africa in particular has experienced a dramatic rise in the incidence rate of CVDs 
and CVD-related deaths, a large proportion of which are HIV-associated heart diseases such 
as pericardial tuberculosis and cardiomyopathy. Two observational studies have shown that 
there is a higher rate of CVDs and MIs in HIV-infected patients (Triant et al. 2007) (Lang et 
al. 2010). This population is further affected by insufficient access to anti-retroviral therapies 
which preserve immune function and thus reduce the incidence of myopericardial disease, 
as well as pulmonary hypertension (a known cause of heart disease which will be explored 
in detail further on) (Ntsekhe & Mayosi 2009; Sliwa et al. 2012).  
 
Figure 1.2 Arterial occlusion leads to Myocardial Infarction(from:http://www.drugs.com/health-guide/heart-attack-
myocardial-infarction.html) 
Heart disease is most often preceded by a heart attack or myocardial infarction (MI) event - 
usually caused by an arterial occlusion (as presented in figure 1.2) - which leads to 
myocardial ischemia and eventual tissue necrosis; resulting in a significant loss of viable, 
contractile myocardium (WHO 2011). 
Following an MI event, there is an immediate loss of global systolic heart function within the 
first 24 hours (Francis et al. 2001). This loss is accompanied by the direct activation of a 
haemostatic compensatory mechanism, which increases left ventricular (LV) pressures in 
order to sustain cardiac output and peripheral tissue perfusion (Packer 1996). This 
mechanism is initiated by the activation of the RAS cascade (Rouleau et al. 1993).  
Myocardial cell death as a result of MI is largely definitive, as the majority of cardiomyocytes 
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chance of recovery following an MI event without some form of therapeutic intervention. In 
the absence of treatment an MI event may occur multiple times or repeatedly over the 
course of the disease’s progression to heart failure. This places increased significance on 
the treatment and prevention of heart failure post-MI (Soonpaa et al. 1998). The many 
components of the RAS cascade and the roles they play in the pathophysiology of heart 
disease will be explored in detail in the next section.  
 
 
1.2 MYOCARDIAL INFARCTION AND PROGRESSION TO HEART FAILURE 
1.2.1 MYOCARDIAL REMODELING 
The critical loss of myocardium that occurs as a result of MI results in immediate activation 
of the RAS cascade and leads inevitably to a pathophysiological remodeling of the left 
ventricle (Cohn et al. 2000). Remodeling is a process that begins within hours of injury to the 
myocardium, and is characterized by a cellular and anatomical response which leads to 
dilatation of the left ventricle (Cohn et al. 2000; Eaton et al. 1979), wall thinning and 
hypertrophy (Pfeffer et al. 1991). The consequences of LV remodeling are presented in 
figure 1.3. Remodeling affects both the infarcted and non-infarcted myocardium, which is 
recruited to counteract the increase in loading conditions experienced with a loss of 
contractile function. This remodeling occurs in accordance with the Frank-Starling 
mechanism, as an increase in left ventricular blood volume through dilatation increases 
stroke volume, thus preserving the cardiac output. It is regulated by mechanical, 
neurohormonal and genetic factors (Rubin et al. 1983). 
The cellular response to an MI event is inflammatory and is initiated by the ischemia and 
consequent necrosis experienced by the affected myocardium. This response occurs 3 to 4 
days post-MI and is characterised by macrophage and neutrophil infiltration, complement 
activation and free radical generation (Pfeffer & Braunwald. 1990). The fibrogenic 
transforming growth factor-beta (TGF-β) is released by both necrotic myocytes and invading 
macrophages during this inflammatory stage (Bujak et al. 2007). TGF-β plays a role in the 
phenotypic transformation of cardiac interstitial fibroblasts to myofibroblasts, which 
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scar formation. In addition, myofibroblasts also play a role in the local formation of Ang II and 
its receptors in the cardiac tissue (Bujak et al. 2007). 
The inflammatory response to MI initiates a process referred to as ‘infarct expansion’, which 
involves degradation of the collagen fibers that make up the extracellular matrix (ECM) in the 
infarcted area and leads to LV wall thinning and chamber dilatation (Olivetti et al. 1990). 
Degradation of the ECM leads to ‘slippage’ between myocardial muscle bundles and 
consequently expands the infarcted area while simultaneously reducing the number of viable 
cardiomyocytes in the infarct zone (Frangogiannis et al. 2002; Hutchins et al. 1978). During 
infarct expansion, extensive proliferation of cardiac fibroblasts occurs under the influence of 
TGF- β. Collagen synthesis in the infarcted myocardium is observed as early as 48 hours 
post-MI, and eventually  results in the formation of a non-contractile collagen scar, which 
entirely replaces the infarcted myocardium by 28 days post-MI (Warren et al. 1988). The 
purpose of this scar is redistribution of the increased mechanical stress experienced by the 
LV wall as a result of post-MI chamber dilatation (Cleutjens, Verluyten, et al. 1995).  
Whilst the collagen scar is formed in the infarct zone, cardiomyocytes in the remote, non-
infarcted myocardium undergo both compensatory hypertrophy (Hochman at al. 1982) and 
wall thinning, resulting in further adaptive LV dilatation for the purpose of maintaining cardiac 
output. However, in the long-term, this dilatation increases LV wall stress according to the 
Laplace law (Anversa et al. 1985). Increased wall stress in turn stimulates further LV 
enlargement, which further increases wall stress thus leading to a pattern of continuous LV 
dilatation and remodeling with long-term detrimental effects on both cardiac function (W 
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Figure 1.3Post-MI LV remodeling in the heart (from: 
http://stemcells.nih.gov/info/Regenerative_Medicine/2006Chapter6.html) 
 
1.2.2 THE ROLE OF ANG II IN MYOCARDIAL REMODELING 
Ang II directly contributes to post-MI LV remodeling by binding to specific Ang II AT1 
receptors, which are responsible for vasoconstriction and cardiovascular remodeling (Flather 
et al. 2000). Cardiomyocyte hypertrophy is both mediated and stimulated by Ang II, which is 
upregulated post-MI as a result of RAS activation (White et al. 1987; Sadoshima et al. 1992). 
Concurrently, mechanical stretch due to dilatation stimulates the local tissue RAS and Ang II 
production by cytoplasmic granules in the myocardium (Lindpaintner et al. 1993). Ang II also 
plays a role in fibrosis and scar formation by promoting expression of the fibrogenic growth 
factor TGF-β. Upregulation of TGF- β expression occurs as part of the inflammatory 
response to cardiac injury (Yasuda et al. 2008) and its expression is downregulated by 
pharmaceutical inhibition of Ang II synthesis (Thompson et al. 1988). Furthermore, Ang II 
stimulates reactive oxygen species (ROS) formation (Griendling & Ushio-Fukai. 2000), which 
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(Peng et al. 2005). Ang II is also a primary stimulant of aldosterone synthesis, which plays a 
role in promoting cardiac fibrosis (Baldi et al. 2002). In the case of pharmaceutical blockade 
of Ang II, studies show that cardiac aldosterone nevertheless successfully mediates post-MI 
LV remodeling, suggesting a significant role for this hormone in the remodeling process that 
remains to be clarified (Delcayre et al. 2000). 
 
1.3 TREATING MI AND PREVENTING HEART FAILURE 
Due to the central role the RAS plays in hypertension and the pathophysiology of heart 
failure, this system has been the target of pharmacological inhibition since the 1970’s (Hall 
2003). While the effects of RAS activation are traditionally considered to be compensatory in 
response to haemodynamic demands, it is well accepted that sustained activation has a 
negative impact on mortality and morbidity in patients suffering from acute MI and heart 
failure (Ranadive et al. 1992; White 1998). For this reason, pharmacological curtailment of 
the RAS and its effects on LV remodeling and blood pressure is critical following an MI 
event. Post-infarction patients are susceptible to reinfarction, heart failure, development of 
atherosclerosis and stroke in the absence of therapeutic intervention (Ma et al. 2010). Three 
classes of RAS intervention drugs have been developed, namely ACE inhibitors, angiotensin 
receptor blockers (ARB) and direct renin inhibitors (DRI). Their mechanisms of action are 
presented below in figure 1.4. 
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ACE inhibitors interrupt the process of Ang II synthesis by preventing hydrolysis of Ang I 
(Ondetti et al. 1977) (Patchett et al. 1980). ACE inhibitors are prescribed to millions of 
patients worldwide and have been shown to be effective in the treatment of hypertension, 
congestive heart failure and renal diseases, as well as dramatically reducing mortality post-
MI (Uresin et al. 2007; Yusuf et al. 2000). The beneficial effects of this treatment have been 
demonstrated to improve clinical outcomes and reduce the risk of myocardial infarction, 
stroke, heart failure and death (Flather et al. 2000; Isnard et al. 2000). Since the early 1990s 
large-scale randomized placebo-controlled clinical trials have unequivocally shown that 
treatment with ACE inhibitors after acute MI produces consistently positive clinical outcomes 
with reduced mortality (Pfeffer et al. 1992; Køber et al. 1995; Bowling et al. 2012). In 
addition, ACE inhibitors have been shown to have beneficial effects on atherogenesis, 
inflammation, endothelial function and cardiac remodeling (DiCarlo et al. 1983; Lonn et al. 
1994; O’Keefe et al. 2001). 
In contrast to ACE inhibitors, ARBs do not prevent Ang II synthesis, but rather specifically 
antagonise Ang II AT1 receptors, thus suppressing this peptide’s vasoconstrictive and 
cellular effects. ARBs are generally used in conjunction with or as a replacement for ACE 
inhibitors, most often in the event of ‘ACE escape’ – a condition in which chronic ACE 
inhibition leads to an eventual rise in Ang II plasma levels up to and beyond initial values 
(Timmermans et al. 1993; St John Sutton et al. 1997; MacFadyen et al. 1999). As ARBs 
have no effect on Ang II synthesis, they are effective regardless of the level of Ang II 
production. ARBs are also often substituted for ACE inhibitors if the patient experiences 
severe negative side effects, as ARBs do not induce the cough often associated with ACE 
inhibitor treatment (Lacourcière et al. 1994; Roig et al. 2000).  In the case of hypertension, 
ARBs have been found to be as effective as ACE inhibitors at lowering blood pressure, and 
have the added benefit of less severe side effects (Benz et al. 1997).  However, their impact 
on LV remodeling is still unclear, although studies have shown that combination ACE 
inhibitor and ARB therapy does attenuate the remodeling process (Chan et al. 1997; Conlin 
et al. 2000).  
DRIs are the most recent drug class to become commercially available for the treatment of 
hypertension, post-MI LV dysfunction and heart failure (Tikkanen et al. 1995). The first and 
only DRI to be approved for clinical use is Aliskiren, an orally-active compound which targets 
the enzyme renin  (Mankad et al. 2001). It has been shown to be effective at lowering blood 
pressure in short-term studies (Stanton et al. 2003; Wood et al. 2003), and has the 
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ARBs or ACE inhibitors (Nussberger et al. 2002; Oparil et al. 2007; Weir et al. 2007). 
Aliskiren has an extremely high specificity for the active site on renin and thus competitively 
inhibits Ang I generation from Angiotensinigen (Wood et al. 2003). As this compound inhibits 
renin activity at the top of the biochemical cascade (the ‘rate-limiting step’), it decreases 
production of Ang I and subsequently the pressor Ang II (Nussberger et al. 2002) while 
increasing plasma renin activity (PRA) – a result of removing the negative feedback 
mechanism of Ang II on renin production. PRA is a measure of both changing circulatory 
renin levels as well as plasma angiotensinogen levels. While this is true of all classes of RAS 
intervention drugs, a review of six large-scale clinical trials with aliskiren found that the 
reactive increase in PRA was far greater with DRIs and resulted in a considerable offset of 
this class’ positive antihypertensive effects (Sealey & Laragh 2007). This is due to the fact 
that while PRA is effectively decreased by Aliskiren, plasma renin concentration (PRC) – is 
elevated to such a degree (up to 500% as a monotherapy (Juerg Nussberger et al. 2005)and 
up to 1200% in combination with a diuretic (Villamil et al. 2007)) that PRA effectively rises. A 
large reactive increase in PRA is also seen in treatment with ARBs, but as described earlier, 
this drug class is able to inhibit the effect of Ang II at receptor level and lower BP. The 
current opinion is that this drug class does not present a superior treatment option over ACE 
inhibitors or ARBs. 
Despite the development of alternative drug classes for RAS inhibition, ACE inhibition 
remains the first-line treatment for hypertension, congestive heart failure (CHF) and acute MI 
(Antman et al. 2004). The haemodynamic effects of ACE inhibition were originally believed 
to be the major contributor to the positive outcomes seen in patients suffering from acute MI 
and heart failure. ACE inhibitors primarily induce vasodilation, thus enhancing the cardiac 
output of the damaged heart by decreasing the loading conditions. More recently however, it 
has been recognised that ACE inhibitors have properties which enhance cardioprotection 
independently of their haemodynamic effects on hypertension. Of particular importance are 
the findings that ACE inhibitors prevent or delay detrimental cardiac remodeling of the LV 
post-MI These benefits on LV remodeling are generally attributed to two factors: the 
decrease of ACE-mediated Ang II production (as discussed previously, Ang II contributes 
negatively towards the remodeling process) and the accumulation of plasma bradykinin 
levels (a peptide with anti-proliferative and anti-hypertrophic properties). The role of 
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1.4 THE RAS IN DETAIL 
1.4.1.1 RENIN AND PRORENIN 
Following an MI event, the RAS cascade is initiated by the synthesis of the glycoprotein 
renin, which is formed by the proteolytic cleavage of the precursor enzyme, prorenin. 
Prorenin is produced renally for the purposes of renin production and it is also secreted 
constitutively into the systemic circulation. It serves as the precursor for renin production in 
the kidneys (Agostoni et al. 1999), and although its circulatory levels in the plasma exceed 
those of renin by up to 100-fold (Hobart et al. 1984), it was until recently believed to have no 
function of its own. However, discovery of a (pro)renin receptor [(P)RR] which binds both 
renin and prorenin, highlighted this enzyme’s potential function as more than an inactive 
element of the RAS (Danser et al. 1998). Binding to this receptor induces a non-proteolytic 
activation of prorenin, as well as increasing the catalytic activity of renin by 4-fold. This 
observation presents a compelling case for the concept of increased renin activity for the 
purpose of Ang II production at a cell-surface level (Sealey et al. 1996; Nguyen et al. 1996;  
Nguyen et al. 2002). 
Renin is synthesized from prorenin within the juxtaglomerular (JG) cells of the renal 
glomerulus of the kidney (Galen et al. 1984). It is stored in the granules of the JG cells and 
released mainly by exocytosis in response to intracellular signalling pathways (Schweda & 
Kurtz. 2004). It is the enzyme responsible for the production of Ang I from Angiotensinogen 
(Leonard T Skeggs et al. 1954). As renin is the major rate-limiting step in the RAS cascade, 
its release is highly regulated by both local and systemic factors. The negative feedback 
mechanism controlling renin production and secretion is influenced by a number of inter-
related factors as described below. The effects of these factors on renin release are 
presented in figure 1.5. 
 
1.4.1.2 RENIN RELEASE: SYSTEMIC FACTORS 
Activation of the RAS cascade is initiated by renin secretion, which is induced mainly by a 
decrease in systemic blood pressure or circulating blood volume (both of which are reflected 
by a decrease in arterial pressure, renal arteriolar pressure and renal perfusion pressure) 
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Arterial circulatory pressures are maintained by two homeostatic inter-related mechanisms: 
cardiac output and peripheral vascular resistance (Frohlich et al. 1969). Mechanoreceptors 
located in the left ventricle (Oberg et al. 1972), the carotid sinus (Eckberg 1977), the aortic 
arch (Heymans 1960) and the renal afferent arterioles (Moss 1982) are responsible for 
sensing any changes in arterial pressure, and thus play a major role in regulating blood 
pressure and volume. A decrease in activation of these receptors has four major effects: 
increased sympathetic nervous activity (Malpas 2010), release of antidiuretic hormone 
(ADH) (Schrier et al. 1999), stimulation of thirst (Stricker 1968) and activation of the RAS.  
In addition to mechanoreceptors, the JG apparatus in the kidney is sensitive to a loss in 
renal arteriolar and perfusion pressure. The JG cells line the afferent (and sometimes the 
efferent) arterioles of the glomeruli, which is situated adjacent to the macula densa cells of 
the distal tubules. The macula densa cells are sensitive to decreases in the sodium chloride 
(NaCl) concentration of the tubular fluid and an inverse relationship exists between the 
tubular Cl- concentration as sensed by the macula densa and renin release (Leonard T 
Skeggs et al. 1954). A decrease in this concentration is indicative of a decreased glomerular 
filtration rate as a result of reduced renal perfusion and stimulates release of renin and 
synthesis of the vasoconstrictor Ang II (see below for mechanism). A drop in renal arteriolar 
pressure also directly stimulates renin release and activation of the RAS (Frohlich et al. 
1969). 
 
1.4.1.3 RENIN RELEASE: EXTRACELLULAR FACTORS 
Local factors responsible for regulating the release of renin include a number of hormones, 
peptides and compounds acting in both a stimulatory and inhibitory capacity by activating 
intracellular mechanisms. The primary extracellular factors responsible for the regulation of 
renin release are reviewed below. 
 
1.4.1.3.1 THE PROSTAGLANDINS 
The prostaglandins E2 and I1 have been shown to stimulate renin secretion in vitro (LA et al. 
1971; Johnson et al. 1973; Egan et al. 1983). It is also known that blockade of prostaglandin 
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The formation of prostaglandins is catalyzed by the two cyclooxygenase isoforms COX-1 
and COX-2 (Hemler & Lands, 1976). Both forms of the enzyme are expressed in the kidneys 
and COX-2 in particular is localised in the macula densa (Harris et al. 1994). COX-2 
expression has been shown to change in congruence to levels of renin synthesis, providing 
evidence of a relationship between the two (Traynor et al. 1999; Wolf et al. 1999). In 
addition, COX-2 expression and the prostaglandins E2 and I1 are believed to play a role in 
the stimulatory effect of decreased NaCl concentrations on renin release. It has been shown 
in vitro that a specific COX-2 blocker (NS-398) prevents the stimulation of renin release by 
low NaCl in isolated perfused JG cells (Saris et al. 2002). This has also been shown in vivo, 
where COX-2 blockers have the same effect on renin release stimulated by a low NaCl diet 
or by treatment with the diuretic furosemide (Traynor et al. 1999; Harding et al. 2000). 
 
1.4.1.3.2 ATRIAL NATRIURETIC PEPTIDE 
Atrial Natriuretic Peptide (ANP) is a hormone that is localized in the myocardial cells of the 
atria (Cantin et al. 1984).  Its release is stimulated by an increase in atrial pressure, and it 
acts to lower blood pressure by promoting natriuresis (sodium excretion) and inhibiting renin 
secretion (Edwards et al. 1988). The ANP driven inhibition of NaCl reabsorption can lead to 
increased macula densa NaCl concentrations, which in turn inhibits the release of renin. 
(Stichtenoth et al. 1998; Jensen et al. 1996; Friis et al. 2005) 
ANP also directly suppresses renin release by stimulating cyclic guanosine monophosphate 
(cGMP) formation in the JG cells (discussed in more detail below). This particular inhibitory 
action has been shown both in vitro and in vivo. (Bolger et al. 1976; Traynor et al. 1999) 
 
1.4.1.3.3 NITRIC OXIDE 
Nitric oxide (NO)-producing cells are located in close proximity to the JG cells and play a 
stimulatory role in the release of renin. This is evidenced by studies with knockout mice, 
which have shown that the primary enzyme responsible for NO synthesis - the neuronal NO 
synthase nNOS - is localized to and expressed by the cells of the macula densa (Wolf et al. 
1999; Hartner et al. 1998; Traynor et al. 1999). As with the studies ofCOX-2, expression of 
nNOS correlates to changes in renin secretion (Harding et al. 2000). In vitro and in vivo 
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although inhibition has also been observed under specific, acute conditions (Kurtz et al. 
1998). These effects are believed to be mediated by the stimulation of guanylate cyclase 
activity in the renin-producing JG cells (Edwards et al. 1988; Stichtenoth et al. 1998; Maack 
et al. 1984). The dual role of cGMP on renin synthesis is discussed in more detail below. 
 
1.4.1.3.4 ANGIOTENSIN II 
As the primary end-product of the RAS cascade, Ang II strongly inhibits renin release as part 
of a negative feedback loop. It does this both directly via specific receptors (Siragy et al. 
2005) and indirectly as a consequence of its systemic haemodynamic effects on arterial and 
renal arteriolar pressures (Vander 1967).  
Renin-releasing JG cells express Ang II AT1 receptors in abundance (Burnett et al. 1986), 
and studies show that both Ang II and its receptors are involved in inhibiting stimulatory 
cyclic adenosine monophosphate (cAMP) activity in renin-producing cells (Obana et al. 
1985a; Henrich et al. 1988). Ang II appears to mediate its inhibitory actions by increasing the 
cytosolic calcium levels in renin-producing cells, which has a strong inhibitory effect on renin 
release (discussed below) (Mundel et al. 1992; Bachmann et al. 1995). 
 
1.4.1.4 CELLULAR MECHANISMS THAT REGULATE RENIN RELEASE 
1.4.1.4.1 CYCLIC AMP 
The primary intracellular stimulant of renin release is cAMP. In vitro studies have shown that 
the hormones responsible for stimulating renin release (such as PGI1 and PGE2) from the JG 
cells do so by increasing intracellular cAMP concentrations in JG cell isolations (Wagner et 
al. 2000; Bosse et al. 1995; Kurtz et al. 1998; Schmidt et al. 1993).  There is also evidence 
that sympathetic stimulation of renin release via B-adrenoreceptors is facilitated by 
intracellular cAMP (Kurtz et al. 1998; Jensen et al. 1997; Kurtz et al. 1986a). The exact 
mechanism through which cAMP triggers the exocytosis of renin is not clear but does involve 
a protein kinase A-dependent step (Castrop et al 2005). 
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In contrast to the solely stimulatory effects of the activated cAMP pathway, cyclic GMP 
appears to fulfill a dual role in regards to regulation of renin secretion, both inhibitory 
(Hautmann et al. 2007; Weinberger et al. 1975) and stimulatory (Friis et al. 1999; Keeton et 
al. 1980). 
In vitro studies with hormones that stimulate cyclic GMP activity (such as natriuretic 
peptides) show that a slight increase in cGMP levels is responsible for renin stimulation, 
while higher concentrations of intracellular cGMP appear to inhibit renin release (Henrich et 
al. 1988; Greenberg et al. 1995; Sayago et al. 2001).   
The duality of renin release in response to cGMP concentration is poorly understood. It has 
most recently been proposed that it may result from the differing affinity of cGMP for two 
intracellular factors, namely phospodiesterase-3 (PDE-3) and cGMP-dependent protein 
kinase II (cGKII) (Schweda & Kurtz. 2004). PDE-3 with a higher affinity for cGMP has been 
shown to be inhibited by cGMP thus decreasing degradation of cAMP and thereby 
stimulating the release of renin (Beavo 1995). Conversely, cGKII with a lower affinity for 
cGMP has been shown to directly inhibit renin release. It would appear that NO acts through 
the cGMP-PDE-3 axis (Kurtz and Wagner 1998) and it might also be surmised that ANP 
could be acting via cGKII. 
 
1.4.1.4.3 CALCIUM 
Finally, intracellular Ca2+ concentrations in the JG cells are considered to be the principal 
inhibitor of renin secretion (Kurtz 2011). Interestingly, although an increase in Ca2+ 
concentrations triggers exocytosis in most secretory cells in the body, in JG cells a Ca2+ 
increase actually reduces exocytosis, thus inhibiting the release of renin (Beierwaltes 2006; 
Obana et al. 1985b). This inverse relationship has been termed the “calcium paradox” (Kurtz 
et al. 1998). As detailed above, ANGII upregulates Ca2+ (as do several other 
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Figure 1.5 The stimulatory and inhibitory factors affecting renin release 
 
1.4.2 ANGIOTENSINOGEN 
Angiotensinogen is a globulin that is produced mainly and constitutively by the liver (Kurtz et 
al. 1986b). Systemic angiotensinogen plasma levels are thus fairly constant and resistant to 
acute fluctuations, and serve as the primary substrate of the RAS.  
Angiotensinogen messenger RNA (mRNA) expression has also been found in many other 
tissues, including the brain, heart and adipose tissue (Grünberger et al. 2006; Ortiz-
Capisano et al. 2007; Campbell et al. 1987). When the RAS is activated following acute MI, 
studies show an increase in tissue levels of angiotensinogen mRNA expression in both the 
kidney and the cardiac ventricular tissue (Sawa et al. 1992; Kelly et al. 1997). 
Angiotensinogen is cleaved by the enzyme renin to form the decapeptide Angiotensin I. 
 
1.4.3 ANGIOTENSIN I 
The production of biologically inactive Ang I is an intermediate step in the cascade towards 
Ang II production. The formation of a precursor is required as Ang II is an extremely potent 
peptide with a remarkably short half-life (approximately 30 seconds in human plasma) 
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studies have shown that local synthesis accounts for more than 90% of intracellular Ang I in 
the myocardium (Filippatos et al. 2001). 
1.4.4 ANGIOTENSIN CONVERTING ENZYME 
The ACE protein is a zinc-dependent dipeptidyl carboxypeptidase, meaning it cleaves two 
amino acids from the carboxyl end of peptides. It is expressed as two isoforms which are 
both transcribed by a single gene (Soffer et al. 1987). The larger isoform is termed somatic 
ACE and is predominantly expressed in the vascular endothelium of the pulmonary system 
(Das et al. 1975). It is also present in the plasma, the vascular endothelium, and the 
epithelial cells of many other tissues, including the kidney (Soffer et al. 1987; Ehlers et al. 
1986). The second isoform is testicular or testis ACE, and is expressed exclusively in male 
germ cells where it is believed to play a crucial role in male fertility (Danilov et al. 1994;  
Langford et al. 1993).  
Somatic ACE is comprised of two homologous catalytic domains. They are termed the N- 
and C-terminal domains, classified according to their relative position on the polypeptide 
chain (Pauls et al. 2003). Each domain is catalytically independent and has a zinc-binding 
motif essential for enzymatic activity (Soubrier et al. 1988). Notably, the testis ACE isozyme 
possesses only the C-domain (Ehlers et al. 1989). These two domains are probably the 
result of an ancient gene duplication, and display 60% sequence homogeneity (Lattion et al. 
1989). It appears that both active sites have been evolutionarily conserved over time, which 
suggest that they each play an essential physiological role in the RAS (Cornell et al. 1995). 
Somatic ACE - referred to as ACE in this work - exists in both a soluble, circulating form, and 
in a physiologically significant membrane-bound form. The soluble form found in plasma is 
thought to be a reflection of the membrane-bound form’s turnover and clearance (Corvol et 
al. 1995). 
ACE is primarily responsible for generating the bioactive vasoconstrictor peptide Ang II by 
hydrolysis of Ang I. It is also responsible for the hydrolysis and degradation of the 
vasodilatory peptide bradykinin (Corvol et al. 1995). In this manner, ACE employs a two-
pronged approach towards hypotension by both synthesizing vasoconstrictive peptides while 
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1.4.5 ANGIOTENSIN II 
As the primary active product of the RAS, Ang II induces vasoconstriction and increases 
blood pressure in response to hypotension or hypovolemia (Georgiadis et al. 2003). It also 
increases sodium and fluid retention in the kidneys by acting on both the adrenal cortex to 
stimulate aldosterone release as well as the posterior pituitary to stimulate the release of 
Antidiuretic Hormone (ADH) (Reid 1992; Davis 1964; Uhlich et al. 1975). Ang II also 
counteracts hypovolemia by stimulating the thirst centers in the brain, thus increasing fluid 
intake and complementing the mechanisms for fluid reabsorption (Brooks et al. 1986). 
Ang II mediates these antagonistic effects towards hypotension and hypovolemia by binding 
to two known plasma membrane receptor sub-types which are responsible for mediating 
diverse and opposing physiological effects. The Ang II type 1 (AT1) receptor is responsible 
for Ang II’s primary actions on the cardiovascular system; namely systemic vasoconstriction, 
sodium retention and cardiac and vascular hypertrophy (Lijnen et al. 2001; Vaughan 2001;  
Savoia et al. 2011). Interestingly, AT1R-specific blockade by direct renal infusion results in a 
highly significant natriuretic response that is not observed under conditions of AT2R 
blockade, which demonstrates a principal role for this receptor in the mediation of natriuresis 
(Bergaya et al. 2004).   
In sharp contrast the role of the Ang II type 2 receptor (AT2) appears to be entirely 
contradictory to the effects of the AT1 receptor. It is widely accepted that AT2 receptors 
promote apoptosis and inhibit fibroblast proliferation and cardiac hypertrophy (Touyz et al. 
2003; Tsutsumi et al. 1999; Tsuzuki et al. 1996). AT2 receptors also appear to counter-
balance the AT1 receptor-mediated vasoconstrictive effects of Ang II by inducing 
vasodilation.  Evidence for this comes from studies in vascular endothelial cells, which show 
that vasodilation caused by NO is mediated by activation of the AT2 receptors (Yamada et al. 
1996). Studies have also shown that AT2 receptor activation leads to production of the 
vasodilatory peptide bradykinin (Wiemer et al. 1993; Katada et al. 2002).  Most notably, AT2 
receptors are capable of binding to AT1 receptors located on cell surfaces, thus directly 
antagonising the AT1 receptor-mediated effects of Ang II (Padia 2006). In addition, 
expression of the AT2 receptor is inhibited by Ang II and upregulated by sodium reduction 
(AbdAlla et al. 2001). These observations regarding the antagonistic nature of the two Ang II 
receptors strongly suggest the existence of internal feedback mechanisms responsible for 
regulating the effects of the activated RAS. The systemic effects of AT1 receptor binding and 
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of the physiological effects of both AT1 and AT2 receptor binding are presented in figure 1.10 
(Section 1.7.3) 
 
Figure.1.6 The Systemic RAS and its peripheral actions 
 
1.5 ADDITIONAL PATHWAYS, PEPTIDES AND ENZYMES OF THE RAS 
1.5.1 THE ALTERNATIVE AXIS 
The generation of Ang II in response to hypovolemia and hypotension is the primary function 
of the RAS. However, upregulation of Ang II production has a number of detrimental effects 
under pathophysiological conditions, hence the need for pharmacological curtailment. The 
discovery of an alternative axis in the RAS has opened up a promising new strategy for 
combating the negative effects of Ang II by enhancing endogenous production of the 
vasodilatory and cardioprotective heptapeptide Ang (1-7). This so-called ‘alternative axis’ is 
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Figure 1.7 Relationship of the alternative Ang (1-7)-producing axis to the Ang II-producing RAS cascade 
The existence of an Ang (1-7) generating pathway within the RAS provides further 
compelling evidence for an internal counter-regulatory mechanism, designed to limit the 
potent effects of Ang II. The diversity of enzymatic pathways for Ang (1-7) generation (as 
described below) also supports the concept of an enhanced counter-regulatory mechanism 
within the RAS (Deddish et al. 1998). 
 
1.5.1.1 ANGIOTENSIN (1-7) 
Ang (1-7) is present at both systemic and tissue levels, and is found in the brain, heart, liver, 
kidneys, reproductive organs and the vasculature (Israili et al. 1992).It binds to the G protein-
coupled receptor Mas, which is present on endothelial cells (Nussberger et al. 1998). It is 
this binding that mediates Ang (1-7)’s vasodilatory, anti-proliferative, anti-inflammatory, 
antithrombotic and antiarrythmogenic effects (Schindler et al. 2007). Studies have also 
shown elevated Ang (1-7) expression in the border zone of infarcted cardiac tissue - further 
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pathophysiological conditions (Santos et al. 2003). It has furthermore been demonstrated 
that exogenous administration of this peptide attenuates the development of heart failure in 
a rat model of MI (Santos et al. 2003). In general, Ang (1-7) plasma levels are extremely low, 
but during ACE inhibition they are elevated as a consequence of higher Ang I levels, as well 
as by the inhibition of its own metabolizing agent ACE (Loot et al. 2002). Additionally, studies 
show that Ang (1-7) is cleaved exclusively by the N-domain of human ACE (Campbell et al. 
1993; Deddish et al. 1998) 
. 
1.5.1.2 ACE2 
ACE2 is a zinc metalloprotease homologue of ACE which is entirely insensitive to ACE 
inhibition and shares just 42% of its sequence identity with ACE (Donoghue et al. 2000). Its 
role in the RAS appears to be counter-regulatory towards Ang II, as it is responsible for the 
generation of Ang (1-7) either directly from Ang II or indirectly by the intermediate synthesis 
of Ang (1-9) (Tipnis et al. 2000a).  
Expression of ACE2 is not as expansive as that of ACE, although ACE2 mRNA is present 
throughout all the tissues of the body. Particularly abundant expression has been noted in 
the venous and arterial endothelial cells, arterial smooth muscle cells, as well as the 
epithelia of the lung and small intestine (Donoghue et al. 2000). Upregulation of ACE2 
expression has recently emerged as a promising therapeutic target for the treatment of MI 
and heart failure (Donoghue et al. 2000), as it inactivates Ang II by upregulating its 
conversion to Ang (1-7), thus minimizing the negative effects of Ang II and augmenting the 
cardioprotective effects associated with Ang (1-7). There is evidence that ACE2 expression 
is locally upregulated in the ischemic heart following MI (Goulter et al. 2004)and studies with 
knockout mice reported cardiac dysfunction under physiological conditions in the absence of 
ACE2 expression (Burrell et al. 2005). 
 
1.5.1.3 NEP 
Neutral endopeptidase (NEP) is also referred to as neprilysin, and is a zinc metallopeptidase 
with a preference for N-terminal cleavage. It has recently been shown to play a role in the 
conversion of Ang (1-9) to Ang (1-7), as well as a possible role in the direct synthesis of Ang 
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1.5.1.4 ANG (1-9) 
While the exact role of Ang (1-9) as more than an intermediate peptide in the generation of 
Ang (1-7) is still unclear, there is evidence that it enhances the actions of the vasodilatory 
agent bradykinin, thus increasing NO synthesis (Crackower et al. 2002). Recent studies 
have shown that Ang (1-9) also has cardioprotective anti-hypertrophic effects in vivo and in 
vitro (Jackman et al. 2002). 
 
1.6 REVIEW OF ADDITIONAL COMPONENTS OF THE RAS 
The primary components of both the Ang II-producing and the counter-regulatory Ang (1-7)-
producing pathways of the RAS have been previously described and defined in the current 
chapter. However, recent studies have shown that our existing view of the RAS must be 
expanded to include a number of angiotensin metabolites with a range of effects that both 
augment and attenuate the actions of Ang II. Figure 1.8 illustrates the major peptides of 
interest in this study, along with the enzymatic pathways responsible for their generation. 
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Figure 1.8 The expanded view of the RAS (adapted from (Poglitsch et al. 2012)) 
1.6.1 ENZYMATIC PATHWAYS 
There are a number of enzymes potentially involved in the processing of angiotensinogen-
derived peptides in addition to renin, ACE and ACE2. (Aminopeptidase A (APA) cleaves 
peptides with an N-terminal acidic amino acid, which includes Ang I and Ang II. It therefore 
converts Ang I to Ang (2-10) (also referred to as Des Asp1 Ang I), and Ang II to Ang III (also 
referred to as Ang (2-8) or Des Asp1 Ang II) (Ardaillou  et al. 1998). 
Aminopeptidase N (APN) hydrolyses peptides with an N-terminal neutral amino acid, 
facilitating the conversion of Ang III to Ang IV (also referred to as Ang (3-8)) (Sjöström et al. 
2000). Dipeptidylaminopeptidase III (DAP) is also active in the RAS, and is responsible for 
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1.6.2 ANGIOTENSIN PEPTIDES 
1.6.2.1 ANG (2-10) 
Ang (2-10) is a nonapeptide produced by the enzymatic cleavage of Ang I by APA. Studies 
support an antagonistic role for Ang (2-10) with regards to Ang II, as it has been shown to 
produce anti-hypertrophic effects on rat cardiomyocytes both in vivo (Sim et al. 1998) and in 
vitro (Min et al. 2000). Two separate groups have also reported an anti-inflammatory effect 
with intravenous or oral administration of Ang (2-10), accompanied by attenuation of infarct 
size in both a permanent ligation (Rufaihah et al. 2006) and ischemia-reperfusion model 
(Wen et al. 2004; Wen et al. 2011) in the rat. 
 
1.6.2.2 ANG III 
The heptapeptide Ang III is produced either by the enzymatic cleavage of Ang II by APA, or 
by ACE activity on Ang (2-10) (Campbell 2003).  
In the peripheral system, Ang III induces aldosterone secretion from the adrenal glomerulosa 
by binding to the AT2 receptor (Yatabe et al. 2011). Recent studies with neonatal cells have 
shown that Ang III also induces protein synthesis in cardiomyocytes and DNA and collagen 
synthesis in cardiac fibroblasts (Wang et al. 2010). Some proinflammatory effects have also 
been observed in rat in vitro studies (Ruiz-Ortega et al. 2000). 
In the local RAS of the CNS, there is evidence that Ang III plays a highly significant 
physiological role. In the CNS, Ang II and Ang III display similar affinities for both the AT1 
and AT2 subtype receptors (Hansen et al. 2000; Marc  et al. 2011).   
Interestingly, Ang III has been shown to mediate many of the same physiological effects as 
Ang II via AT1 receptor binding in the CNS – namely induction of vasoconstriction and 
vasopressin release (Zini et al. 1996).   
Studies employing APA blockers in the CNS have shown that the conversion from Ang II to 
Ang III is critical for the stimulation of vasopressin release and elevation of BP that is 
observed with exogenous administration of Ang II (Zini et al. 1996; Zini et al. 1998). In the 
renal system, similar studies have found that this Ang II to Ang III conversion is required for 
the AT2 receptor-mediated natriuretic response observed with exogenous renal infusion of 
Ang II (Padia et al. 2008). 
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1.6.2.3 ANG IV 
Ang IV is a hexapeptide which is directly generated from Ang III by the hydrolysis of the N-
terminal by aminopeptidase N (APN). It is also converted from Ang II by the actions of 
diaminopeptidases (DAP) – in fact, DAP has a higher substrate affinity for Ang II than that of 
APN, and this is the preferred pathway of Ang IV synthesis (Lee et al. 1982; Erdös et al. 
1990). 
Ang IV has a wide range of physiological effects in the local RAS at various tissue sites. In 
the CNS it has been shown to play a role in learning acquisition and memory recall (Wright 
et al. 1993; Wright et al. 1995), and these effects are mediated by the angiotensin receptor 
subtype AT4  in the hippocampus (Swanson et al. 1992). In the renal system, Ang IV 
promotes natriuresis (Yoshida et al. 1996), while in the vascular system it has a vasodilatory 
effect and improves both cerebral (Kramár et al. 1997) and renal blood flow (Swanson et al. 
1992). 
In addition, there is evidence that Ang IV can promote the synthesis and release of 
prostaglandins, further enhancing its vasodilatory role in the RAS (Yoshida et al. 1996). Ang 
IV mediates these effects by binding to an insulin-regulated aminopeptidase receptor (IRAP), 
which is also assumed to be an AT4 receptor (Albiston et al. 2001).  
 
1.6.2.4 ANG (3-7) 
Ang (3-7) is produced by a variety of pathways and is converted either directly from Ang IV 
by ACE2, or indirectly from Ang (1-7) and Ang III by the proteolytic actions of ACE2 and 
aminopeptidases (Neves et al. 1995). It has been reported that this peptide plays a 
functional role in the local RAS of the CNS, where it has been shown to improve recognition 
memory in rats (Braszko et al. 1995). It is believed to produce these effects by interaction 
with either the AT4 receptors (as is the case with Ang IV) or possibly the AT1 receptors 
(Braszko et al. 1994). 
 
1.6.2.5 ANG (1-5) 
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Forming part of the alternative Ang (1-7)-producing axis of the RAS, Ang (1-5) is produced 
by the hydrolytic action of ACE on Ang (1-7), and is thus susceptible to ACE inhibition 
(Yamada et al. 1998). Interestingly, a review of the literature showed conflicting reports as to 
whether Ang (1-7) was cleaved primarily by the C-domain (Allred, Debra I Diz, Carlos M 
Ferrario, Mark C Chappell, et al. 2000) or the N-domain (Andrade et al. 1998; Deddish et al. 
1998) of ACE. The role of Ang (1-5) as more than an inactive metabolite of the RAS is not 
known, although Roks et al. (1999) did show that this peptide has an inhibitory effect on ACE 
at extremely high concentrations. However, under ACE inhibition, Ang (1-7) levels are 
elevated while Ang (1-5) levels are dramatically decreased, thus making this peptide an 
unlikely candidate for the cardioprotective effects observed with the administration of ACE 
inhibitors (Chappell et al. 1998).  
 
1.7 REVIEW OF RELATED COMPONENTS OF THE RAS 
1.7.1 BRADYKININ 
The peptide bradykinin (1-9) (BK (1-9)) is a potent vasodilatory product of the kallikrein-kinin 
system (KKS) (Silva et al. 1949; Fox et al. 1961). The KKS is a metabolic cascade that 
produces a number of vasoactive peptides and is an important mediator of 
pathophysiological conditions of cardiovascular disease (Sharma 2006; Costa-neto et al. 
2008). The RAS and the KKS are linked by ACE, which is responsible for the metabolic 
breakdown of BK (1-9) (Morice et al. 1987). Thus the vasodilatory product of the KKS serves 
as a physiological counterbalance to the vasoconstrictive product of the RAS (Erdös et al. 
1967). Interestingly, it has also been shown that ACE has a higher substrate affinity for 
bradykinin than that demonstrated for Ang I (Yang et al. 1970).  
BK (1-9) is synthesized either directly by the proteolytic cleavage of kininogen by tissue 
kallikrein, or indirectly by the ACE-mediated cleavage of the intermediate kallidin or lys-
bradykinin (Schmaier 2002). Bradykinin is hydrolysed rapidly by the kininases ACE and NEP 
and has a half-life of less than 30 seconds in vivo (Schmaier 2002). Due to this short half-
life, bradykinin is synthesized locally at various tissue sites, including the heart and 
vasculature. The pathway of bradykinin formation and degradation is presented in figure 1.9. 
Bradykinin binds to two known G protein-coupled receptors – B1 and B2. The B2 receptors 
are widely expressed under physiological conditions by various tissues, including endothelial 
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cells (Benzing et al. 1999), smooth muscle cells (Farmer et al. 1991) and cardiomyocytes 
(Minshall et al. 1995). The B1 receptors are only expressed under pathological conditions 
induced by tissue injury – as is the case with myocardial infarction (Schmaier 2002; Raidoo 
et al. 1997). B2 receptors mediate bradykinin’s vasodilatory actions primarily by stimulating 
endothelial NO synthase expression and NO production as well as by generating 
prostaglandin E2 (Figueroa et al. 2001).  B1 receptors appear to have the same 
haemodynamic effects as B2 receptors, but their complete physiological role is not clearly 
defined (Foucart et al. 1997; Schremmer-Danninger et al. 1998). Anti-hypertrophic and anti-
proliferative effects on cardiomyocytes and fibroblasts have also been attributed to the B2 
receptor (Siragy et al. 1997; Duka et al. 2001). Several studies with B2 kinin receptor 
antagonists have shown that bradykinin is responsible for attenuating both left ventricular 
hypertrophy and progression to heart failure after an MI event (Xu et al. 2005; McAllister et 
al. 1993). There is evidence that B2 receptor-binding preserves stores of glycogen and 
energy-rich phosphates in the myocardium, a possible mechanism for bradykinin’s 
cardioprotective effects during ischemia (Ishigai et al. 1997). Indeed, studies show that 
kinins are released continuously under ischemic cardiac conditions such as MI (Linz et al. 
1992).  
The upregulation of kinin release during MI has been shown to be a critical factor in survival 
rates after coronary artery ligation in a rat model. In addition, pretreatment with a B2 receptor 
agonist completely reverses these cardioprotective effects under ischemic conditions. 
(Wollert et al. 1997; Madeddu et al. 1998) This implies that the B2 receptors play a crucial 
role specifically during MI despite the upregulation of B1 receptor expression.  
ACE inhibitors are known to potentiate the effects of bradykinin by preventing or hindering its 
degradation. Studies with recombinant ACE mutants have unequivocally shown that both the 
C- and N-domains of ACE metabolise bradykinin with similar kinetic efficiencies (Jaspard et 
al. 1993). Although NEP also plays a role in metabolizing bradykinin, ACE accounts for 45 – 
100% of this activity (depending on the species) (Blais et al. 1997). A quantitative 
relationship between bradykinin degradation and the potentiating effects of ACE inhibition 
has been observed in studies with domain-selective ACE inhibitors (B Tom et al. 2001). 
Bradykinin is equally cleaved by both ACE domains, so blockade of only one domain allows 
this peptide to be degraded approximately 50% more than that which occurs with full 
inhibition (Abbas et al. 1999). The uninhibited enzymatic action of ACE leads to the 
sequential formation of the metabolites BK (1-8), BK (1-7) and BK (1-5) from the BK (1-9) 
precursor (Campbell 2003).  
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There is also evidence that bradykinin potentiation by ACE inhibitors could be a result of 
degradation-independent mechanisms. Co-localization of ACE, AT1 receptors and B2 
receptors appear to be necessary for the potentiating the effects of ACE inhibition. ACE and 
B2 receptors appear to form a heterodimer, thus enhancing the efficiency of B2 signalling 
(Abadir et al. 2006).  
 
Figure 1.9 Inhibition of bradykinin metabolism by ACE inhibition 
 
1.7.2 CHYMASE 
During chronic ACE inhibition, a phenomenon known as ‘ACE escape’ occurs (Ennezat et al. 
2000). In this condition, ACE inhibitors become ineffective at reducing circulating Ang II 
levels in the long-term, suggesting a role for alternative pathways of Ang II synthesis. It has 
been suggested that this phenomenon could be attributable to the serine protease chymase, 
which is responsible for ACE-independent Ang II generation from Ang I in the local 
cardiovascular system in some species (Urata et al. 1990). Chymase is found mainly in the 
secretory granules of mast cells – where it is stored until its release into the interstitial space 
- although it has also been identified in the endothelial cells of human cardiac tissue 
(Zablocki & Sadoshima. 2011). An increase in bradykinin (as a result of ACE inhibition) may 
in fact be responsible for chymase elevation, leading to an increase in chymase activity and 
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maintenance of Ang II levels despite ACE inhibition (Urata et al. 1993). Wei et al. identified a 
bradykinin-sensitive receptor on mast cells in mice, indicating a role for this peptide in 
chymase activation and Ang II generation (Urata et al. 1993) 
Chymase expression and its role in Ang II generation is highly variable between species 
(Wei et al. 2010). In humans, dogs (Wei et al. 2010) and hamsters (Miyazaki et al. 2006), 
chymase has been shown to play a significant role in Ang II generation – indeed, in the 
human heart, the majority of Ang II generation (> 80%) appears to result from the actions of 
chymase (Wolny et al. 1997). However, in the rat, mouse and rabbit, no such active Ang II-
generating role for chymase has been observed (Abbas et al. 1999).  
It should be noted, however, that the recently discovered angiotensin peptide Ang (1-12) 
serves as a substrate for chymase-mediated Ang II generation in both rat (Abbas et al. 1999) 
and human (Okunishi et al. 1993) cardiac tissue. However, in rats, administration of a 
chymase inhibitor does not suppress Ang II synthesis, while treatment with lisinopril does. 
Furthermore, sequence analysis of rat chymase has clearly demonstrated its inability to form 
Ang II from the Ang I substrate. Thus, any contribution to Ang II levels by Ang (1-12) 
chymase-mediated hydrolysis is expected to be negligible (Prosser et al. 2009). 
In humans in late-stage heart failure (Ahmad et al. 2011) and in myocardial infarction models 
in both the hamster (Jin et al. 2001) and the dog (Jin et al. 2004), mast cell density and 
chymase activity in the infarcted area is significantly upregulated post-MI (as is ACE activity). 
In a hamster model, administration of chymase inhibitors does not affect plasma Ang II 
concentrations, but does improve cardiac function and mortality rates (Miyazaki et al. 2006). 
In a dog model of MI, plasma Ang II levels decrease following administration of a chymase 
inhibitor (Batlle et al. 2006). It has been suggested that inhibition of chymase activity may 
have an anti-arrhythmic effect on the infarcted heart, as treatment with a chymase inhibitor 
reduces the incidence of ventricular arrhythmias in a dog model of MI (Jin et al. 2003). 
Several studies have demonstrated that stimulation of AT1 receptors by Ang II has an 
arrhythmogenic effect (reviewed in (Jin et al. 2004)), thus inhibition of cardiac Ang II 
generation significantly reduces the incidence of arrhythmia. 
In addition to Ang II generation, chymase activates the transforming growth factor-β (TGF-β), 
which plays a role in cardiac remodeling by increasing fibroblast proliferation and collagen 
deposition (Jin et al. 2004; Garg et al. 2006). Consequently, despite the absence of 
chymase-mediated Ang II generation in the rat, chymase inhibition in an MI model in this 
animal does attenuate fibrosis and improve left ventricular function (Kanemitsu et al. 2006). 
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1.7.3 N-ACETYL-SER-ASP-LYS-PRO (ACSDKP) 
AcSDKP is a tetrapeptide released from the precursor thymosin β4 by the serine peptidase 
prolyl oligopeptidase (POP) (Vavasin et al. 2004). While studies have shown that AcSDKP 
has angiogenic, anti-inflammatory and antifibrotic effects (Ocaranza et al. 2010; Rousseau et 
al. 1995; Wang et al. 2004), its principal function is believed to be as a natural inhibitor of 
hematopoietic stem cells, preventing proliferation by hindering their entry into the S phase of 
the cell cycle (M Lenfant et al. 1989). Inhibition of AcSDKP may therefore have positive 
effects on stem cell recruitment under pathophysiological conditions, despite the 
suppression of other effects – such as fibrosis - that may contribute positively towards 
cardiac remodeling. It does not form part of the RAS, but as it is cleaved by ACE, 
endogenous levels are affected by ACE inhibition. Administration of non-selective ACE 
inhibitors showed that the plasma concentration of AcSDKP increased by 5-fold, confirming 
that ACE is the major enzyme responsible for degradation of this peptide (Azizi et al. 1996). 
It has furthermore been shown that AcSDKP is hydrolysed almost exclusively by the N-
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1.8 DEVELOPMENT OF A NOVEL C-DOMAIN SELECTIVE ACE INHIBITOR 
1.8.1 BRIEF HISTORY OF CLINICALLY-AVAILABLE ACE INHIBITORS 
The first ACE inhibitor was developed in the late 1960s, and was isolated from the 
venom of the Brazilian arrowhead viper (Bothrops jararaca). It was originally named 
bradykinin-potentiating peptide (BPP) as it inhibited kininase II, an enzyme 
responsible for bradykinin degradation. It was later discovered that ACE and kininase 
II were in fact the same enzyme, and that BPP actually inhibited Ang II production by 
interrupting the RAS at the ACE level. (Ferreira et al. 1965; Ferreira et al. 1970) 
(Cushman & Cheung 1971)  
Teprotide – a synthetic analogue of BPP – was shown to effectively lower blood 
pressure in hypertensive patients, as well as demonstrate positive haemodynamic 
effects in patients suffering from heart failure (Ferreira et al. 1970). This inspired the 
search for orally active ACE inhibitors, as the teprotide had to be administered 
parenterally or intravenously, making it an inadequate long-term therapy in the 
clinical setting (Johnson et al. 1975). 
The very first orally active ACE inhibitor was Captopril (Gavras et al. 1978). 
Commercially released in 1981, Captopril contained a sulfhydryl group, which was 
eventually found to be responsible for the many side effects experienced by patients 
(such as skin rashes and proteinuria) (Jaffe 1986). The sulfhydryl group was 
consequently replaced by a carboxyl group, which conferred the drugs Enalapril and 
Lisinopril – developed in the 1980s - with improved lipophilicity (Ferreira et al. 1970). 
Fosinopril, Quinapril, Benazepril and Ramipril followed in the early 1990s, and in the 
mid-1990s, Perindopril, Moexipril and Trandolapril were released (Sica 2010). The 
majority of ACE inhibitors on the market contain the carboxyl group, with fosinopril as 
the only exception with a phosphinyl group as its reactive moiety (Patchett et al. 
1980). ACE inhibitors differ in terms of half-lives and routes of elimination, although 
they are predominantly cleared by the renal system (Ma et al. 2010). Most ACE 
inhibitors – with the exception of lisinopril and captopril - are administered in a 
prodrug form (which has enhanced bioavailability when administered orally) which 
remains inactive form until de-esterified by the liver (Brown et al. 1998).   
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1.8.2 ADVERSE EFFECTS OF ACE INHIBITORS 
In 2010, 168.7 million prescriptions for ACE inhibitors were dispensed by pharmacies 
in the United States alone (IMS Institute for Healthcare Informatics 2010). 
Considering the considerable number of patients to whom ACE inhibitor therapy is 
administered, the incidence and severity of adverse side effects are of serious 
concern. 
ACE inhibitor side-effects are mainly classified as class effects, as they tend to apply 
to all drugs in the class. Not unexpectedly, the main side effect of ACE inhibition is 
hypotension. Patients in renin-dependent states are more susceptible to 
hypotension, and their dosages are carefully monitored (Banerjee et al. 2003). 
Hyperkalemia is another common side-effect, as ACE is responsible for stimulating 
aldosterone release from the kidney (Mancini et al. 1996). In addition, deterioration of 
renal function is often associated with ACE inhibitor treatment. This is caused by the 
reduction in glomerular filtration rate, which is a direct consequence of Ang II 
inhibition (Ang II causes vasoconstriction of the efferent arterioles in the kidney, 
which are responsible for regulating glomerular filtration rates) (Schartl et al. 1994). 
However, this condition is reversible when ACE inhibitor administration is ceased 
(Hodsman et al. 1983; Hall et al. 1977). 
The most frequent side-effect of ACE inhibitor therapy is a dry, persistent cough, 
which studies report affects 3 to 35% of patients (Warren et al. 1980; Hall et al. 
1981). The exact cause of the cough is still unknown, but may be attributable to 
elevated levels of bradykinin, prostaglandins and the neuropeptide substance P. 
Bradykinin and substance P metabolism is dependent on ACE activity, and in the 
case of inhibition, these peptides accumulate in the lungs (where ACE expression is 
most prevalent) and upper airways (Irwin et al. 1990; Smyrnios et al. 1995). The only 
treatment for this cough is complete cessation of ACE inhibitor therapy and 
substitution with another drug class such as ARBs (Dicpinigaitis 2006). 
Finally, drug-induced angioedema is a rare but potentially life-threatening side-effect 
of ACE inhibition, and is estimated to affect 0.1 to 2.2% of patients on ACE inhibitor 
therapy (Israili et al. 1992; Brown & Vaughan. 1998). Angioedema involves the 
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swelling of the dermis, subcutaneous and submucosal tissues, and is characterized 
by localized swelling of the tongue, lips, mouth, throat and other facial areas 
(Vleeming et al. 1998; Kostis et al. 2004). The rate of angioedema is highest in the 
first months following treatment, and should it occur, discontinuation of the drug is 
essential (Weber et al. 2008). As with the persistent cough experienced by some 
patients, angioedema has been attributed to the elevated levels of bradykinin 
observed during ACE inhibition (Banerji et al. 2009; Fox et al. 1996). 
 
1.8.3 DOMAIN-SELECTIVE ACE INHIBITORS 
ACE consists of two homologous catalytic domains, each playing different yet 
essential roles in the metabolism of RAS and KKS peptides. The orally active ACE 
inhibitors currently in clinical use were all designed before the three-dimensional 
structure of ACE was successfully elucidated, and thus target both domains relatively 
equally. The first generation ACE inhibitor Captopril was designed based on the 
known structure of carboxypeptidase A - an enzyme which was believed to be similar 
in catalytic activity to ACE (Ondetti et al. 1977). Captopril has since been found to be 
slightly more selective towards the N-terminal of ACE (Wei & Clauser. 1992). The 
second generation ACE inhibitors – enalapril and lisinopril – were developed based 
on the inhibition of the zinc metalloproteinase thermolysin (Patchett et al. 1980) and 
lisinopril in particular has since been shown to be marginally more C-domain 
selective (Corradi et al. 2006). However, the modest selectivity of these ACE 
inhibitors towards either domain has not produced any significant difference in terms 
of treatment efficacy. Thus the development of ACE inhibitors that exclusively target 
one of the two domains were required to explore the physiological ramifications of 
domain-selective inhibition both in vitro and in vivo. Our current knowledge of the 
physiological roles of each domain is attributable to both the development of domain-
selective ACE inhibitors as well as ACE gene knockout studies in mice (which will be 
expanded on in sections 1.8.3.1 and 1.8.3.2). The physiological roles of the C- and 
N-domains of ACE are summarized below in figure 1.11. 
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Figure 1.11 The roles of the N- and C-domains of ACE 
 
1.8.3.1 THE ROLE OF THE N-DOMAIN AND RXP 407 
The role of the N-domain was the first to be explored with the development of the 
domain-selective ACE inhibitor RXP 407 (figure 1.13) identified by the group Dive et 
al. in 1999 (Dive et al. 1999). A phosphinic tetrapeptide, this inhibitor is 1000-fold 
more selective for the N-terminal than the C-terminal of ACE. This selectivity was 
attributed to the presence of a C-terminal amide group, an N-terminal acetyl group 
and an aspartic side chain in the P’2 position of the inhibitor. The structural design of 
RXP 407 was found to inhibit binding of the inhibitor to the C-domain of ACE while 
binding to the N-domain was well-tolerated by the enzyme. As such, the domain-
selectivity of RXP 407 is duly ascribed to the antagonistic nature of its structural 
design towards the C-domain. (Dive et al. 1999) 
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Figure 1.12 The chemical structure of RXP 407 (N-selective ACE inhibitor) 
 
In vitro studies by Dive et al. (1999) with RXP 407 showed that the N-domain of ACE 
was chiefly responsible for metabolizing the peptide AcSDKP (acetyl-Ser-Asp-Lys-
Pro-COOH). Later in vivo studies with mice demonstrated that selective inhibition 
with RXP 407 increased plasma AcSDKP levels by up to 6-fold (Junot et al. 2001). 
Further studies with N-domain knockout (N-KO) mice supported this finding and 
showed that AcSDKP levels are increased by 7.3-fold in N-KO mice as compared to 
wild-type (WT) mice (Nchinda et al. 2006). While classic non-selective ACE inhibition 
blocks AcSDKP degradation and elevates endogenous levels, C domain-selective 
inhibition should thus have no effect on metabolism of this peptide.  
 
1.8.3.2 THE ROLE OF THE C-DOMAIN AND RXP A380 
Following the development of RXP 407 came RXPA 380 (figure 1.12), another 
phosphinic peptide with an affinity 1000-fold higher for the C-domain than the N-
domain of ACE (Georgiadis et al. 2003). RXPA 380 is therefore a potent, highly 
specific C-terminal selective ACE inhibitor. This domain-selectivity was initially 
attributed to the presence of a pseudo-proline group at P1’ which interacted with the 
S1’ pocket of ACE, and a tryptophan group at P2’ which interacted with the S2’ pocket 
of ACE (Tzakos et al. 2005). Clarification on this topic came with the determination of 
the crystal structure of RXP A380 in complex with tACE (which has an active site 
homologous to the C-domain of somatic ACE). RXP A380’s domain selectivity was 
explained by the interaction of bulky moieties (in this case tryptophan) at the P2’ 
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position with residues unique to the C-domain in the S2 and S2’ ACE subsites 
(Corradi et al. 2007). 
 
Figure 1.13 The chemical structure of RXP A380 (C-selective ACE inhibitor) 
 
In vitro studies with RXPA 380 originally showed that both domains are responsible 
for degrading both Ang I and Bradykinin.  However, in the case of Ang I in vivo 
studies have shown that the C-domain demonstrates far more efficient cleavage than 
the N-domain and is thus chiefly responsible for Ang II production and blood 
pressure regulation (Georgiadis et al. 2003; Junot et al. 2001).  
This discrepancy was further confirmed by the group of Bernstein et al., who 
demonstrated that in ACE N-domain knockout (N-KO) mice with normal blood 
pressures, plasma renin and Ang II levels were identical to those of wild-type (WT) 
mice. However, in C-domain knockout (C-KO) mice, while the animals’ blood 
pressures were normal, their plasma renin and Ang II levels were found to be 
significantly greater - by 2.6-fold and 7-fold respectively - than those of their WT 
counterparts (Bernstein et al. 2011). This as a consequence of the inefficiency of the 
N-domain to cleave Ang I and resultant overexpression of both renin – and 
consequently Ang II – in an effort to maintain normal BP in these animals.  This study 
provides strong evidence for both the inefficiency of the N-domain in terms of Ang II 
production as well as the different mechanisms by which ACE-mediated Ang I 
metabolism occurs under in vivo and in vitro conditions.  
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Based on the current body of work concerning the differing roles of the two ACE 
domains, it appears that a C-domain selective ACE inhibitor should have a more 
desirable clinical profile than non-selective ACE inhibitors. Despite the success of 
non-selective ACE inhibitors in the treatment of cardiovascular diseases and 
hypertension, angioedema associated with ACE inhibition is a serious side-effect that 
can only be remedied by discontinuing ACE inhibitor therapy. Bradykinin 
accumulation has been implicated in the development of angioedema during both 
ACE inhibition and dual ACE-NEP inhibition. The opportunity to reduce the effect of 
dual-domain ACE inhibition on bradykinin metabolism by developing a domain-
selective ACE inhibitor presents an attractive option for future, rational drug design. 
As in vivo studies have convincingly demonstrated the critical role of the C-domain in 
Ang II production and blood pressure control in vivo, inhibition of this domain in 
pathophysiological conditions is essential. Based on our current understanding, a C-
domain selective ACE inhibitor should attain an acceptable level of inhibition of Ang II 
production in vivo while simultaneously reducing the effect of ACE inhibition on 
bradykinin plasma levels, and consequently, the incidence or severity of adverse 
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1.8.4 DEVELOPMENT OF LISINOPRIL-TRYPTOPHAN: A C-DOMAIN SELECTIVE 
ACE INHIBITOR 
 
Figure 1.14 Crystal structure of human somatic ACE in complex with the ACE inhibitor lisinopril (Kanemitsu 
et al. 2006) 
 
The three-dimensional structure of ACE was first elucidated through X-ray 
crystallography visualisation of human tACE (representing only the C-domain of 
ACE) in complex with the ACE inhibitor lisinopril (figure 1.14 illustrates the more 
recent visualisation of lisinopril in complex with somatic ACE) (Natesh et al. 2003). 
The three-dimensional visualization finally revealed the molecular basis behind the 
ACE substrate-binding pockets and their interactions with lisinopril, as well as 
demonstrating that human ACE bears little resemblance to carboxypeptidase A 
(which was used as the basis for second generation ACE inhibitor drug design). 
Insights into the significance of the S1, S1’ and S2’ pockets of ACE in the binding of 
this complex highlighted their importance for future rational drug design (figure 1.15). 
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The S2’ subsite was found to be particularly crucial to the potency of lisinopril, as the 
interaction of this inhibitor’s P2’ moiety at this subsite actually increases ACE potency 
by 25-fold (Patchett et al. 1985).  
 
Figure 1.15 Lisinopril (yellow) in complex with human tACE – significant binding subsites are circles and 
labeled in red. 
 
The Sturrock group extended on the work done by Dive et al. on domain-selective 
ACE inhibitors by incorporating the key feature of RXP A380 – the tryptophan moiety 
– into the P2’ position of the clinically available ACE inhibitor lisinopril (Nchinda, 
Chibale, Redelinghuys, et al. 2006). The chemical structures of lisinopril and its 
analogue are presented below in figure 1.16. This approach was taken as a C-
domain selective ACE inhibitor with the favourable pharmacological profile and 
efficacy of lisinopril holds significant therapeutic potential. Synthesis of this lisinopril 
analogue – referred to as lisinopril-tryptophan or lisW – produced a diastereomeric 
mixture of two isomers requiring purification and separation by HPLC. In vitro 
inhibition assays confirmed the inhibitory potential of these two compounds, and 
found that they inhibited only the C-domain, although they differed in terms of Ki 
values. Modeling of the two compounds with both tACE (for the C-domain) and a 
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observations of C-domain selectivity. The conclusion of this work was that the S-
enantiomer was determined to be 100-fold more selective for the C-domain than 
lisinopril (which has a C-domain-selectivity of 2.6 fold), while the second analogue 
was found to be just 25-fold more C-domain selective than lisinopril. The more 
selective LisW-S enantiomer was thus chosen for future ACE inhibitory studies, 




Figure 1.16 The chemical structures of lisinopril and LisW-S 
 
Further studies by the Sturrock group to assess the inhibitory potential of the novel 
C-domain selective inhibitor led to the successful modeling of lisW-S complexed with 
tACE. These studies clearly demonstrated the depth of the S’2 pocket of ACE, which 
accommodated lisW-S’s bulky P’2 moiety with ease. This modeling also revealed 
additional binding interactions between lisW-S and C-domain specific S’2 residues 
that are not observed in the lisinopril-tACE complex, and could therefore be 
responsible for the 258-fold greater selectivity demonstrated by lisW-S towards the 
C-domain (as opposed to the 2.6-fold selectivity of lisinopril for this domain) in vivo. 
This work further supported the implications presented in previous studies evaluating 
the importance of the deep S’2 subsite and its interaction with a bulky P’2 moiety on 
the conformation and C-domain-selectivity of ACE inhibitors (Georgiadis et al. 2004; 
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Natesh et al. 2004). Co-crystallization of both lisinopril and the chosen lisW-S 
enantiomer with tACE also showed the similarity of their conformation when binding 




Figure 1.17 LisW-S (in grey) takes a similar conformation to lisinopril (in black) when binding to the active 
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1.9 AIM  
As described in the previous section, this ACE inhibitor has been extensively 
characterized in vitro by the Sturrock group and its domain-specificity both quantified 
and validated with inhibition assays and modeling of the compound to both the tACE 
molecule (homologous with the C-domain of ACE) and the molecular recombinant N-
domain of ACE. The results of this work showed that lisW-S has the potential to fulfill 
the role of a successful C-domain specific ACE inhibitor.  
Our knowledge of the RAS and the complex interdependency of the cascade on RAS 
peptide levels as described in this chapter presents an enticing opportunity to apply 
the C-domain selective inhibitor LisW-S therapeutically in an effort to improve the 
clinical profile of ACE inhibition. The most common adverse side-effect of non-
specific ACE inhibitor treatment is the persistent cough experienced by up to 35% of 
patients and believed to be attributable to elevated levels of bradykinin. A less 
common but life-threatening side-effect is angioedema, affecting up to 2.2% of 
patients. As described in section 1.8.2, there is evidence to suggest that this too is a 
result of bradykinin accumulation.  
Sections 1.8.3.1 and 1.8.3.2 addressed our current knowledge of the physiological 
roles of each ACE domain and their influence on both RAS and non-RAS peptide 
levels. The work of Bernstein et al. in domain knockout mice was particularly 
enlightening with regards to the domain-specific actions of ACE in a physiological 
model. Indeed, this work reminds us that results in vitro do not necessarily predict 
results in vivo, as prior in vitro studies suggested that both ACE domains were 
responsible for metabolizing Ang I and Bradykinin, while Bernstein and others have 
shown that the C-domain is chiefly responsible for Ang II degradation.  
The sum of our knowledge on the roles of the C- and N-domains of ACE are 
summarized in Figure 1.11. The hypothesis is thus that a C-domain specific ACE 
inhibitor should largely inhibit Ang I metabolism and subsequent Ang II generation as 
well as partly inhibit Bradykinin breakdown and the subsequent rise in this peptide’s 
levels as observed with non-selective ACE inhibition. In addition, as the N-domain 
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remains unaffected, we would expect to see a rise in levels of the cardioprotective 
peptides Ang (1-7) and AcSDKP – both of which would be expected to have positive 
effects post-MI. Ang (1-7) forms part of the alternative axis of the RAS (reviewed in 
section 1.5.1) and elevated levels of this peptide in a pathophysiological setting has 
the added advantage of providing greater insight into the counter-regulatory effect of 
this axis on Ang II. The role of Ang (1-7) is briefly reviewed in section 1.5.1 and more 
extensively discussed in section 4.6.5, while AcSDKP is reviewed in section 1.7.3. 
The long-term aim of this research is to establish the potential of a C-domain specific 
ACE inhibitor as a superior therapeutic option to currently available non-specific ACE 
inhibitors. To this end, the aim of this work was the initial characterisation of the 
novel C-domain specific ACE inhibitor LisW-S in an animal model of MI. Given the 
complexity of the RAS and the range of physiological effects resultant from 
activation, a strong understanding of the specific effects of lisW-S on relevant RAS 
peptides in vivo is essential. Thus, the main aim of this study was to deliver and 
reach therapeutic circulatory levels of lisW-S in a rat model of MI and to assess 
quantitatively the effects of this novel ACE inhibitor on the RAS cascade. Importantly, 
the availability of highly sensitive assays and techniques for plasma peptide 
quantification was a major determinant in the design of this study.  
The clinical outcomes of this treatment were not measured or considered at this 
stage. As reviewed in this chapter, ACE inhibitors are responsible for a range of 
physiological effects, many of which are inter-dependent and thus do not necessarily 
offer an accurate view of RAS peptide levels.  
Three main objectives were pursued in order to achieve this characterization. 
In the first objective, enzyme kinetics and inhibition assays were utilized to assess 
the inhibitory potential and domain-selectivity of the novel ACE inhibitor in an 
extracellular environment relevant to clinical application – namely plasma.  
Once domain-selectivity and effective inhibitory concentrations were established in 
plasma, the bioavailability and achievable dosages of LisW-S in a rat model were 
determined in a range of pharmacokinetic studies.  
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Finally, the in vivo domain-selectivity and therapeutic potential of LisW-S in terms of 
RAS management was evaluated by quantifying the peptide products of the RAS 
cascade using a novel technique known as RAS-fingerprinting. As a long-tem goal is 
the determination of efficacy of LisW-S in reducing pathological remodeling post-MI 
and ACE inhibitors are a frontline treatment post-MI, the impact of LisW-S on RAS 
peptides (and other relevant peptides) was assessed in a rat MI model.  
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Chapter 2 INHIBITION ASSAYS 
2.1  INTRODUCTION 
A series of inhibition assays were performed to assess the C-domain specific 
inhibitory efficacy of lisW-S in vitro in rat plasma. These assays also aided in 
determining the plasma lisW-S concentration required to obtain an effective inhibitory 
dosage in the animals for the proposed MI studies. 
The assay needed to be optimized for use with rat plasma specifically, as the 
proposed RAS peptide level studies with lisW-S would be conducted in vivo in a rat 
model. It was important to validate the C-domain specificity of lisW-S in rat plasma. 
LisW-S is a known C-domain selective inhibitor of human ACE, and so human serum 
was used as a control to validate the assays. Although inhibition profiles were 
obtained by Nchida et al. (2006) in their development of lisW-S, these were 
performed on isolated human recombinant ACE domains in the absence of any 
plasma or serum.   
The work of Jullien et al. (Jullien et al. 2006) highlighted the disparity in both ACE 
inhibitor and substrate specificities between different ACE species. The difference 
between species’ domain selectivity of the substrates Mca-Ala-Ser-Asp-Lys-DpaOH 
(Mca-Ala) and Mca-Arg-Pro-Pro-Gly-Phe-Ser-Pro-DpaOH (Mca-BK(1-8)) were 
explored in this work. The selectivity of the Mca-Ala for the N-domain was shown to 
vary significantly between rat and human ACE. Mca-Ala is an N-domain selective 
substrate for human ACE, but appears to be much more selective for the C-domain 
in rat ACE.  Inhibition profiles of Mca-BK(1-8)) showed that while all three species do 
display C-domain selectivity towards this substrate, rat ACE has substantially the 
highest substrate affinity (while mouse ACE had the lowest). Differences in the 
binding affinity of the inhibitor RXP 407 to the C- and N-domains of mouse, rat and 
human ACE were also observed. RXP 407 is a known N-domain specific inhibitor of 
human ACE (Dive et al. 1999) and displays a similar profile in the mouse. Binding of 
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this inhibitor to rat ACE demonstrated a slightly lower affinity for the N-domain as 
compared to the other two species, but was still N-domain selective.  
The conclusion of this work was that there are significant differences between 
human, mouse and rat ACE in terms of domain selectivity. These distinctions have 
only recently come to light, and make a compelling case for the need to define 
domain-selective inhibitor specificity in rat ACE prior to embarking on rat model-
based efficacy studies. 
 
2.1.1  QUANTIFICATION OF ACE ACTIVITY 
An in vitro technique to measure the catalytic activity of ACE is an essential tool in 
the development of pharmacological interventions with the potential for more 
stringent management of the RAS in a clinical setting. The first successful technique 
was developed in 1971 and played an integral role in the development and synthesis 
of the first ACE inhibitor, Captopril (Cushman et al. 1971). The concept was based 
on the hydrolysis of a substrate by ACE and the quantification of the hydrolytic 
product by spectrophotometry. The development of this spectrophotometric assay 
facilitated the discovery of the first ACE inhibitory peptides. 
Other methods to measure ACE activity in human serum include fluorometric 
(Friedland et al. 1976; Carmel et al. 1979), radiometric (Rohrbach 1978), 
radioimmunoassay (Hiwada et al. 1987) and HPLC (Meng & Oparil. 1996). While all 
of these techniques have had a place in ACE activity research for decades, they do 
have serious limitations. These include low sensitivity, expense and complexity, as 
well as the inability to continuously monitor the enzymatic reaction.  
Fluorescence resonance energy transfer (FRET) is a highly sensitive fluorometric 
technique used to measure ACE activity.  The process is rapid and samples are 
assayed directly in the fluorometer in either a cuvette or a plate. Most importantly, 
measurable fluorescence occurs immediately after substrate hydrolysis, allowing for 
continuous assessment of ACE activity over a specific period.  
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2.2.2.1  FLUORESCENCE RESONANCE ENERGY TRANSFER 
Fluorescent resonance energy transfer (FRET) is an assay comprising of a 
fluorescent donor group attached to one amino acid residue in the peptide sequence 
and a quenching acceptor group attached to another residue in the sequence. Prior 
to cleavage, excitation of the donor group releases fluorescence which is quenched 
by the closely situated acceptor group. If cleavage occurs at any point between the 
donor/ acceptor pair, the donor group is released and is no longer in close proximity 
to the acceptor. Fluorescent excitation of the donor emits fluorescence which is no 
longer quenched by the acceptor, and thus can be measured continuously, providing 
a quantitative measurement of enzyme activity (figure 2.1).  
 
 
Figure 2.1 FRET is a distance-dependent excited state interaction in which emission of one fluorophore is 
coupled to the excitation of another. (Adapted from Carmona et al. 2006) 
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The specific fluorogenic substrates developed for assaying ACE activity were initially 
based on the bradykinin sequence. Bradykinin was chosen as it has a Km value for 
hydrolysis by ACE that is 100 x lower than that of angiotensin I (Dorer et al. 1974) (E 
G Erdös 1975). The bradykinin analogues were synthesized and the donor/ acceptor 
pair Abz (ortho-aminobenzoic acid) and EDDnp (N-[2,4-dinitrophenyl]-
ethylenediamine) were added to the N- and C-terminal respectively. These internally 
quenched bradykinin-related peptides were successfully hydrolysed by ACE and 
enzyme activity was determined in human plasma (Araujo et al. 1999).  
Following on this work, the same group investigated the substrate specificity 
requirements of the C- and N-domain of ACE (Araujo et al. 2000). This study 
assayed the activity of two full-length ACE mutants, each with a single functional site 
– either the C- or N-domain. Two bradykinin-related peptides based on the Abz/ 
EDDnp donor/ acceptor pair were used as substrates for ACE mutant hydrolysis. The 
result was the synthesis of the first domain specific bradykinin-related peptide 
substrates – Abz-GFSPFFQ-EDDnp was found to be preferentially hydrolysed by the 
C-domain of ACE, while Abz-GFSPFQQ-EDDnp was shown to be N-domain specific. 
A further advance was the successful synthesis of an AcSDKP internally quenched 
fluorescent analogue (Abz-SDK(Dnp)P-OH), utilizing the same donor acceptor pair 
and demonstrated to be highly N-domain specific. The addition of the free C-terminal 
carboxyl group to this substrate significantly improved the cleavage efficiency by 
wild-type recombinant human ACE , making it preferable to previously developed 
bradykinin analogues. Finally, this group also synthesized the peptide Abz-
FRK(Dnp)P-OH, and showed it to be an efficiently cleaved, non-specific substrate in 
the presence of the ACE inhibitor captopril (Figure 2.2) (Araujo et al. 2000).  
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Figure 2.2 Chemical structure of Abz-FRK(Dnp)P-OH 
 
Later, Bersanetti et al. made use of positional scanning combinatorial libraries of 
FRET peptides to assess the effect of the S3 to S1’ subsites of ACE on domain 
selectivity. The result was the design and synthesis of the peptide Abz-LFK(Dnp)-
OH, which was found to be highly C-domain selective for human ACE (Figure 2.3) 
(Bersanetti et al. 2004). 
 
 
Figure 2.3 Chemical structure of Abz-LFK(Dnp)-OH 
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In this study, FRET has been employed using both the C- domain specific and non-
specific substrates – namely Abz-LFK(Dnp)-OH and Abz-FRK(Dnp)P-OH 
respectively, to characterise the domain-selectivity of the novel inhibitor lisW-S in rat 
ACE. Both the non-specific and N-domain specific inhibitors lisinopril and RXP 407 
respectively, were used comparatively and as controls throughout these assays.    
 
2.2  METHODS 
2.2.1 SUBSTRATES AND INHIBITORS 
A panel of inhibitors and FRET substrates were employed to characterise the 
domain-selectivity of LisW-S in rat ACE. Known domain specificities in human ACE 
of each inhibitor and peptide are highlighted in the table 2.1. 
 




Inhibitor Specificity in 
human 
Specificity in rat 
Abz-LFK(Dnp)-OH  C-domain Unknown 
Abz-FRK(Dnp)P-OH  Non-specific Unknown 
 Lisinopril Non-specific Unknown 
 LisW-S C-domain Unknown 
 RXP 407 N-domain N-domain 
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2.2.2 FRET PEPTIDE ASSAYS 
The powdered fluorogenic substrates Abz-LFK(Dnp)-OH and Abz-FRK(Dnp)P-OH 
(kindly provided to Prof Sturrock’s laboratory by Prof Adriana K. Carmona of the 
Federal University of São Paulo, Brazil) were prepared to an approximate stock 
solution of 10 mM in DMSO. Concentrations were confirmed spectrophotometrically 
at an absorbance of 365 nM and 10 µM working solutions were made up in Tris 
buffer (50 mM Tris (tris(hydroxymethyl)aminomethane) (pH 7.0), 50 mM NaCl and 10 
µM ZnCl2 in ddH2O). All chemicals were purchased from Sigma-Aldrich (Germany). 
Cleavage of these substrates was monitored in a continuous assay in a 96 well 
microassay plate at ambient temperature (20 – 25oC), under initial rate conditions of 
less than 10 % hydrolysis, over time (s). Briefly, in triplicate, 25 µL of a 10% human 
serum or rat plasma sample was added to substrate concentration ranges of 0 – 100 
or 0 - 500 nM, to a final volume of 300 µl in Tris buffer. Fluorescence was measured 
with excitation (Ex) at 320 nm, and Emission (Em) at 420 nm. Arbitrary fluorescent 
units (AFU) were converted to the units of number of mols of substrate hydrolyzed 
per ml of plasma per minute (nmol/ ml/ min) using a standard curve (see below). All 
figures were plotted using GraphPad Prism 5 software.  
 
2.2.3 BLOOD COLLECTION 
2.2.3.1 HUMAN SERUM SAMPLES 
Whole blood was collected from healthy volunteers by a registered medical 
practitioner at Groote Schuur Hospital, Cape Town, South Africa. Blood was 
collected into a sterile tube with no anticoagulant present and allowed to stand for 20 
to 30 minutes. Blood samples were centrifuged at 3000 g for 15 minutes (4oC). 
Serum was collected and transferred to an eppendorf tube and stored at -80oC.  
2.2.3.2 RAT PLASMA SAMPLES 
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All animal experiments were approved by the Animal Research Ethics Committee of 
the University of Cape Town and were performed in accordance with the National 
Institutes of Health (NIH, Bethesda, MD) guidelines. 
Whole blood was collected from recently sacrificed rats by cardiac puncture. 5 to 10 
ml of blood was collected per animal into a 10 ml lithium-heparin coated blood 
collection tube. The tube was inverted at least 8 times to ensure thorough mixing of 
the contents. Blood samples were centrifuged at 3000 g for 15 minutes (4oC). 
Plasma was collected and transferred to an eppendorf tube and stored at -80oC. 
 
2.2.4 STANDARD CURVE 
Standard curves of AFU vs. nmol/ml/min were generated for both human serum and 
rat plasma for the determination of hydrolytic activity of respective rat and human 
ACE in further assays. Species-specific samples were pooled to ensure the accuracy 
of the assays and avoid potential variability between plasma and serum samples.  
Briefly, a dilution series of 0.3, 0.6, 0.9, 1.2, 1.8, and 2.4 nmol/L was prepared from 
the 10 µM Abz-LFK(Dnp)-OH stock. In the initial attempt at establishing the standard 
curve, full hydrolysis was not achieved. As such, all plasma and serum samples were 
spiked with 2.4 µg tACE to accelerate hydrolysis to completion. The standard curve 
was calculated by measuring the difference between the basal fluorescence and 
fluorescence at complete hydrolysis of the standards. To obtain basal fluorescence, 
10% dilutions of plasma or serum were incubated with 50 µM lisinopril for 90 minutes 
to completely inhibit all endogenous ACE activity and effectively provide a ‘zero’ 
control. Zero samples were added to an equal volume of Tris buffer and plated in 
triplicate. Standard samples were prepared as a 10% dilution of plasma or serum in 
25 mM Tris buffer. These were added to an equal volume of the substrate dilution 
series and plated in triplicate. 
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2.2.5 INHIBITION ASSAYS 
Lisinopril (Zeneca pharmaceuticals, United Kingdom) was made up from powdered 
form to a 500 nM stock solution in ddH2O and a dilution series of 0 – 500 nM was 
prepared. LisW-S and RXP 407 were prepared from powdered form to 100 nM stock 
solutions in ddH2O. A dilution series of 0-100 nM was prepared for both inhibitors. 
Equal volumes of each inhibitor solution and 10% pooled human serum (n = 5) or 
pooled rat plasma (n = 6) were incubated for 90 minutes at ambient temperature. 
25µl of this complex was added to 275µl of 10 µM substrate in triplicate, and the 
residual activity was monitored by fluorescence as described in 2.2.2. Substrate 
concentrations were selected to ensure less than 10% hydrolysis of substrate in 
order to observe initial rate conditions. 
 
2.3 RESULTS 
2.3.1 STANDARD CURVES 
The standard curves were plotted as AFU vs. the known Abz-LFK(Dnp)-OH 
concentration (nmol) as seen in figure 2.4. A slope of 278.4 was obtained for the 
standard curve with human serum, with a curve fit of R2 = 0.9758 (figure 2.4 (a)). A 
slope of 213.7 was obtained for the standard curve with rat plasma, with a curve fit of 
R2 = 0.9757 (figure 2.4 (b)). 
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Figure 2.4 Standard curves for (a) human serum and (b) rat plasma. Standard deviation is indicated on all 
plots 
2.3.2 LISINOPRIL INHIBITION ASSAYS 
The ACE inhibitor lisinopril was used as an experimental control to validate the 
inhibition assay protocol. The inhibition profile of lisinopril on hydrolysis of the FRET 
substrate Abz-LFK(Dnp)-OH by somatic ACE in both human serum and rat plasma 
were determined. As mentioned previously, Abz-LFK(Dnp)-OH has been shown to 
be preferentially cleaved by the C-domain of human ACE. However, as seen in the 
work of Jullien et al (2006), this must be validated in rat plasma too as substrate 
specificities have been shown to differ between species (section 2.1).  
AFUs were converted to nmol Abz-LFK(Dnp)-OH hydrolysed/ml/min using the 
standard curves in figures 4 (a) and 4 (b) and taking the dilution factor of 400 into 
account. Percent inhibition was calculated by normalising the 0 pM lisinopril reaction 
values to 0% inhibition and plotted against an x-axis of the log of lisinopril 
concentration (figures 2.5 and 2.6). 
 
2.3.2.1 LISINOPRIL INHIBITION PROFILE OF ABZ-LFK(DNP)-OH SUBSTRATE IN 
HUMAN SERUM 
The results of this assay (figure 2.5) showed that a maximum of 90% inhibition of 
human somatic ACE was achieved at a lisinopril concentration of approximately 25 
pM (indicated by a red arrow). No inflection point was observed in this profile. 70% 
inhibition was observed at 2.5 pM (indicated by blue arrow).   
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Figure 2.5 Plot of % inhibition of Abz-LFK(Dnp)-OH substrate vs. lisinopril dilution series (pM) in human 
serum. Red arrow indicates  90% inhibition. Blue arrow indicates 70% inhibition. 
 
 
2.3.2.2 LISINOPRIL INHIBITION PROFILE OF ABZ-LFK(DNP)-OH SUBSTRATE IN 
RAT PLASMA 
AFUs were converted to nmol Abz-LFK(Dnp)-OH hydrolysed/ml/min using the 
standard curve in figure 2.4 (b), taking the dilution factor of 400 into account. Percent 
inhibition was calculated by normalising the 0 pM lisinopril reaction values to 0% 
inhibition and plotted against an x-axis of the log of lisinopril concentration (figure 
2.6). The results of this assay showed that rat somatic ACE was completely inhibited 
at a lisinopril concentration of approximately 50 pM (indicated by a red arrow), while 
70% inhibition was observed at 2.5 pM (indicated by blue arrow)  
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Figure 2.6 Plot of % inhibition of Abz-LFK(Dnp)-OH substrate vs. lisinopril dilution series (pM) in rat plasma. 
Red arrow indicates 90% inhibition. Blue arrow indicates 70% inhibition. 
 
2.3.3 LISW-S INHIBITION ASSAYS 
Inhibition profiles of lisW-S (C-specific for human ACE) were generated using the 
FRET substrates Abz-LFK(Dnp)-OH and Abz-FRK(Dnp)P-OH to assess the domain-
selectivity of this inhibitor on rat somatic ACE. Prior to conducting the Abz-LFK(Dnp)-
OH assay in rat plasma, the protocol was validated using human serum.  
The FRET substrate Abz-FRK(Dnp)P-OH has previously been shown to display no 
domain selectivity for human ACE. This substrate was used to further assess the 
domain-selective  behaviour of lisW-S in rat ACE and was not conducted in human 
serum. AFUs were converted to nmol Abz-LFK(Dnp)-OH/Abz-FRK(Dnp)P-OH 
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hydrolysed/ml/min using the standard curves in figures 2.4 (a) and 2.4 (b), taking the 
dilution factor of 400 into account. Percent inhibition was calculated by normalising 
the 0 nM lisW-S reaction values to 0% inhibition and plotted against an x-axis of the 
log of lisW-S concentration. 
 
2.3.3.1 LISW-S INHIBITION PROFILE OF ABZ-LFK(DNP)-OH SUBSTRATE IN 
HUMAN SERUM 
The results of this assay (figure 2.7) showed that a maximum inhibition of 80 – 85% 
was achieved at a lisW-S concentration of 100 nM (indicated by red arrow). A ten-
fold higher lisW-S concentration did not increase the percentage inhibition. No 
inflection was observed on this profile.  
 
Figure 2.7 Plot of % inhibition of Abz-LFK(Dnp)-OH substrate vs. lisW-S dilution series (nM) in human serum. 
Red arrow indicates 85% inhibition at 100 nM 
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2.3.3.2 LISW-S INHIBITION PROFILE OF ABZ-LFK(DNP)-OH SUBSTRATE IN RAT 
PLASMA 
The results of this assay (figure 2.8) showed that rat somatic ACE was completely 
inhibited (± 90%) at a lisW-S concentration of approximately 5 µM. (indicated by red 
arrow). 70% inhibition was achieved at a lisW-S concentration of 100 nM (indicated 
by blue arrow). No point of inflection was observed on this profile. 
 
 
Figure 2.8 Plot of % inhibition of Abz-LFK(Dnp)-OH substrate vs. lisW-S dilution series (nM) in rat plasma. 
Red arrow indicates 100% inhibition. Blue arrow indicates 70% inhibition at 100 nM. 
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2.3.3.3 LISW-S INHIBITION ASSAY OF ABZ-FRK(DNP)P-OH SUBSTRATE IN RAT 
PLASMA 
The results of this assay (figure 2.9) demonstrate that hydrolysis of Abz-
FRKP(Dnp)P-OH was completely inhibited at approximately 500 µM LisW-S 
(indicated by red arrow), and a clear point of inflection was observed at 
approximately 65% inhibition and between 1 and 5 µM lisW-S (indicated by blue 
arrow).  
 
Figure 2.9 Plot of % inhibition of Abz-FRK(Dnp)P-OH substrate vs. lisW-S dilution series (nM) in rat plasma. 
Red arrow indicates 100% inhibition. Blue arrow indicates point of inflection. 
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2.3.4 RXP 407 INHIBITION ASSAY OF ABZ-LFK(DNP)-OH SUBSTRATE IN RAT 
PLASMA 
The phosphinic peptide RXP 407 has previously been shown to selectively inhibit the 
N-domain of both human and rat ACE. To further characterise the domain selectivity 
of the Abz-LFK(Dnp)-OH substrate on rat ACE, the inhibition profile of hydrolysis of 
this peptide by RXP 407 was determined and compared to that of lisW-S (figure 
2.10). 
AFUs were converted to nmol Abz-LFK(Dnp)-OH hydrolysed/ml/min using the 
standard curves in figures 2.4 (a) and 2.4 (b), taking the dilution factor of 400 into 
account. Percent inhibition was calculated by normalising the 0 nM lisW-S and RXP 
407 reaction values to 0% inhibition and plotted against an x-axis of the log of both 
lisW-S and RXP 407 concentrations (figure 2.10). 
The results clearly show that rat somatic ACE inhibition occurs at a much lower 
concentration with lisW-S than that seen for RXP 407. For example complete (±90%) 
inhibition was observed at approximately 5 µM as opposed to 250 µM for LisW-S and 
RXP407, respectively.  
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2.4.1 ASSAY VALIDATION AND OPTIMIZATION 
The first aim of this study was to establish the FRET assay protocol for use with rat 
ACE and lisW-S. Lisinopril and lisW-S inhibition profiles of Abz-LFK(Dnp)-OH 
hydrolysis were successfully validated with human serum ACE before any studies 
were done to evaluate their inhibitory effects on rat ACE. The results of these assays 
on human ACE were also of interest as there is the possibility that ACE will behave 
differently with regards to inhibitor and substrate specificity between species (Jullien 
et al. 2006).  
Inhibitor (nM) 
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The assays required optimization for use with plasma and serum. An initial finding in 
the first set of assays was that rat plasma and human serum endogenously quench 
ACE activity dramatically. Attempts to eliminate or reduce the quenching effect 
observed included adding a protease inhibitor cocktail to all plasma samples, which 
had no effect, as well as enriching the ACE in plasma samples by passing plasma 
through an anti-human serum albumin (HSA) column. Unfortunately, this only 
removed approximately 2% of the total protein in the samples and was therefore not 
repeated. Maximal ACE activity was observed at a dilution of 10% human serum or 
rat plasma, and this concentration was therefore used in subsequent assays. 
When setting up the standard curve, a problem encountered was that complete 
hydrolysis was not achieved with human serum or rat plasma samples alone. The 
decision was therefore made to add purified tACE to the plasma or serum samples to 





2.4.2 ASSESSMENT OF DOMAIN-SELECTIVITY OF LISW-S ON RAT ACE 
The second aim of this study was to evaluate the C-domain selectivity of lisW-S in rat 
plasma ACE in vitro.  
The lack of an inflection in the inhibition profile obtained for lisW-S on Abz-LFK(Dnp)-
OH for rat plasma (figure 2.8) suggests either that lisW-S is not domain-selective and 
successfully blocks both domains equally, or that Abz-LFK(Dnp)-OH is exclusively 
cleaved by one domain of rat ACE.  
To further investigate the domain specificity of lisW-S on rat ACE, we employed a 
second FRET substrate, Abz-FRK(Dnp)P-OH, previously shown to be non-domain-
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specific for human ACE (figure 2.9). These results demonstrated an inflection at 65% 
inhibition at between 1 and 5 µM lisW-S. This inflection point represents the complete 
inhibition of one domain of ACE, while the other domain is still actively hydrolysing 
Abz-FRK(Dnp)P-OH, and suggests that lisW-S is indeed selective for one domain of 
rat ACE. However, this assay did not verify the specific domain-selectivity of lisW-S. 
Of interest was the inflection point at 65% inhibition as opposed to 50%, which would 
be expected for a non-selective substrate. This suggests that Abz-FRK(Dnp)P-OH 
may in fact be more domain-selective for rat ACE than non-selective, as is the case 
for human ACE. It was further noted that the concentration required of LisW-S to 
achieve the inflection point in rat plasma coincided with that required for maximal 
inhibition of Abz-LFK(Dnp)-OH. Similarly 45% inhibition of Abz-FRK(Dnp)P-OH which 
corresponds to approximately 70% inhibition of the domain being inhibited prior to 
the inflexion point is 100 nM. These correlations also suggest that Abz-LFK(Dnp)-OH 
is cleaved by the rat ACE C-domain and that this domain is preferentially inhibited by 
LisW-S. 
In order to further elucidate the particular domain-selectivity of lisW-S for rat ACE, we 
compared the effects of the known N-domain specific ACE inhibitor RXP 407 and 
lisW-S on the hydrolysis of Abz-LFK(Dnp)-OH (figure 10). The inhibition profile of 
RXP 407 demonstrated a complete shift to the right indicating that a much higher 
concentration of this inhibitor was required to block the hydrolysis of Abz-LFK(Dnp)-
OH compared to lisW-S. This provides strong evidence suggesting that Abz-
LFK(Dnp)-OH is indeed exclusively cleaved by the C-domain of rat ACE, as very 
high concentrations of the N-selective inhibitor RXP 407 were required to inhibit this 
hydrolysis. Furthermore, the much lower concentrations of lisW-S required for 
inhibition of Abz-LFK(Dnp)-OH hydrolysis strongly suggest that it is, in fact, a C-
domain selective inhibitor in rat plasma, capable of efficiently blocking hydrolysis of 
the C-selective substrate at relatively low concentrations.  
An inhibition profile of lisW-S on a known N-domain selective rat ACE substrate 
would have confirmed the C-domain selectivity of the inhibitor. Unfortunately there 
were no N-domain selective substrates available for assay in this study. There is very 
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limited information on the domain specificity of substrates for rat ACE, and Jullien et 
al. (2006) have shown that the domain specificity of substrates in human ACE do not 
necessarily correlate with that of rat ACE. For example, Mca-Ala is an N-domain 
selective substrate for human ACE, but a C-selective substrate for rat ACE. Thus the 
selection of an N-domain specific substrate to further assess the domain selectivity of 
lisW-S on rat ACE would first need to be carefully validated with known rat ACE 
domain selective inhibitors such as RXP 407 and RXPA380.  
 
2.4.3 DETERMINATION OF LISW-S DOSAGE REQUIRED FOR EFFECTIVE ACE 
INHIBITION 
The third and final aim of this study was to determine the concentration of lisW-S 
required for effective inhibition in rat ACE.  
The results of the lisinopril and Abz-LFK(Dnp)-OH inhibition assays showed that a 
concentration of 25 pM lisinopril successfully inhibited human ACE at a maximum of 
90% while 50 pM lisinopril achieved more than 95% inhibition in rat plasma ACE. 
This suggested that lisinopril is a slightly more effective ACE inhibitor in rats than in 
humans.   
The lisW-S inhibition assays using both rat and human samples and the Abz-
LFK(Dnp)-OH substrate demonstrated 70% inhibition at approximately 100 nM lisW-
S and this result was confirmed in a duplicate assay (data not shown). Using the 
molecular weight of lisW-S (494.2 g/mol), the concentration required to inhibit 70% of 
ACE activity was calculated to be 49.4 ng/ml. As these assays also showed that a 
substantially larger concentration of 494.2 ng/ml lisW-S would be required to achieve 
just 20% greater inhibition, it was decided that 70% ACE inhibition would be a 
reasonable and effective level to aim for.  It should be noted that a 1000-fold lower 
concentration of lisinopril (0.1 nM) achieved complete inhibition in rat ACE, 
suggesting that lisinopril is a vastly more effective ACE inhibitor than lisW-S of rat 
ACE in plasma. This was further verified in the inhibition assays conducted with 
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human serum, where lisinopril was shown to be more effective than lisW-S by 
approximately 4000-fold. The results of the lisW-S inhibition assays were used for 
the subsequent pharmacokinetic studies, which were aimed at verifying the 
administered dose of lisW-S that would be needed to achieve a 100 nM (50 ng/ml) 
plasma concentration and 70% ACE inhibition in vivo.  
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Chapter 3 PHARMACOKINETICS 
3.1 INTRODUCTION 
A series of pharmacokinetic (PK) studies were done in order to assess the 
bioavailability, behaviour and stability of LisW-S in vivo. LisW-S was administered by 
three routes: intravenous (IV) injection, oral gavage and subcutaneous mini-osmotic 
pump infusion. In addition, studies were conducted with lisinopril to serve as a 
closely matched control and to evaluate its ACE inhibitory action in a rat model in 
vivo.  
The primary purpose of these studies was, first, to assess the bioavailability of lisW-
S, and second, to determine whether an in vivo dosage could be achieved that 
allowed for adequate inhibition. It was reasoned from the ex vivo studies detailed in 
chapter 2 that a plasma concentration of approximately 40-50 ng/ml would be 
minimally required to achieve significant inhibition. In addition, two routes of 
administration (oral and pump infusion) were evaluated in order to decide which one 
provided the best constant dose in the therapeutic range desired for ACE inhibition 
over a given period of treatment. LisW-S was also converted into a maleate salt in an 
effort to enhance bioavailability.  
 
3.2 PHARMACOKINETICS OF LISINOPRIL 
The main goal of the PK studies was the determination of an optimal and effective 
dosing regimen for the administration of lisW-S. As lisW-S is closely related to 
lisinopril, PK studies of lisinopril are discussed below. Lisinopril was developed in the 
late 1970’s, and PK data was first collected on this compound’s behaviour in the 
1980’s. With 30 years worth of research on the subject, the PK behaviour of lisinopril 
in human subjects is well-established. 
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In a clinical setting, Lisinopril is administered orally once a day. It has a bioavailability 
of approximately 25-30% in normal subjects (Ulm et al. 1982; Beermann et al. 1989) 
although this value varies widely between individual patients. Absorption is not 
affected by food intake (Mojaverian et al. 1986) and a twice daily dose ensures that 
plasma concentrations reach a steady state within 24 hours. The plasma half-life for 
this drug is estimated to be about 12 hours, and peak serum concentrations are 
reached within 6 to 8 hours. Terminal serum half-life is estimated to be about 40 
hours. Lisinopril is not metabolized, but is eliminated completely unchanged by the 
kidneys. (Ulm et al. 1982; Dickstein 1987; Gomez et al. 1987; Bjorn 1988; Beermann 
et al. 1989) 
Although direct PK studies on lisinopril have not been reported for the rat model, 
plasma ACE activities in both dogs and rats have been measured in the 24 hours 
following oral lisinopril administration. Hamlin et al. administered lisinopril to healthy 
dogs at an oral dose of 0.5 mg/kg. ACE activity in plasma samples was analysed by 
ultraviolet-kinetic techniques. This study found that ACE was inhibited between 1.5 
and 3 hours after administration of the ACE inhibitor. However, after the 3 hour time 
point, ACE activity rapidly increased and it was surmised that plasma lisinopril 
concentrations were no longer within a therapeutic range. (Hamlin & Nakayama 
1998) 
Jackson et al. measured the ACE activity in rat plasma and tissue homogenates 
using quantitative radioinhibitor binding. Plasma ACE was acutely inhibited within 2 
hours of administration of a 10 mg/kg dose. ACE remained effectively inhibited for a 
further 6 hours, and only began to rise again after the 8 hour time point. This is 
somewhat in accordance with human PK studies of lisinopril, which observe a peak 
plasma concentration – and presumably maximum ACE inhibition – 6 hours after 
administration. (Jackson et al. 1987) 
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3.3.1 HPLC PURIFICATION OF LISW-S 
Once the lisW-S ACE inhibitor had been synthesized, it required purification on a 
High Performance Liquid Chromatography (HPLC) column with a low pH 
trifluoroacetic acid (TFA) buffer. 
Lisinopril did not require any purification as it is commercially available and was 
purchased from Zeneca Pharmaceuticals (United Kingdom). 
RP-HPLC purification and separation of the diastereomeric lisW-S mixture was 
performed using a Jupiter 5U C18 300A, size 250 x 4.60 mm column with gradient 
elution of  t = 0 min (50% A, 50% B) and t = 50 min (40% A, 60% B); solvent A = 
0.1% TFA in H2O (or 10 mM HCl) and solvent B = 0.1% TFA (or 10mM HCl) and 
75% CH3CN in H2O; a flow rate of 1.0 mL/min and a 215 and 280 nm UV wavelength 
detection.     
(HPLC methods have been adapted from the supplementary material in Nchida et al. 
(2006). All chemicals were purchased from Sigma-Aldrich (Germany). 
 
3.3.2 SALT FORMATION OF LISW-S 
LisW-S was converted to a maleate salt by neutralization in a basic solution to form a 
lisW-S/MS analogue.  
Salt formation is a commonly used and highly effective method of increasing both the 
solubility and dissolution rates of acidic and basic drug compounds (A.T.M. 
Serajuddin 2007). It is the most utilized method of improving the solubility of liquid 
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solutions administered parenterally (Sweetana et al. 1996). The widely-used ACE 
inhibitor enalapril is also administered in an oral maleate salt form (Davies et al. 
1984). 
  
3.3.3 ORAL GAVAGE 
LisW-S and lisinopril were prepared by weighing out the powder form and dissolving 
it in ddH2O to the required concentration. Both lisW-S and lisinopril were 
administered at a dosage of 5 mg/kg. Animals were weighed immediately prior to 
gavage, and the dose adjusted accordingly. All animals were administered 1 ml of 
the ACE inhibitor solution and blood samples were taken at -5 minutes (‘zero’ time 
point prior to administration), 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours 
and 24 hours post-administration. 
 
3.3.4 INTRAVENOUS INJECTION 
The lisW-S solution was made up from the powdered form in ddH2O to the required 
volume and concentration and filter-sterilized. Animals were restrained in a custom-
built rodent restrainer which granted access to the tail. The injection site was cleaned 
with an alcohol swab. A minimum volume of 100 µl was injected into the tail vein, 
although this was adjusted according to weight. Haemostasis at the injection site was 
ensured by applying pressure to the area with a gauze swab.  
3.3.5 MINI-OSMOTIC PUMP IMPLANT 
3.3.5.1 PUMP SELECTION 
A long-term aim is the assessment of lisW-S efficacy in the context of a rat MI model 
and therefore a pump was chosen that was designed to deliver a solution 
continuously for 28 days. This pump has a volume of approximately 220 µl and a 
pump rate of 0.25 µl/hr (Model 2004, Alzet). The solubility of lisW-S also had to be 
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considered, as the maximum concentration that could be obtained in solution with 
ddH2O was 30 mg/ml. The following equation was used: 
ko (µg/hr) = Q (µl/hr) x Cd (µg/µl); 
Where ko is the mass delivery rate, Q is the pumping rate of the selected model, and 
Cd is the concentration of the drug solution. Using this equation, the mass delivery 
rate was ascertained to be 7.5 µg/ hour or 180 µg/ day. 
 
3.3.5.2 PUMP PREPARATION 
Alzet micro-osmotic pumps were prepared under sterile conditions, as per the 
manufacturer’s instructions. The solutions of lisW-S and lisinopril were made up from 
the powdered form in ddH2O to the required volume and concentration and filter-
sterilized. Pumps were filled as per the manufacturer’s instructions. After filling, 
pumps were transferred to a 50 ml tube filled with 0.9% sterile saline solution and 
placed in the incubator at 37oC (5% CO2) for 48 hours as recommended by the 
manufacturer. This pre-incubation period ensures that the pumps are fully functional 
upon subcutaneous implant. 
 
3.3.5.3 ANAESTHESIA AND PREPARATION 
The rat was initially anaesthetized by being placed in an induction chamber for a 
minimum of 2.5 minutes. During the induction phase the vaporizer was set to 
anaesthetize the animal with 5% Isoflurane, at a flow rate of 1.5% Oxygen. At the 2.5 
minute mark, the animal was removed from the chamber, weighed (and body weight 
recorded), and an area of the back lateral to the spinal column was shaved. The 
animal was then transferred in a prone position to the pre-warmed operating table (a 
heating pad maintained the table at approximately 37oC) and a nose cone was 
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placed over the snout. Anaesthesia was adjusted and maintained with 1.5 - 2% 
Isoflurane and 0.3% oxygen for the duration of the procedure.  
The animal was secured in a prone position with surgical tape and two front paws 
and one distal paw were taped down. The remaining paw was left free to monitor 
depth of anaesthesia during surgical procedure (movement of the paw is indicative of 
a decrease in anaesthesia depth). The surgical area was then cleaned with an iodine 
solution. Depth of anaesthesia was checked by non-responsiveness to a tail pinch 
with forceps.  
 
3.3.5.4 SURGICAL PROCEDURE 
A small 1 to 1.5 cm skin incision was made to the right of and at a 90o angle to the 
spinal column, approximately midway between the front and hind legs. The skin was 
raised with toothed forceps and a haemostat was gently inserted into the 
subcutaneous space. The haemostat was used to create a pocket of sufficient size to 
accommodate the mini-osmotic pump. The pump was then handled sterilely and 
inserted inside the subcutaneous pocket. The incision was closed with 4-0 silk 
sutures, and the surgical area was cleaned with iodine solution. An analgesic dose of 
0.05 mg/kg buprenorphine was administered by intramuscular injection to the hind 
leg. The average duration of the procedure was 10 to 15 minutes.  
 
3.3.5.5 POST-OPERATIVE CARE 
The animals were monitored daily for the duration of the study. Water and food 
intake was monitored, and their weights were recorded once a week. The incision 
site and sutures were checked for the first three days post-surgery to ensure 
adequate healing. A single dose of analgesic (0.05 mg/kg buprenorphine) was 
administered 24 hours post-surgery.  
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3.3.6 BLOOD SAMPLING 
Following administration of lisinopril or lisW-S, blood sampling at specified time 
intervals was required for periods of 24 hours up to 4 weeks. The same procedure 
was followed for each blood sample taken.  
 
3.3.6.1 PREPARATION 
Animals were placed in a chamber heated to 45oC 5 to 10 minutes prior to sampling 
in order to aid blood flow following venipuncture of the tail vein. 
 
3.3.6.2 PROCEDURE 
As anaesthesia was not recommended for the LC/MS/MS sample analysis, the 
animals were restrained in a custom-made rodent restrainer which allowed access to 
the tail vein.  
The venipuncture site was cleaned with an alcohol swab. A 26G needle was used to 
draw a 100ul blood sample into a 1ml syringe. The needle was then removed from 
the syringe to prevent haemolysis of the blood sample upon injection. The sample 
was injected into a 2ml lithium-heparin coated blood collection tube. The tube was 
inverted at least 8 times to ensure thorough mixing and kept at room temperature. 
Haemostasis at the blood collection site was ensured by applying pressure to the site 
with a gauze swab.  
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3.3.6.3 PLASMA COLLECTION 
Blood samples were centrifuged at 3000 g for 15 minutes (4o C). Plasma was 
collected and transferred to an eppendorf tube and stored at -80oC.  
 
3.3.7 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (LC/MS/MS) ANALYSIS 
LisW-S was analyzed using a validated LC/MS/MS assay protocol established for 
this study.  A protein precipitation extraction method using 100 µl plasma and 200 µl 
methanol was employed to process the samples. The precipitation solvent was 
spiked with the internal standard Verapamil at a concentration of 14 ng/ ml. Isocratic 
chromatography was performed on a Phenomenex, Luna 5 µm PFP(2), 100 A, 50 
mm × 2 mm analytical column, using acetonitrile, methanol and 0.1% formic acid as 
a mobile phase (15:15:70), and was delivered at a flow rate of 300 µl/min.  An AB 
Sciex API 4000 mass spectrometer was operated at unit resolution in the multiple 
reaction monitoring (MRM) mode, monitoring the transitions of both the protonated 
molecular ions at m/z 495.0 to the product ions at m/z 84.3 for lisW-S, and the 
protonated molecular ions at m/z 455.1 to the product ions m/z 165.5 for the internal 
standard.   
The accuracies obtained for lisW-S were between 96.4% and 102.8% at low, 
medium and high quality control (QC) levels during inter-batch validation.  The 
precision for lisW-S during inter-batch validation was less than 7.6% at low, medium 
and high QC levels.  The calibration range for lisW-S was between 7.04 and 451 
ng/ml.  
The same protocol was used for lisinopril analysis by LC/MS/MS assay. 
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3.4 EXPERIMENTS 
3.4.1 PILOT PK STUDY: LISW-S AND LISINOPRIL 
A pilot study was conducted in order to assess the plasma concentrations of lisW-S 
and lisinopril that could be achieved in vivo following oral gavage. The initial planned 
experimental procedure was to administer a single dose of lisW-S by oral gavage 
once every 24 hours, thereby mimicking a clinical setting and a daily dose of ACE 
inhibitors as prescribed to the patient.  
 
3.4.1.1 EXPERIMENTAL DESIGN 
The pilot study comprised a total of 12 rats (n= 6 for the lisinopril group, and n = 6 for 
the lisW-S group). LisW-S purified by HPLC with TFA buffer was used (LisW-S/TFA). 
All compounds were administered by oral gavage, at a concentration of 5 mg/kg and 
a constant volume of 1 ml with dH2O as solvent. All rats were in the weight range of 




3.4.1.2.1 LISINOPRIL  
The concentration vs. time profile of  lisinopril is presented in figure 3.1.  A maximum 
plasma concentration of 129.1 ± 43.7 ng/ml  was measured at the 1 hour time point.  
At the 4 hour time point this concentration had decreased slightly to 98 ± 43.6 ng/ml, 
after which the drug concentration decreased steadily to baseline levels (12.8 ± 6.9 
ng/ml) at 12 hours.  
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Figure 3.1 Mean concentrations of lisinopril (ng/ml) vs. time (n=6) 
 
Table 3-1 Mean concentrations of lisinopril (ng/ml) at various time points 
 
 






















Time point 0 hr 0.5 1 hr 4hr 8hr 12hr 24hr 
Mean Concentration (ng/ml) 0 46.3 129.1 98.0 44.8 14.9 12.8 
ST DEV (ng/ml) 0 18.6 43.7 43.6 20.0 6.0 6.9 
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As seen in figure 3.2 and table 3.2, LisW-S/TFA reached a maximum concentration 
of approximately 46.2 ± 11.5 ng/ml by the 1 hour time point, after which a gradual 
decline to 34.1 ± 15.1 ng/ml was observed until the 4 hour time point. By 8 hours, 
plasma concentration levels had dropped significantly to 13.1 ± 7.6 ng/ml and by 12 
hours they had returned to baseline values. 
 
 
Figure 3.2 Mean concentrations of lisW-S/TFA (ng/ml) vs. time (n=6) 
 





















0 hr 0.5 1 hr 2hr 4hr 8hr 12hr 24hr 
Mean Concentration (ng/ ml) 8.8 19.4 46.2 39.5 34.1 13.1 6.4 4.6 
ST DEV (ng/ml) 8.2 14.0 11.5 15.2 15.1 7.6 1.9 0.5 
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3.4.2 LISW-S MALEATE SALT 
3.4.2.1 EXPERIMENTAL DESIGN 
In an effort to enhance the bioavailability of lisW-S the compound was converted to a 
maleate salt form (LisW-S/MS). This increased the weight of the compound by 20%, 
and so all dosages were adjusted accordingly. A total of 5 rats weighing between 180 
and 250g were used. LisW-S/MS was administered by oral gavage at a dosage of 5 
mg/kg and a constant volume of 1 ml with dH2O as solvent. Blood samples were 
collected at the following time points: zero (prior to administration), 1 hr, 2 hrs, 4 hrs, 
8 hrs, 12 hrs and 24 hrs after pump implant. 
 
3.4.2.2 RESULTS 
The results were similar to those obtained in the pilot gavage study with lisW-S/TFA 
(see figure 3.2). As seen in figure 3.3 and table 3.3, LisW-S/ MS salt reached a peak 
plasma concentration of 52 ± 24.4 ng/ml by the 2 hour time point, after which levels 
steadily declined until returning to baseline by the 24 hour time point. 
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Figure 3.2 Mean concentration of lisW-S/MS (ng/ml) salt dosage vs. time (n=5) 
 
Table 3-3 Mean concentration lisW-S/MS (ng/ml) at various time points 
 
3.4.3 BIOAVAILABILITY EVALUATION: LISW-S 
On completion of the pilot study, the next objective was to determine the oral 
bioavailability of lisW-S. Oral and intravenous (IV) single dose regimens are used to 
calculate the percentage oral bioavailability of a drug. This was assessed by 
comparing the dosage and AUC (Area Under the Curve – referring to the curve 






















Zero 1 hr 2hr 4hr 8hr 12hr 24hr 
Mean concentration (ng/ ml) 0.0 35.8 52.0 39.8 21.0 13.7 2.4 
ST DEV (ng/ml) 0.0 16.5 24.4 21.6 6.4 4.1 4.1 
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administration against the dosage and AUC obtained with IV administration of lisW-
S. Absolute bioavailability is defined as the fraction of the drug absorbed (F), and is 
calculated as follows:    
𝐹 =   
𝐴𝑈𝐶 𝑜𝑟𝑎𝑙
𝐴𝑈𝐶 𝐼𝑉





3.4.3.1 EXPERIMENTAL DESIGN 
In order to evaluate bioavailability, two animal experiments were required; one in 
which lisW-S/ TFA was administered orally, and one in which lisW-S/ TFA was 
administered intravenously. LC/MS/MS assay of the plasma samples obtained from 
these two studies enabled us to plot graphs of plasma drug concentration (ng/ ml) vs. 
time and calculate the AUC for each group in order to obtain a final F value. 
 
3.4.3.1.1 ORAL GROUP 
LisW-S/ TFA was administered by oral gavage at a dosage of 5mg/ kg to 20 animals. 
Blood samples were collected into heparinised tubes at the following time points: 0, 
1, 2, 4, 8, 12 and 24 hours after administration. Samples were centrifuged and 
separated and plasma was stored at -80oC.  
 
3.4.3.1.2 INTRAVENOUS GROUP 
LisW-S/ TFA was administered intravenously via the tail vein at a dosage of 1 mg/ kg 
to 6 animals. Blood samples were collected at the following time points: 0, 5 minutes, 
1, 2, 4, 8, 12 and 24 hours after administration.  
 
 Chapter 3  
  80 
 
3.4.3.2 RESULTS 
3.4.3.2.1 ORAL GROUP 
As seen in figure 3.4 and table 3.4, the results for the oral group showed a mean 
maximum lisW-S concentration of 47.1 ± 13 ng/ml was reached by the 2 hour time 
point. By 4 hours, the mean plasma concentration of lisW-S had dropped to almost 
half of the maximum plasma levels seen (26.5 ± 5 ng/ml). Levels continued to 
decrease until 12 hours which was the last sample taken from which lisW-S/ TFA 
levels were detectable.   
 
Figure 3.3 Mean concentration of lisW-S/TFA (ng/ml) vs. time - oral administration (n=20) 
 
Table 3-4 Mean concentrations of lisW-S/TFA (ng/ml) at various time points with oral administration (n=20). 





















Zero 1 hr 2hr 4hr 8hr 12hr 24hr 
Mean Concentration (ng/ ml) 0.0 42.1 47.1 26.5 17.6 11.3 ND 
STDEV (ng/ml) 0 21 13 5 4 3 ND 
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3.4.3.2.2 IV GROUP 
The results for the IV group are presented in figure 3.5 and table 3.5 and showed a 
higher maximum lisW-S/TFA concentration in the plasma than that seen in the oral 
group – 2660 ± 428 ng/ml immediately following administration. However, levels 
declined rapidly and reached an effective baseline by the 2 hour time point. By 12 
hours lisW-S/TFA was no longer detectable in the plasma samples. 
 
 
Figure 3.4 Mean concentrations of lisW-S/TFA (ng/ml) vs. time - IV administration (n=6) 
 























0.083 hr 1 hr 2hr 4hr 8hr 12hr 24hr 
Mean Concentration (ng/ ml) 2660 334 60.0 18.8 8.08 6.13 ND 
ST DEV (ng/ml) 428 138 11 4 2 ND ND 
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3.4.3.3 PK MODEL RESULTS 
The PK parameters for modeling were derived from the results obtained in the oral 
group (figure 3.3). Parameters were calculated using WinNonlin software.  
 
3.4.3.3.1 ORAL GROUP 
As seen in table 3.6, the mean half-life of lisW-S/ TFA by oral administration was 
determined to be 6.3 hours. The peak plasma concentration reached after 
administration (Cmax) was 52 ng/ ml, and the time taken to reach Cmax (Tmax) was 
approximately 1.6 hours. The mean oral AUC up to 12 hours was 286.2 ng.h.ml-1.  
 
Table 3-6 Mean PK parameters for lisW-S – oral administration 
 
3.4.3.3.2 IV GROUP 
As seen in table 3.7, the mean half-life of lisW-S/TFA by IV administration was 
determined to be 2.7 hours. The peak plasma concentration reached after 








Mean Value 6.3 1.6 52.0 286.2 353.7 
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Table 3-7 Mean PK parameters for lisW-S - IV administration 
 
3.4.4 PUMP STUDY: LISW-S 
The results of the pilot and bioavailability studies showed that plasma clearance of 
lisW-S/ TFA was relatively fast, with concentrations reaching a peak of approximately 
45 – 50 ng/ml around the 2 hr mark at a dose of 5 mg/kg. Plasma clearance 
appeared complete at approximately 12 hrs, when concentrations returned to basal 
levels. Were we to follow our initial experimental setup of administration of lisW-S 
once every 24 hours, our cycle would include 12 hours of non-effective treatment per 
cycle. Thus it was decided to pursue a second route of administration via 
subcutaneous mini-osmotic pumps.  
Mini-osmotic pumps are a reliable and effective method of delivering compounds at a 





Half-life (h) Cmax (ng/ml) AUC 0-12 
(ng.h.ml-1) 
Mean Value 2.7 2660 1866.5 
In conclusion, based on both the oral and IV results, mean bioavailability of lisW-
S/TFA was determined to be 3.1%. 
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3.4.4.1 EXPERIMENTAL DESIGN 
This study was run for a duration of 4 weeks to assess the stability and delivery of 
lisW-S in a subcutaneous environment.  
A dosage of 15 mg/ ml was administered to a sample size of n = 4 for a duration of 4 
weeks. Blood samples were collected at the following time points: zero (prior to 
administration), 8 hrs, 24 hrs, 48 hrs, 4 days, 1 week, 2 weeks, 3 weeks and 4 weeks 




The results presented in table 3.8 and figure 3.6 showed an initial peak in plasma 
concentrations, followed by a significant drop to a steady state condition. The 
maximum mean concentration obtained was 40.1 ±16.6 ng/ml at the 24 hour time 
point. After this, plasma concentration levels of lisW-S/TFA decreased to 24.9 ± 5.4 
ng/ml after 1 week of administration. A second maximal peak was observed at the 2 
week time point, when lisW-S/TFA levels were raised to 32.6 ± 2.9 ng/ml, but this 
decreased and remained at approximately 20 ng/ml for the remaining 2 weeks of the 
study.  
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Figure 3.5 Mean concentrations (ng/ml) of 15 mg/ ml lisW-S/ TFA dosage vs. time (n = 4) 
 
















































40.1 38.5 30.5 24.9 32.6 23.2 21.9 
ST DEV (ng/ml) 0 4.1 16.6 21.1 11.6 5.4 2.9 3.7 0.5 
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3.4.5 PUMP STUDY: LISINOPRIL 
3.4.5.1 EXPERIMENTAL DESIGN 
The plasma concentration levels of lisinopril were used primarily as a control 
throughout this work (its ACE inhibitory properties are well-established). As it is an 
orally administered compound its behaviour under subcutaneous pumping conditions 
needed to be assessed. Lisinopril was pumped at the same concentration and 
duration as the 4-week lisW-S/TFA pump study (section 3.4.4). 
A dosage of 15 mg/ml was administered to a sample size of n = 3 for a duration of 4 
weeks. Blood samples were collected at the following time points: zero (prior to 




The results presented in figure 3.5 showed that lisinopril behaved differently to lisW-
S under subcutaneous pumping conditions. This was not unexpected due to the 
higher oral bioavailability of lisinopril. ‘Zero’ samples were measured above 0 ng/ml, 
possibly due to contamination of the samples. Table 3.7 shows that an initial peak of 
51.7 ± 41 ng/ml was seen at the 8 hour time point, after which mean concentrations 
ranged between 48.2 ± 10.7 ng/ml and 46.3 ± 23.7 ng/ ml for the next 2 weeks. An 
unexpected maximum peak of 76.7 ± 36.2 ng/ml was observed at the 3 week time 
point, after which levels returned to a mean concentration of 48.4 ± 25.1 ng/ml by 4 
weeks. This is suggestive that the 3 week time point is artefactual and stems from an 
unknown error that occurred during the quantification of this time point.  
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Figure 3.6 Mean concentration (ng/ml) of 15 mg/ ml lisinopril dosage vs. time (n=3) 
 














































7.5 51.7 36.8 48.2 38.2 39.5 46.3 76.7 48.4 
STDEV (ng/ml) 67.3 41.0 132.6 10.7 24.1 19.8 23.7 36.2 25.1 
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3.5 DISCUSSION 
The results of the pilot oral gavage study showed that lisW-S reached a maximum 
plasma concentration close to the desired therapeutic range of 50 ng/ml by the 1 
hour time point, after which levels slowly decreased until reaching a baseline level by 
12 hours. A similar profile was observed for lisinopril, thus showing that this 
behaviour was not exclusive to the lisW-S compound. Based on these results, it was 
concluded that a once daily dose by oral gavage was not an effective method of drug 
delivery, and other routes of administration needed to be explored.  
This decision was validated by the bioavailability study, which determined the half-life 
of lisW-S to be approximately 6 hours, and the time to reach peak plasma or serum 
concentrations to be 1.6 hours with oral dosing. The oral bioavailability of the C-
domain selective ACE inhibitor was determined to be just 3.1%. Considering the 
early stage of development (Veber et al. 2002), this does not exclude lisW-S as a 
potential therapeutic agent, although it is generally recognised that an oral 
bioavailability of at least 20% in the rat is a predictor of a compound’s success in 
human trials. While it is difficult to speculate as to the cause, the presence of 
tryptophan in the compound may be a contributor, as a study by Boyko et al. also 
observed low bioavailability in the pharmacokinetic evaluation of a tryptophan-
containing dipeptide (Boyko et al. 2007). It should also be noted that the estimate of 
bioavailability comes in part from IV administration as presented in Figure 3.4, which 
is based upon plasma samples drawn from a timepoint of 0.08 hours to 12 hours. 
Blood drawn at an earlier timepoint may have illustrated a different AUC and thus the 
bioavailability determined in this study may in fact be underestimated.  
In order to compensate for low oral bioavailability, we explored the possibility of 
intravenous infusion. The results of the IV study demonstrated an initial peak 
followed by a rapid decline and a return to basal levels at 12 hours. These results 
provided a further incentive to explore alternative solutions, and resulted in the 
decision to utilize subcutaneous mini-osmotic pumps for continuous infusion of lisW-
S within the therapeutic range. A significantly lower volume of lisW-S is required for 
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infusion relative to oral dosing (6 mg/kg/day vs. 56 mg/kg/day). A further advantage 
of these pumps is that the animal undergoes a single, small surgical procedure at the 
start of the study, thus minimizing long-term stress. The pumps are highly accurate 
and continuously deliver solutions at a specified rate for a set duration.  
The 4-week study infused lisW-S at a concentration of 15 mg/ml and demonstrated 
that after an initial peak at 24 hours, plasma levels decreased to an approximate 
steady state of 20 ng/ml. While delivery of the C-domain selective ACE inhibitor was 
consistent, the 15 mg/ml dosage did not result in a satisfactorily high plasma 
concentration. A 2-fold higher concentration of 30 mg/ml was therefore considered to 
be an appropriate dosage for administration by miniosmotic pump infusion, as based 
on the in vitro data reported in Chapter 2, a plasma concentration of 40 ng/ml would 
achieve 60% ACE inhibition in plasma.    
In comparison, Lisinopril infused for 4 weeks at 15 mg/ml did reach the therapeutic 
target of 50 ng/ml. Considering that this compound has a bioavailability of 
approximately 25%, this was as expected.  
A maleate salt preparation of lisW-S was also evaluated in a preliminary effort to 
improve bioavailability. Despite the high efficacy of pharmaceutical salts at improving 
the solubility and oral bioavailability of pharmaceutical compounds (A.T.M. 
Serajuddin 2007), in this case the lisW-S/MS preparation did not show an improved 
pharmacokinetic profile over lisW-S/TFA. 
Based on the results of the above pharmacokinetic studies, we concluded that the 
steady state plasma concentrations achieved by infusing lisW-S at a dosage of 1 
mg/kg/day would be sufficient to adequately inhibit ACE and have a significant effect 
on ACE activity in the RAS. Thus, it was decided to administer both lisW-S and 
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Chapter 4 IN VIVO ANGIOTENSIN PEPTIDE QUANTIFICATION 
4.1 INTRODUCTION 
Following the assessment of the ex vivo efficacy and pharmacokinetics of Lis-W-S, a 
detailed analysis of RAS peptide levels was carried out in infarcted animals treated with the 
domain-selective ACE inhibitor in order to determine in vivo specificity and efficacy. The 
components of both the Ang II-producing and the counter-regulatory Ang (1-7)-producing 
pathways of the RAS have been previously described and defined in Chapter 1. Figure 4.1 is 
once again presented below for reference purposes. It illustrates the major peptides of 
interest in this study, along with the enzymatic pathways responsible for their generation. 
 
4.1 The expanded view of the RAS (adapted from (Poglitsch et al. 2012) 
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4.2 QUANTIFICATION OF RAS PEPTIDES 
The endogenous plasma levels of angiotensin peptides are in the low nanomolar range 
when measured by radioimmunoassay in both humans (A. C. Lawrence et al. 1990) and rats 
(Campbell et al. 1994). Previously, studies quantifying the effects of ACE inhibition and 
infarction on plasma peptide levels have been done using enzyme-linked immunosorbent 
assay (ELISA) kits (Leuschner et al. 2010) and radioimmunoassay combined with HPLC 
(Campbell et al. 1994). A major drawback of the ELISA method is low-sensitivity, up to 36% 
cross-reactivity with other angiotensin peptides and time-consuming methodology (Cayman 
Chemicals 2012).  
Radioimmunoassay has greater sensitivity although it too relies on peptide-specific 
antibodies for identification and is thus also susceptible to cross-reactivity (H. John et al. 
2004), especially in the case of RAS peptides with their closely homologous structures. As a 
result of the drawbacks of these two methods of quantification, and in conjunction with 
advances in high performance liquid chromatography (LC) - mass spectrometry (MS) 
instrumentation, LC-MS has recently emerged as the new gold standard for peptide 
quantification (John et al. 2004). Briefly, LC-MS is used to identify a peptide with high 
accuracy based on its molecular weight, and LC-MS/MS is used to confirm peptide 
identification by structure-specific fragmentation (Cui et al. 2007). An internal standard is 
then used for absolute peptide quantification (Kirkpatrick et al. 2005). Studies using this 
method have been able to quantify up to four angiotensin peptides in a single LC-MS/MS run 
(Cui et al. 2007).  
More recently a highly sensitive and novel method of LC-MS/MS peptide quantification has 
been developed by Apeiron Biologics (Vienna, Austria). Referred to as ‘RAS Fingerprinting’, 
this technique allows for the simultaneous analysis of a full range of known RAS 
angiotensin-derived peptides from a single low volume plasma sample (Poglitsch et al. 
2012). Briefly reviewed in the work by Poglitsch et al. (2012), this quantification method has 
a detection limit of 2 pg/ ml, and incorporates a novel enzyme inhibitor cocktail (patent 
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pending) which arrests the RAS at the moment of plasma collection - thus preserving the 
steady state levels of the angiotensin peptides of interest. This novel method was employed 
in this study for the purposes of detailed analysis of the in vivo response of the RAS to both 
MI and domain-selective and non-selective ACE inhibition. The aim of the present study was 
to assess the inhibitory potential and the therapeutic potential of the C-domain-selective 
ACE inhibitor in the context of MI. In addition, this technique allowed for the benchmarking of 
this novel methodology in a rat model of MI, as well as providing the opportunity to compare 
this work against other published data. The peptides quantified by the RAS fingerprinting in 
this study are presented below in Table 4.1. 
 
Table 4-1 Peptides measured by the RAS-fingerprinting method by Apeiron-Biologics 
Angiotensin Peptides Kinin Peptides 
Ang I (1-10) Ang (1-9) BK (1-7) 
Ang II (1-8) Ang (1-7) BK (1-5) 
Ang III (2-8) Ang (1-5)  
Ang IV (3-8) Ang (2-7) 
Ang (2-10) Ang (3-7) 
 
4.3 EXPERIMENTAL DESIGN 
In vivo myocardial infarction studies in the rat model with relevant ACE inhibition were 
conducted to quantify angiotensin and kinin peptide concentrations in plasma samples by 
immunoassay and RAS-fingerprinting at 1 and 7 days post-MI. The studies were carried out 
in infarcted rats as the long-term aim is the evaluation of Lis-WS efficacy as a therapy for the 
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adverse remodeling that results from MI. Additionally, MI has been reported to elevate levels 
of a number of key angiotensinogen-derived peptides (Duncan et al. 1997) (Ocaranza et al. 
2006). Thus it was reasoned that this would facilitate detection and also allow for a detailed 
analysis of these critical peptides after an infarction with the newly developed LC-MS/MS 
technology. Importantly, MI was confirmed histologically in all treatment groups by 
quantification of infarct size. 
 
4.3.1 EXPERIMENTAL DESIGN : SEVEN DAY TIME POINT  
The first study had a one week time point which - based on a review of the literature - was 
chosen as the point at which peptide levels after infarction were adequately elevated for 
quantification (Ocaranza et al. 2006) (Campbell et al. 2008).  
A total sample size of 30 male Wistar rats (180 – 220g) were divided into four groups as 
shown in table 4.2. Each group underwent either sham surgery or induction of myocardial 
infarction by permanent ligation of the left anterior descending artery (LAD). Immediately 
following surgery, miniosmotic pumps containing either saline, lisinopril (30 mg/ml) or lisW-S 
(30 mg/ml) were implanted subcutaneously.  
Seven days after surgery, blood was collected by cardiac puncture for peptide quantification. 
Hearts were explanted and processed histologically to facilitate quantification of infarct size 
and confirmation of successful induction of MI. AcSDKP and Ang II plasma levels were 
quantified by EIA assay. RAS-fingerprinting of both angiotensin and kinin plasma peptide 
levels was done by Apeiron-Biologics. Additionally, PK validation of the plasma samples in 
the infarcted LisW-S-treated group was done by LC/MS/MS assay to ensure the success of 
the miniosmotic pumps.  
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Table 4-2 Animals were divided into four groups for the 7-day study as shown below 
Group Number of animals Procedure Treatment 
1 6 Sham Saline 
2 8 MI Saline 
3 8 MI Lisinopril 
4 8 MI LisW-S 
 
4.3.2 EXPERIMENTAL DESIGN: ONE DAY TIME POINT 
The second study was conducted in order to evaluate the short-term effects of C-domain 
ACE inhibition in an MI model. A total sample size of 12 male Wistar rats (180 – 220g) were 
divided into two groups as shown in table 4.3. Animals underwent either sham or MI-
induction surgery, followed by subcutaneous miniosmotic pump implant. The pumps 
contained either saline or lisW-S (30 mg/ml) solutions. Animals were sacrificed one day (24 
hours) after treatment and blood was collected by cardiac puncture for peptide quantification. 
RAS-fingerprinting of plasma samples by Apeiron-Biologics was used to quantify both 
angiotensin and kinin plasma peptide levels. 
Table 4-3 Animals were divided into two groups for the one-day study as shown below 
Group Number of animals Procedure Treatment 
1 6 Sham Saline 
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2 6 MI LisW-S 
 
4.4 METHODS 
4.4.1 MYOCARDIAL INFARCTION 
4.4.1.1 ANAESTHESIA AND PREPARATION 
Rats were initially anaesthetized with isoflurane and were placed in an induction chamber for 
a minimum of 2.5 minutes. During the induction phase the vaporizer was set to anaesthetize 
the animal with 5% Isoflurane, at a flow rate of 1.5% Oxygen. After 2.5 minutes of induction  
the animal was removed from the chamber, weighed (and body weight recorded), and the 
chest area shaved. The animal was then placed back into the induction chamber under the 
same conditions for a further 2.5 minutes.  
Following complete induction the animal was removed from the chamber and placed on the 
intubation table at an inclined angle of 45 degrees for intubation. The method of tracheal 
intubation required the use of an otoscope for laryngoscopic visualization of the vocal cords. 
A guide wire was then passed through the open vocal cords and into the trachea, followed 
by a 16 gauge IV catheter. The guide wire was removed and the rat was immediately 
transferred to the pre-warmed operating table (a heating pad maintained the table at 
approximately 37 degrees Celsius). The catheter was then attached to the ventilator, and the 
animal was mechanically ventilated at 5% Isoflurane and 0.3% Oxygen for a further two to 
three minutes. Following induction and intubation the animal was maintained under 
anaesthesia with 1.5 - 2% Isoflurane and 0.3% Oxygen. The tidal volume and respiration 
rate of the ventilator was adjusted for the size of the animal according to the following 
formulas: tidal volume (Vt, ml) = 6.2 x M1.01 (M = animal mass, kg); respiration rate (RR, min-
1) = 53.5 x M-0.26. The animal was secured in a dorsal recumbent position on the pre-warmed 
operating table with surgical tape. The two front paws and one distal paw were taped down. 
The remaining paw was left free to monitor depth of anaesthesia during surgical procedure 
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(movement of the paw is indicative of a decrease in anaesthesia depth). The surgical area 
was then cleaned with an iodine solution. Depth of anaesthesia was checked by non-
responsiveness to a tail pinch with forceps.  
4.4.1.2 SURGICAL PROCEDURE (MI/ SHAM) 
A left intercostal thoracotomy was performed to gain access to the heart. A 1 – 1.5 cm 
incision was made in the area of the fourth intercostal space, at a 90o angle to the sternum.  
Cotton buds and forceps were used to open the surgical area by separating the dermal layer 
from the muscles. Cotton buds were used to pull the chest muscles aside by blunt dissection 
technique and expose the fourth intercostal space (clearly identified by the greater width of 
the fourth space in comparison to the fifth). Chest muscles were retracted and a pre-heated 
haemostat was used to gently penetrate the intercostal space, thus opening up the thoracic 
cavity. A small retractor was used to separate the fifth and sixth ribs in order to clearly 
visualise the beating heart. 
Prior to arterial ligation of the myocardium, the pericardium was removed to enable clear 
visualisation of the left anterior descending (LAD) artery. The pericardium was removed by 
grasping the thymus - which tends to cover a large upper portion of the heart – with forceps 
and lifting it upwards until the membranous pericardium could be clearly seen. The 
pericardium was then torn and removed from the heart with small, sharp-edged forceps. 
Once this has been done, the thymus tends to retract away from the heart, exposing more of 
the myocardium. At this point in a sham operation, the ligation step was skipped. In the MI 
operations, however, a 6-0 proline suture was passed randomly through the myocardium. 
This suture was not tied off and was used as a ‘guiding’ suture, as it could be held and used 
to manipulate the position of the heart in the chest. This manipulation greatly improved the 
chance of correctly identifying the LAD – which often lies further towards the dorsal side of 
the heart wall, and so is difficult to see immediately upon opening the chest. Once the LAD 
was identified, a second 6-0 proline suture was carefully passed through the myocardium 
and around the artery. This second suture was then tied off, at which point ischemia of the 
left ventricular wall was clearly observed. 
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The first ‘guiding’ suture was then pulled out and the retractor removed. Two 4-0 silk 
intercostal sutures were used to re-approximate the ribs. The first suture was tightened 
before manual compression of the chest (to remove residual air in the cavity and aid lung re-
expansion), after which the second suture was quickly tied off. The chest muscles were also 
re-approximated with a single 4-0 silk suture. The skin incision was closed with 4-0 silk 
sutures, and the area was cleaned with iodine. At this point, the animal was removed from 
the mechanical ventilator. Once spontaneous respiration was achieved, an analgesic dose of 
buprenorphine (0.05 mg/kg) was administered by intramuscular injection to the hind leg. The 
catheter was left in place in the trachea to maintain the open airway during recovery. The 
animal was then placed in a solitary cage to prevent other animals from pulling the sutures 
out from the incision site. Once consciousness had been regained, the animal was 
extubated and provided with food and water.  
 
4.4.1.3 POST-OPERATIVE CARE 
The animals were monitored daily for the duration of the study. Their water and food intake 
was monitored, and their weights recorded. The incision site and sutures were checked for 
the first three days post-surgery to ensure adequate healing. Analgesia was administered 
twice daily for 48 hrs after surgery.  
 
4.4.2 PUMP IMPLANT 
Mini-osmotic pumps were prepared and implanted as described in Section 3.3.5. 
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4.4.3 BLOOD COLLECTION 
Due to the volume of blood required for analysis, blood was collected by cardiac puncture at 
the experimental endpoint. Animals were anaesthetized with halothane for this procedure. 
Following blood collection, animals were euthanised by injection of saturated potassium 
chloride (KCl) solution into the left ventricle. 
4.4.3.1 ACSDKP SAMPLES FOR EIA  
Blood was collected on ice in heparinised tubes. The ACE inhibitor captopril was 
immediately added to a final concentration of 10-5 M. Blood samples were separated by 
centrifugation at 1600 g for 20 minutes (4oC). Plasma samples were stored at -80oC. 
4.4.3.2 ANG II SAMPLES FOR EIA AND RAS PEPTIDE FINGERPRINTING 
Blood was collected on ice with a 5% enzyme inhibitor cocktail (Apeiron patent pending). 
Direct communication from Apeiron detailed that suitable QC has been carried out showing 
complete effectivity of the cocktail in inhibiting peptide hydrolysis in whole blood spiked with 
all relevant peptides. Blood samples were separated by centrifugation at 3000 g for 20 
minutes (4oC). Plasma samples were stored at -80oC. 
 
4.4.4 QUANTIFICATION OF INFARCT SIZE 
4.4.4.1 EXPLANT 
Animals were anaesthetized, blood was extracted and hearts were injected with 1 ml 
saturated potassium chloride to arrest the heart in diastole for histological analysis. Hearts 
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were explanted, washed and perfused with saline before being transferred to a 4% 
paraformaldehyde solution for 24 hours before histological processing. μ 
4.4.4.2 HISTOLOGY 
After this fixation period, hearts were cut transversely into 4 equal sections and processed 
through graded alcohol (Illovo Sugar Ltd., South Africa) and xylene (Saarchem, South Africa) 
using a Tissue-Tek Rotary Tissue Processor (Sakura Finetek, Japan). Embedded in paraffin 
wax (Merck, Germany) the sections were cut into 2 - 3 μm slices, picked up on glass slides 
(Marienfeld GmbH & Co. KG, Germany) and baked on a hot plate at 60 oC (Kunz 
Instruments AB, Nynäshamn, Sweden) before being dewaxed through xylene, agitated in 
absolute alcohol and hydrated in running tap water. Lastly sections were stained with 
haematoxylin and eosin (H&E) and mounted on glass slides. 
 
4.4.4.3 IMAGE ACQUISITION 
Images were acquired by microscopy (Nikon Eclipse 90i, Nikon Corporation, Japan) and 
captured by digital camera (Nikon DXM-1200C, Nikon Corporation, Japan) . Image analysis 
for quantification of infarct size was done using the VIS-Visiopharm Integrator system 
(Visiopharm, Hørsholm, Denmark).  
 
4.4.4.4 IMAGE ANALYSIS 
Infarct sizes were acquired and quantified with Visiopharm Integrator Systems (Visiopharm, 
Hørsholm, Denmark) according to the method of Takagawe et al. (Takagawa et al. 2007). 
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Briefly, the sum of all midline infarct lengths was divided by the sum of all midline 
circumferences for all sections and expressed as a final percentage. 
 
4.4.5 ENZYME-LINKED IMMUNOSORBENT ASSAY 
4.4.5.1 ACSDKP QUANTIFICATION 
The concentration of AcSDKP in the plasma samples was quantified using an AcSDKP 
enzyme-linked immunosorbent (EIA) assay kit (Cayman Chemicals, France). This was 
performed according to the manufacturer’s instructions. The 96-well microplate is precoated 
with a mouse anti-rabbit antibody. The assay is based on competitive binding to the coated 
wells between acetylcholinesterase (AChE) linked to an AcSDKP tracer and free AcSDKP in 
the plasma sample. Plasma samples were extracted with methanol and evaporated to 
dryness by vacuum centrifugation prior to assay. 
Briefly, wells were washed five times with wash buffer (300 µl/ well). After each wash, the 
wells were aspirated and any remaining droplets shaken out. Wells for blanking Ellman’s 
reagent were left empty. Reconstituted EIA buffer was added to both non-specific binding 
(NSB) and maximum binding wells. A range of AcSDKP standards from 0.09 – 12.5 nM and 
plasma samples were plated in duplicate. The AcSDKP AChE tracer was added to all wells, 
while the AcDHP antiserum was added to all but the NSB wells. 
The plate was then covered and incubated at 4oC for 18 hours. The next day, the plate was 
washed five times with wash buffer, and any remaining droplets were shaken out. 200 µl of 
Ellman’s reagent was then added to all wells, including the blanks. The plate was covered 
with aluminium foil and incubated in the dark for 1.5 hrs at ambient temperature. The plate 
was read continuously at 414 nM on a Benchmark Microplate Reader (Biorad, Japan) as the 
absorbance of the maximum binding wells increased from 0.2 to 0.8 units.  
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4.4.5.2 ANG II QUANTIFICATION 
The concentration of Ang II in the plasma samples was quantified using an Ang II EIA assay 
kit (Cayman Chemicals, France). This was performed according the manufacturer’s 
instructions. The 96-well microplate is precoated with a specific anti-Ang II monoclonal 
antibody. Plasma samples were extracted with phenyl cartridges (Phenomenex/ Strata, 
USA) and methanol and evaporated to dryness prior to assay. 
Briefly, wells were washed five times with wash buffer (300 µl/ well). After each wash, the 
wells were aspirated and any remaining droplets shaken out. Wells for blanking Ellman’s 
reagent were left empty. Reconstituted EIA buffer was added to NSB wells. Ang II standards 
in the range of 0.98 – 125 pg/ml and plasma samples were plated in duplicate. The plate 
was then incubated for 1 hour at ambient temperature with gentle agitation. Gluteraldehyde 
was added to all wells (excluding blanks) to covalently link Ang II to the plate and incubated 
for 5 minutes at ambient temperature with gentle agitation. Gluteraldehyde was blocked to 
permit binding to a monoclonal antibody AChE-labelled tracer by adding borane-
trimethylamine and incubating as with the gluteraldehyde step. The plate was washed five 
times as before and anti-Ang II IgG tracer was added to all wells (excluding blanks). The 
plate was then covered and incubated overnight at 4oC. The next morning, the plate was 
washed five times as before. Wash buffer was added to all wells and the plate was 
incubated for 10 minutes at ambient temperature with gentle agitation. Finally, the plate was 
washed a further five times as before and Ellman’s reagent was added to all wells (including 
blanks). The plate was covered with aluminium foil and incubated in the dark on an orbital 
shaker for 1 hour at ambient temperature. The plate was read continuously at 414 nM on a 
Benchmark Microplate Reader (Biorad, Japan).  
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4.4.6 RAS PEPTIDE FINGERPRINTING 
LC-MS/MS quantification of angiotensin peptides was performed by Apeiron-Biologics AG. 
Plasma samples were shipped on dry ice to Vienna, Austria.  
Plasma samples were spiked with 100 pg/ml stable isotope-labeled internal standards and 
processed with a solid phase extraction using Sep-Pak cartridges (Waters, USA) according 
to the manufacturer’s instructions. Efficient stabilization of endogenous angiotensin peptides 
was assured by addition of stable isotope labeled internal standard peptides. 
Following elution and solvent evaporation, samples were reconstituted in 50 µl 50% 
acetonitrile/ 0.1% formic acid and subjected to LC-MS/MS analysis using a reversed phase 
analytical column (Luna C18, Phenomenex) The gradient ranged from 10% acetonitrile/ 
0.1% formic acid to 70% acetonitrile/ 0.1% formic acid (t = 9 minutes). The eluent was 
analysed with a QTRAP-4000 mass spectrometer (AB Sciex) operated in the MRM mode 
using dwell times of 25 milliseconds, at a cone voltage of 4000 volts and a source 
temperature of 300°C. For each peptide and corresponding internal standard, two separate 
mass transitions were measured. Angiotensin peptide concentrations were calculated by 
relating endogenous peptide signals measured to internal standard signals with a signal-to-
noise ratio above 10. The quantification limits for individual peptides were found to be 
between 1 pg/ml and 5 pg/ml in undiluted plasma samples. (Adapted from Poglitsch et al., 
2011) 
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4.4.7 PK VALIDATION OF LISW-S PLASMA CONCENTRATIONS 
Separate blood samples were collected and prepared from animals treated with lisW-S as 
described in Section 3.3.6. In order to ascertain lisW-S plasma concentrations following 
administration, these samples underwent LC/MS/MS analysis as previously described in 
Section 3.3.7. 
 
4.4.8 STATISTICAL ANALYSIS 
Two-tailed student t-tests were used to assess the differences between two groups. 
Comparisons between multiple groups were made by means of a one-way ANOVA 
(Statplus-Pro, AnalystSoft Inc., USA), followed by Fisher’s LSD test. Statistical significance 
was defined as p < 0.05. All data are expressed as means ± standard error. 
 
4.5 RESULTS  
4.5.1 QUANTIFICATION OF INFARCT SIZE 
Seven Days 
Prior to performing plasma peptide quantification, myocardial infarction was confirmed by 
histological staining and image analysis. An example of the images obtained for 
quantification is presented below in figure 4.2. Infarct sizes are expressed as a percentage 
of left ventricular midline measurements. Table 4.4 shows the mean infarct sizes and sample 
sizes for each group (one animal in the lisinopril-treated group died following induction of 
MI). Substantial infarctions were confirmed in all infarcted animals with a mean value of 
34.98 ± 10.38 % and infarct size was not significantly different between groups (p=NS). 
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Table 4-4 Mean infarct size quantified by image analysis (%) 
Group Mean Infarct Size (%) Std Error (%) 
MI (n = 8) 36,48 15.65 
MI/Lisinopril (n = 7) 29,80 4.03 
MI/LisW-S (n = 8) 38,24 7.34 
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Figure 4.2 H&E staining of representative cardiac tissue sections. Arrows demarcate the infarct zone in A) MI group, B) 
MI/lisinopril-treated group and C) MI/lisW-S-treated groups. Bar represents 1 mm 
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4.5.2 ELISA 
4.5.2.1 ACSDKP EIA 
Seven Days 
The results of this assay are presented below in figure 4.3. No significant difference is 
observed between the untreated sham and MI groups (Sham: 4.75 ± 0.38 nM; MI: 4.62 ± 
1.04 nM. p=NS). However, a significant elevation of plasma AcSDKP levels is observed in 
the lisinopril-treated MI group versus the MI and sham groups (MI/Lisinopril: 13.41 ± 0.77 
nM. p<0.05 vs. sham and MI) as a result of non-selective ACE inhibition. No significant 
difference was observed between the sham and MI control groups and the MI/lisinopril-
treated group (MI/LisW: 4.05 ± 1.72 nM. p=NS vs. sham and MI). However, mean AcSDKP 
levels were significantly elevated by more than 3-fold in the MI/lisinopril treated group vs. the 
MI/lisW-S-treated group (p<0.05). 
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4.5.2.2 ANG II EIA 
Seven Days 
As shown in figure 4.4, the MI group showed a trend towards an increase by approximately 
1.5-fold in plasma Ang II levels when compared to the sham group (MI: 105.39 ± 56.24 
pg/ml. p=0.16 vs. sham).  The mean plasma concentration of Ang II was significantly 
reduced by 2.6-fold in the MI/lisinopril-treated group in comparison to the untreated MI group 
(MI/lisinopril: 41.24 ± 23.36 pg/ml. p<0.01 vs. MI). However, as is clearly seen in figure 4.4, 
Ang II levels are significantly elevated 1.7 fold relative to the MI group by administration of 
the novel domain-selective ACE inhibitor lisW-S (MI/lisW-S: 189.25 ± 54.42 pg/ml. p<0.01 
vs. MI).  
 
Figure 4.4 Mean Ang II concentrations (pg/ ml) in plasma at 1 week after MI induction as obtained by EIA assay. (* 
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Due to the significant amount of data points generated – as well as the multi-faceted nature 
of the relationships between the component peptides of the RAS – the data is presented 
below in several different formats to facilitate understanding. Figures 4.5 and 4.6 show a 
graphical interpretation of the flow of angiotensin-derived peptides through the RAS cascade 
in treated and untreated groups at 7 days post-MI. In addition, Table 4.7 presents the mean 
concentrations and standard deviation of each peptide analysed at this time point. Figure 4.7 
and table 4.8 present the data obtained 1 day post-MI. The sections below include a detailed 
discussion of every measured peptide in the cascade at both timepoints, as well as 
comparisons between groups and graphical presentations of peptide levels with relative 
significance indicated. It should be noted that a significant number of the data points 
obtained for Ang (1-9) fall below the limit of quantification (BLQ) due to a high signal-to-noise 
ratio, and so analysis of this peptide and its ACE/NEP-mediated conversion to Ang (1-7) 
could not be included in this study. In addition, all measurements of Ang (2-7) fell BLQ, and 
thus have been omitted. 
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Figure 4.5 RAS-fingerprints of mean angiotensin peptide plasma concentrations for the sham and MI groups at 7 days 
post-MI. All measurements are in pg/ml, and the size of the representative spheres corresponds to the measured 
amount of each peptide. Figure provided by Apeiron Biologica. 
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Figure 4.6 RAS-fingerprints of mean angiotensin peptide plasma concentrations for MI/lisinopril and MI/lisW-S groups 
at 7 days post-MI. All measurements are in pg/ml, and the size of the representative spheres corresponds to the 
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Figure 4.7 RAS-fingerprints of mean angiotensin peptide plasma concentrations for the MI and MI/lisW-S-treated 
groups at 1 day post-MI. All measurements are in pg/ml, and the size of the representative spheres corresponds to the 
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Sham Mean 785 73 24 7 149 8 ND 
Std Error 149 10 4 1 30 0 ND 
MI 
 
Mean 1544 104 45 11 319 9 ND 
Std Error 200 17 9 2 45 1 ND 
MI/ lis- 
inopril 
Mean 3946 12 4 1 1114 10 4 




Mean 8624 162 66 17 2251 26 4 
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MI Mean 974 102 47 9 202 9 1 




Mean 4211 48 30 6 1499 22 3 
Std Error 929 13 10 2 392 3 1 
 
4.5.3.2 ANALYSIS OF INDIVIDUAL ANGIOTENSIN PEPTIDE DIFFERENCES 
4.5.3.2.1 ANG I 
Seven Days 
Significant differences in Ang I plasma concentrations were observed between all four 
groups as shown in figure 4.8. An almost 2-fold increase in Ang I peptide levels was 
observed in the infarcted group relative to sham (MI = 1544.14 ± 20.45 pg/ml; Sham = 
784.54 ± 149.29 pg/ml; p<0.05) as a result of RAS activation post-MI and upregulation of 
renin-mediated Ang I synthesis.   
A highly significant elevation of 2.6-fold was also observed for the MI/lisinopril-treated group 
relative to MI (MI/lisinopril = 3946.21 ± 277.13 pg/ml; p<0.01).  
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Most interestingly, Ang I was even more strikingly elevated after treatment with LisW-S 
(MI/lisW-S = 8624.21 ± 1102.77 pg/ml), demonstrating a 5.6-fold increase relative to MI 
(p<0.01) and a 2.2-fold increase relative to MI/lisinopril (p<0.01). 
 




As shown in figure 4.9, a significant 4.3-fold elevation in Ang I was observed in the MI/lisW-S 
group relative to the untreated MI group when peptide quantification was performed one day 
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Figure 4.9 Mean Ang I plasma concentrations (pg/ml) at 1 day (*p<0.01 vs. MI) 
 
4.5.3.2.2 ANG II 
Seven Days 
The plasma concentrations of the vasoconstrictor Ang II at seven days post-MI are 
presented in figure 4.10. No significant difference was observed between the sham and MI 
groups (sham = 72.96 ± 9.55 pg/ml; MI = 103.95 ± 47.60; p=NS). The MI/lisinopril-treated 
group showed a highly significant 8.8-fold decrease relative to MI (MI/lisinopril = 11.75 ± 
1.34 pg/ml; p<0.01), while in sharp contrast the MI/lisW-S-treated group exhibited a 
significant 13.8-fold elevation relative to the MI/lisinopril-treated group, a trend towards a 1.6-
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sham (MI/lisW-S = 161.98 ± 28.47 pg/ml; p<0.01 vs. MI/lisinopril; p=NS vs. MI; p<0.05 vs. 
sham).  
 
Figure 4.10 Mean Ang II plasma concentrations (pg/ml) at 7 days (γ  p<0.01 vs. all groups, *p<0.05 vs. sham) 
 
One Day 
Mean plasma concentrations of Ang II one day after MI are presented in figure 4.11. A 
significant 2.1-fold decrease was observed in the lisW-S-treated group relative to the 
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Figure 4.11 Mean Ang II plasma concentrations (pg/ml) at 1 day (*p<0.05 vs. MI) 
 
4.5.3.2.3 ANG II/ ANG I 
Seven Days 
The ACE-mediated conversion ratios of Ang I to Ang II seven days post-MI are presented 
below in figure 4.12. The sham group showed a conversion ratio of 0.123 ± 0.01, which was 
significantly higher than that seen in the MI group (Ang II/Ang I=0.08 ± 0.01; p<0.01 vs. 
sham). As expected, the MI/lisinopril-treated group demonstrated a dramatic 21.6-fold 
reduction relative to MI with Ang II/Ang I=0.003 ± 0.001 (p<0.01 vs. MI). A significant 3.4-fold 
decrease in Ang II/Ang I relative to MI was observed in the MI/lisW-S-treated group, (Ang 
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Figure 4.12 Conversion ratios: Ang II/ Ang I at 7 days (*p<0.01 vs. sham; ∗∗  p<0.01 vs. MI) 
 
One Day 
The conversion ratios of Ang I to Ang II conversion one day post-MI are presented below in 
figure 4.13. The untreated infarcted group displayed a conversion ratio of 0.13 ± 0.01; while 
a highly significant 8-fold decrease was observed in the MI/lisW-S group, with Ang II/ Ang I = 
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Figure 4.13 Conversion ratios: Ang II/ Ang I at 1 day (*p<0.01 vs. MI) 
 
4.5.3.2.4 ANG (2-10) 
Seven Days 
Mean plasma concentrations of Ang (2-10) seven days post-MI are presented in figure 4.14. 
A significant 2.1-fold increase was observed in the MI group relative to the sham (MI = 
319.32 ± 45.2 pg/ml; p<0.05). The MI/lisinopril-treated group showed a 3.5-fold increase 
relative to MI (1114.41 ± 100.8 pg/ml; p<0.01), while the MI/lisW-S-treated group exhibited a 
large 7-fold elevation in plasma Ang (2-10) levels relative to MI (2250.55 ± 385.09 pg/ml; 
p<0.01) and a 2-fold increase over the MI/lisinopril-treated group (p<0.05).  
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Mean plasma concentrations of Ang (2-10) one day post-MI are presented in figure 4.15. A 
highly significant difference was observed between the untreated MI group and the MI/lisW-
S-treated group (MI = 201.61 ± 18.16 pg/ml; MI/lisW-S = 1498.86 ± 391.89; p<0.01), as 
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Figure 4.15 Mean Ang (2-10) plasma concentrations (pg/ml) at 1 day (∗  p<0.01 vs. MI) 
 
4.5.3.2.5 ANG III 
Seven Days 
Ang III plasma concentrations measured at seven days post-MI are presented in figure 4.16. 
A 1.9-fold elevation in mean peptide levels was observed in the MI group relative to the 
sham (MI = 44.87 ± 9.29 pg/ml; Sham = 24.09 ± 4.37 pg/ml; p=NS). A significant 2.8-fold 
increase was further observed in the MI/lisW-S-treated group relative to the sham (MI/lisW-S 
= 65.5 ± 10.9 pg/ml; p<0.01)). In contrast, a highly significant 10.1-fold decrease relative to 
MI and a 14.8-fold decrease relative to MI/lisW-S was observed in peptide levels in the 
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Figure 4.16 Mean Ang III plasma concentrations (pg/ml) at 7 days (* p<0.01 vs. Sham; ∗∗  p<0.01 vs. MI and MI/lisW-S) 
 
One Day 
As shown in figure 4.17, no significant difference in Ang III plasma concentration was 
observed between the untreated MI group and the MI/lisW-S-treated group one day post-MI 
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Figure 4.17 Mean Ang III plasma concentrations (pg/ml) at 1 day (p=NS) 
 
4.5.3.2.6 ANG IV 
Seven Days 
Plasma concentrations for Ang IV measured seven days post-MI are presented in figure 
4.18. The results show a similar trend to that observed following quantification of Ang III 
plasma levels. No significant difference was observed between the sham and MI groups 
(Sham = 6.55 ± 0.94 pg/ml; MI = 11.11 ± 2.13 pg/ml). However, a significant 2.4-fold 
elevation was observed in the MI/lisW-S-treated group relative to sham (MI/lisW-S = 16.83 ± 
3.34; p<0.05), while the 1.5-fold elevation of this group relative to MI was not significant. 
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relative to sham, 12.1-fold relative to MI and 18.3-fold relative to MI/lisW-S (MI/lisinopril = 
0.92 ± 0.18 pg/ml; p<0.01). 
 
Figure 4.18 Mean Ang IV plasma concentrations (pg/ ml) at 7 days (∗∗  p<0.01 vs. all groups; *p<0.05 vs. sham) 
 
One Day 
Ang IV plasma concentrations one day post-MI are presented in figure 4.19, and clearly 
show no significant difference between treated and untreated groups (MI = 8.76 ± 1.19 
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Figure 4.19 Mean Ang IV plasma concentrations (pg/ ml) at 1 day (p=NS) 
 
4.5.3.2.7 ANG (1-7) 
Seven Days 
As seen in figure 4.20, Ang (1-7) in plasma was at non-detectable levels in the sham and MI 
groups at seven days post-MI. In the MI/lisinopril and MI/lisW-S-treated groups there were 
substantial levels of Ang (1-7) and these values were essentially identical (MI/lisinopril = 
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Figure 4.20 Mean Ang (1-7) plasma concentrations (pg/ml) at 7 days; BLQ = Below Limits of Quantification) 
 
One Day 
Mean plasma concentrations of Ang (1-7) one day post-MI are presented in figure 4.21. The 
levels for the two groups assessed in this study are very similar to those seen at seven days. 
The MI/lisW-S-treated group having appreciable levels (MI/lisW-S = 29.17 ± 8.31 pg/ml) and 
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Figure 4.21 Mean Ang (1-7) plasma concentrations (pg/ml) at 1 day  
 
4.5.3.2.8 ANG (1-5) 
Seven Days 
Figure 4.22 shows the relative mean plasma concentrations of Ang (1-5) at seven days post-
MI. No significant difference was observed between the sham, MI and MI/lisinopril-treated 
groups (Sham = 7.62 ± 0.50 pg/ml; MI = 9.28 ± 1.15 pg/ml; MI/lisinopril = 9.78 ± 1.64 pg/ml). 
However, the MI/lisW-S-treated group showed a highly significant (MI/lisW-S = 25.95 ± 3.03 
pg/ml; p<0.05) 2.8-fold elevation in plasma levels of Ang (1-5) relative to the MI group, and a 
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Figure 4.22 Mean Ang (1-5) plasma concentrations (pg/ml) at 7 days (γ  p<0.01 vs. all groups) 
 
One Day 
Ang (1-5) plasma concentrations measured one day post-MI are presented in figure 4.23. A 
2.3-fold elevation was observed in the MI/lisW-S-treated group relative to the untreated MI 
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Figure 4.23 Mean Ang (1-5) plasma concentrations (pg/ ml) at 1 day  
 
4.5.3.2.9 ANG (3-7) 
Seven Days 
Mean plasma concentrations of Ang (3-7) at seven days post-MI are presented in figure 
4.24. This peptide was not quantifiable in both the sham and MI groups. Ang (3-7) levels in 
MI/lisinopril-treated and MI/lisW-S-treated groups were quantifiable (MI/lisinopril = 3.56 ± 
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Figure 4.24 Mean Ang (3-7) plasma concentrations (pg/ml) at 7 days  
 
One Day 
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4.5.3.3 QUANTIFICATION OF BRADYKININ METABOLITES 
The metabolism of the vasodilator bradykinin (1-9) was reviewed in Chapter 1, and detailed 
the hydrolysis of BK (1-9) to the products BK (1-7) and BK (1-5) by ACE. The RAS-
fingerprinting technique was unable to quantify plasma levels of BK (1-9) itself although it 
was possible to measure BK (1-9)’s metabolites concurrently with angiotensin peptide 
analysis for each sample.  
 
4.5.3.3.1 BK (1-7) 
Seven Days 
The results at seven days post-MI are presented below in figure 4.25. Plasma peptide levels 
were raised by 1.1-fold in the MI group relative to the sham group (MI = 4113.58 ± 164.71 
pg/ml; Sham = 3627.71 ± 131.88 pg/ml; p<0.05). BK (1-7) was significantly elevated by 
approximately 2-fold relative to MI in both the MI/lisinopril and MI/lisW-S-treated groups 
(MI/lisinopril = 8462.46 ± 770.64 pg/ml; MI/lisW-S = 8403.54 ± 424.57 pg/ml; p<0.05 vs. MI 
and sham).  
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Figure 4.25 Mean BK (1-7) plasma concentrations (pg/ml) at 7 days (*p<0.01 vs. sham and MI, **p<0.05 vs. sham) 
 
One Day 
As shown in figure 4.26, plasma peptide levels at one day post-MI were significantly 
elevated by 1.6-fold in the MI/lisW-S-treated group relative to the untreated MI group 
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Figure 4.26 Mean BK (1-7) plasma concentrations (pg/ml) at 1 day (*p<0.01) 
 
4.5.3.3.2 BK (1-5) 
Seven Days 
As shown in figure 4.27, when measured at seven days post-MI BK (1-5) displayed an 
upward trend with peptide levels significantly raised by 2.5-fold in the MI group relative to the 
sham group (MI = 1746.36 ± 437.26 pg/ml; Sham = 688.35 ± 62.64 pg/ml; p<0.05). 
Thereafter peptide levels were significantly increased by 2.1-fold in the MI/lisinopril-treated 
group (MI/lisinopril =3691.85 ± 554.69 pg/ml; p<0.01) and 3.4-fold in the MI/lisW-S-treated 
group (5880.87 ± 486.64 pg/ml; p<0.01) relative to MI. A highly significant 1.6-fold increase 
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BK (1-5) levels at one day post-MI are presented below in figure 4.28. A significant 5-fold 
elevation in plasma peptide levels was observed in the MI/lisW-S-treated group relative to 
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Figure 4.28 Mean BK (1-5) plasma concentrations (pg/ml) at 1 day (p<0.01) 
 
4.6 DISCUSSION 
RAS fingerprinting and EIA techniques were successfully utilized in this study to determine 
the effects of domain-selective and non-selective ACE inhibition on plasma peptide levels at 
two different timepoints post-MI in a rat model of infarction.  A discussion of the peptide 
quantification results previously presented in this chapter now follows; both in their 
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RAS cascade. A summary of the results in this chapter is presented below in figure 4.29 for 
reference. 
 
Figure 4.29 Summary of RAS fingerprint results for all treatment groups and timepoints 
Day 1 post MI Day 7 post MI 
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4.6.1 ACSDKP 
AcSDKP is not a product of the RAS system although it is metabolised exclusively by the N-
domain of ACE (Rousseau et al.1995). Previous studies in both humans (Azizi et al. 1996) 
and rats (Cavasin et al. 2004) have demonstrated that administration of a non-selective ACE 
inhibitor blocks hydrolysis of AcSDKP and results in a 4 to 5-fold elevation of plasma peptide 
levels (Azizi et al. 1996). There is also evidence that increased levels of this antifibrotic 
peptide appear to have positive therapeutic effects on the pathophysiology of heart disease 
in some species. Administration of AcSDKP above endogenous levels was shown to reverse 
cardiac fibrosis and inflammation following induction of MI in rats – independent of both ACE 
inhibitor therapy and haemodynamic changes (Yang et al. 2004). Additionally, increased 
plasma levels of this peptide have been shown to reduce cardiac fibrosis in uninfarcted 
hypertensive rats (Peng et al. 2003) while reduced basal levels promote cardiac and renal 
fibrosis in normal rats (Cavasin et al. 2007). The sum of the research thus far points to 
positive antifibrotic effects above endogenous levels and negative profibrotic effects below 
basal levels. 
The interruption of ACE-mediated AcSDKP metabolism in this study was clearly 
demonstrated by the 3-fold elevation of this peptide observed in the MI/lisinopril-treated 
group and measured by EIA. Conversely, no such increase of the non-hydrolysed peptide 
was observed in the sham, MI or MI/lisW-S-treated groups. The C-domain selective ACE 
inhibitor lisW-S was predicted to have no effect on endogenous levels due to a lack of 
interaction with the N-domain (Watermeyer et al. 2010). No change in AcSDKP plasma 
levels in the MI/lisW-S-treated group was observed relative to either the sham or MI and it is 
possible to conclude that while elevation of plasma peptide levels – and the subsequent 
antifibrotic effects – may be inhibited by lisW-S, this treatment should not result in negative 
profibrotic outcomes as endogenous levels of AcSDKP were not significantly altered. 
Conversely, the lack of AcSDKP elevation seen with C-domain selective ACE inhibition 
could also prove to have an adverse effect on the positive remodeling and associated 
antifibrotic outcomes observed with non-selective ACE inhibition. It has been shown that 
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AcSDKP must at least partly mediate the antinflammatory and antifibrotic effects in cardiac 
and renal tissue observed with ACE inhibition. Studies in normotensive rats treated with an 
AcSDKP-specific monoclonal antibody have demonstrated that endogenous levels of 
AcSDKP do not participate in regulating cardiac collagen content, while exogenous 
administration of AcSDKP achieves the same elevated plasma peptide levels as treatment 
with a non-selective ACE inhibitor (Peng et al. 2005). Interestingly, these antifibrotic effects 
have also been observed in rats treated with Ang II to induce hypertension and exogenous 
AcSDKP despite continued systemic hypertension and resultant aortic hypertrophy (Lin et al. 
2008), which further validates a different mechanism of action unrelated to the anti-
hypertensive effects of ACE inhibitor therapy, but rather reliant on elevated plasma levels of 
AcSDKP. The withdrawal of the positive effects of elevated AcSDKP in the presence of non-
domain specific ACE inhibitor therapy is therefore a concern in the context of lisW-S as a 
therapeutic option for MI and warrants further exploration of the implications for post-MI 
remodeling in future studies. It should be noted that in humans AcSDKP is predominantly 
found in the plasma and white blood cells (Pradelles et al. 1990), thus presenting the 
possibility of exogenous administration of AcSDKP as an option in conjunction with lisW-S 
treatment.  
The results of the ACSDKP EIA were thus encouraging as they provided the first in vivo data 
in support of the C-domain specificity of lisW-S, thus reinforcing the findings of the in vitro 
studies in Chapter 2.  
 
4.6.2 ANGIOTENSIN I 
The results by RAS-fingerprinting showed a significant 2-fold elevation in plasma Ang I 
levels in the untreated MI group relative to the sham at seven days post-MI. Similar results 
were observed in a study conducted by the Campbell group in which both plasma renin 
activity and plasma Ang I levels were measured in a rat model at two and three days post-
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infarction (Duncan et al. 1997). The 30 to 40% elevation of plasma Ang I observed in that 
study was shown to correlate with increases in plasma renin concentrations, thus confirming 
that elevated Ang I reflects the compensatory response by the RAS to MI. While plasma 
renin activity was not measured in the present study, based on the literature it is safe to 
assume the increase observed in the present study reflects this compensatory response. 
Interestingly, when the results obtained in pg/ml by RAS-fingerprinting in this study were 
converted to femtamoles/ml for comparative purposes within the literature, the plasma Ang I 
concentrations measured in the untreated sham and MI groups at seven days post-MI were 
approximately 7 to 10-fold higher than those reported by Campbell’s group in various studies 
at the same timepoint (Campbell et al. 1994; Duncan et al. 1996; Duncan et al. 1997). 
Concurrently, this discrepancy may be attributable to the inhibitor cocktail provided by 
Apeiron Biologica (described in section 4.6.3.2), which may allow for greater preservation of 
angiotensin peptides following whole blood collection than the cocktail described by that 
group (A. M. Duncan et al. 1996) (A. M. Duncan et al. 1997). A methodological argument for 
overestimation in the present study could be made in the case of inadequate enzyme 
inhibition following blood collection. As discussed by Campbell et al. (Campbell et al. 2004), 
Ang I generation and consequent Ang II formation by endogenous lysozymes in a tissue 
sample is a possible outcome of poor sample preparation. To our knowledge the collection 
methods and Apeiron Biologica’s inhibitor cocktail used in this study are more than sufficient 
for highly accurate peptide quantification by the RAS fingerprinting technique. As the 
inhibitor cocktail is currently the subject of a pending patent application, data relating to its 
inhibitory potential can not be given at present. However, Apeiron Biologica has 
communicated that the cocktail is an effective inhibitor when tested in plasma spiked with 
reference angiotensin peptides and incubated at 37oC for several hours. In the present study 
blood samples was collected within a 90 second window into a chilled, heparinized tube 
containing the inhibitor cocktail and immediately placed on ice prior to snap-freezing within 
60 minutes from the time of collection. In addition Apeiron has confirmed that in their own 
studies the loss of lysozyme-generated Ang II within a sample to the glass or plastic material 
of the collection tube is minimal. Thus, it appears unlikely that the results presented above 
are an overestimation of in vivo peptide levels at the time of blood collection.   
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Relative to the MI group, Ang I plasma levels were elevated by 2.6-fold in the MI/lisinopril-
treated group. A significant increase in this peptide was anticipated as ACE inhibition 
prevents the hydrolysis of Ang I and the consequent formation of Ang II (Brown et al. 1998), 
thus activating the negative feedback mechanisms within the RAS. As described previously, 
renin secretion is dependent on Ang II plasma levels and stimulation of AT1 receptors 
(DeMello et al. 2009). In the case of ACE inhibition, Ang II plasma levels are decreased and 
receptor stimulation is inhibited (Siragy et al. 2005), leading to upregulation of renin 
secretion and Ang I generation in an effort to restore endogenous levels of Ang II. The 
Campbell group has previously assessed the effects of ACE inhibition on angiotensin and 
bradykinin peptide levels in a rat model of MI. In that study, the ACE inhibitor perindopril was 
administered at a dose of 2mg/kg/day via the animals’ drinking water from 48 hours following 
infarction for a period of twenty-six days, at which point angiotensin peptides were quantified 
by radioimmunoassay (Duncan et al. 1996). Perindopril belongs to the same dicarboxylate-
containing group of ACE inhibitors as enalapril, ramipril, lisinopril and lisW-S (Brown et al. 
1998) and thus those results are comparable to ours (despite differing timepoints). In the 
present study, a dose of 1 mg/kg/day was administered by miniosmotic pump infusion, 
resulting in a 2.6-fold increase in Ang I in the MI/lisinopril-treated group relative to the MI 
group at seven days post-MI. In their study, the Campbell group observed a 6-fold elevation 
in plasma Ang I levels at twenty-eight days post-MI following oral administration of 
perindopril. 
In another study, that group administered both lisinopril and perindopril to non-infarcted rats 
for a period of seven days followed by quantification of angiotensin peptide levels by 
radioimmunoassay (Campbell et al. 1994). That study concluded that perindopril possessed 
approximately 10-fold the potency of lisinopril with regards to its effects on angiotensin 
plasma levels, which could possibly account for the differences seen with regards to 
elevation of Ang I relative to MI between our study and Duncan et al. (1996). However, there 
is no definitive study that has found any one ACE inhibitor to be therapeutically superior over 
another, although perindopril has been shown to have a slightly higher lipophilicity than 
lisinopril (Furberg. 2000). A recent randomized study with human subjects measured the 
effects of the hydrophilic ACE inhibitor lisinopril and the lipophilic ACE inhibitor perindopril on 
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circulatory Ang II levels and found no discernible difference in their efficacy (Ruzicka et al. 
2010). While studies in rats have shown that lipophilic ACE inhibitors prevent adverse 
cardiac remodeling to a greater degree than hypophilic ACE inhibitors (Ruzicka & Leenen 
1995; Ruzicka et al. 1995), this concept has not yet been satisfactorily proven and the 
observations of the Campbell group in this respect must be carefully considered. 
A significant increase in Ang I levels was observed in the MI/lisW-S-treated groups at both 
one and seven days post-MI relative to both the untreated MI and MI/lisinopril-treated 
groups. When peptide levels were quantified by RAS-fingerprinting at seven days post-MI, 
treatment with lisW-S raised Ang I by 5.6-fold relative to MI. At one day post-MI, a 4.3-fold 
increase in Ang I was observed in the MI/lisW-S-treated group relative to MI. The results 
obtained for the seven day timepoint are closely comparable to those of the Campbell 
group’s, which showed an approximate 6-fold increase in Ang I with perindopril treatment 
relative to untreated MI at 28 days (Duncan et al. 1996).  
The 2.6-fold increase in the MI/ lisinopril-treated group in this study amounts to less than half 
the fold increase observed by the Campbell group with perindopril in a similar study. As we 
believe our sample collection and quantification methods are sound, the difference may be 
attributable to the timepoints utilized in each study. The Campbell group conducted a long-
term study in which angiotensin peptides were measured at 28 days post-MI, a timepoint by 
which necrotic myocardium has been completely replaced by collagen in the rat myocardium 
(Cleutjens et al. 1995). Comparatively, at 7 days post-MI, collagen in the myocardium is only 
microscopically detectable and the heart is in a state of inflammatory flux. The development 
of heart failure as a consequence of cardiac remodeling is thoroughly reviewed in Section 
1.2.  
It should be noted however that when the results of the MI/lisW-S-treated group at 7 days 
are taken together with the significant elevation observed after just 24 hours of treatment in 
the present study, the results obtained by RAS-fingerprinting strongly suggest that the RAS 
compensatory mechanism initiated by ACE inhibition is significantly more pronounced 
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following treatment with lisW-S than lisinopril. There is a possibility that this could be related 
to the potency of the domain-selective ACE inhibitor as was suggested to be the case with 
administration of perindopril in the aforementioned Campbell study. Further reasons for this 
and possible implications will be discussed in the context of the Ang II measurements 
presented in the next section.  
4.6.3 ANGIOTENSIN II 
Ang I is hydrolysed by the C-domain of ACE to form the vasoconstrictor Ang II (Erdos et al. 
1967). Both non-selective and C-domain selective ACE inhibition may reduce Ang II levels 
below those of an untreated MI control group. However, it has been reported in the literature 
that plasma ang II plasma levels may not be reduced due to upregulation of ANG-I levels via 
the upregulation of renin activity (Yamagishi et al. 1993; Duncan et al. 1996).  
In the first instance, the relatively inexpensive and rapid method of EIA was utilized to 
provide preliminary results with regards to the effects of ACE inhibition on plasma Ang II 
levels at seven days post-MI. The untreated MI group showed a trend towards an increase 
relative to the sham group, presumably as a result of RAS activation. The MI/lisinopril-
treated group exhibited a significant reduction in plasma Ang II levels, which was as 
expected based on previous studies in both humans (Dickstein 1987; Gomez et al. 1987) 
and rats (Forest et al. 2005; Wollert et al. 2010). However, an increase in plasma Ang II 
levels was measured in the MI/lisW-S-treated group that significantly exceeded the levels 
measured in the sham, MI and MI/lisinopril-treated groups. The results of this assay 
compelled us to further explore the effects of lisW-S on the key components of the RAS by 
utilizing the highly sensitive method of RAS-fingerprinting. 
At seven days post-MI, a non-significant increase of approximately 40% was observed in 
plasma Ang II levels in the MI group relative to the sham. As previously stated, in the sham 
and MI groups a 7 to 10-fold difference in plasma Ang I levels was observed between the 
present study and those reported by the Campbell group. Interestingly, the Ang II plasma 
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levels observed for those treatment groups in the present study differ by only 1.5 to 2-fold 
from those previously reported by the Campbell group (Campbell et al. 1994; Duncan et al. 
1996; Duncan et al. 1997).  
In the MI/lisinopril-treated group, Ang II generation was successfully inhibited and Ang II 
plasma levels significantly reduced by 8.8-fold relative to MI. This clearly demonstrates the 
high efficacy of lisinopril as an ACE inhibitor under pathophysiological conditions in a rat 
model. Furthermore, in a study conducted by the Campbell group (Campbell et al. 1994) in 
which uninfarcted rats were orally administered (via drinking water) a wide range of doses of 
the ACE inhibitors lisinopril and perindopril, the highest lisinopril dose investigated (0.156 
mg/kg/day) did not elicit a decrease in plasma Ang II, while perindopril doses above 1.4 
mg/kg/day resulted in a 2.2-fold reduction in plasma Ang II levels relative to untreated control 
animals. In that study the Campbell group also concluded that lisinopril had approximately 
one tenth the potency of perindopril. As the present study delivered a lisinopril dose equal to 
1 mg/kg/day, it appears that administration by miniosmotic pump infusion is an extremely 
effective method of drug delivery.  
In the MI/lisW-S-treated group, a non-significant trend was observed towards an estimated 
50% increase in Ang II levels relative to the untreated MI group seven days post-MI. This 
was in accordance with the results obtained by EIA quantification. Intriguingly, RAS 
fingerprinting at one day post-MI showed a contrasting and significant 2.1-fold decrease in 
plasma Ang II relative to the MI group and in response to treatment with lisW-S. This was 
despite significantly elevated levels of plasma Ang I at the same time point. In order to 
explain these results, the efficacy of lisW-S at inhibiting ACE was explored by analysing the 
ratio of Ang II produced relative to the Ang I substrate. This ratio reflects ACE activity in the 
plasma and is discussed in the following section. 
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4.6.4 ANG II/ ANG I 
The inhibition of conversion of Ang I substrate to Ang II product is the primary goal of ACE 
inhibition and thus analysis of the Ang II/ Ang I ratio is useful for gaining a true reflection of 
the inhibitory activity of both lisinopril and lisW-S in vivo. This method of ACE activity 
quantification was successfully demonstrated by the Campbell group ( Campbell et al. 1991) 
and more recently validated by Claasen at al. (Claassen et al. 2013). One week after 
infarction, the efficacy of lisinopril in a rat model was clearly demonstrated by a substantial 
decrease in Ang II/Ang I values relative to the untreated MI group. This result was not 
unexpected, as lisinopril was administered at a dosage achieving close to 100% ACE 
inhibition (as described in Chapter 2).  
In addition, ACE inhibition by lisW-S was clearly demonstrated at both one and seven days 
post-infarction, where Ang II production from Ang I was decreased by 8-fold and 3.4-fold 
respectively relative to MI. These results confirm that significant inhibition was achieved 
despite the low bioavailability of lisW-S as well as delivery of this compound at a dosage that 
achieved a maximum of 60% ACE inhibition. 
A similar study by the Campbell group was previously described in which both lisinopril and 
the highly potent ACE inhibitor perindopril were administered to uninfarcted rats for seven 
days and angiotensin peptide levels quantified by radioimmunoassay (D J Campbell et al. 
1994). Interestingly, perindopril administered by drinking water at a dosage of 0.156 
mg/kg/day achieved a 10-fold reduction in Ang II/Ang I, close to the inhibition observed at 
one day post-MI with lisW-S (which was administered at a dosage of 1 mg/kg/day). 
However, at the seven day timepoint the inhibitory effect of lisW-S on the Ang II/ Ang I ratio 
was reduced by approximately 1.5-fold relative to that seen at one day, despite the superior 
route of administration by miniosmotic pump infusion. This loss of inhibitory efficacy in vivo 
could be attributed to the decrease in lisW-S plasma levels observed one week after 
subcutaneous miniosmotic pump implant (as described in section 3.4.5). In that instance, 
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lisW-S plasma concentrations fell by almost 40% relative to peptide plasma levels one day 
after implant. In addition, reduced efficacy in the MI/lisW-S-treated group seven days post-MI 
might also be a consequence of the elevated Ang II plasma levels measured at this time 
point.  
A second study by the Campbell group (Duncan et al. 1996) performed peptide 
quantification twenty-eight days post-MI, and found that orally administered dosages of 0.2 
and 2 mg/kg/day perindopril resulted in reduction of the Ang II/Ang I ratio by 7- and 14-fold 
respectively. It appears that the results obtained in that study one month post-MI with the 
lowest perindopril dose are most similar to the results found in the present study, one day 
post-MI and at a lisW-S dose five times that of perindopril. 
 
4.6.5 ANG (1-7) AND THE CARDIOPROTECTIVE AXIS 
The cardioprotective peptide Ang (1-7) is formed primarily by the ACE2-mediated hydrolysis 
of Ang II (Donoghue et al. 2000) although it is also generated directly from Ang I by the 
hydrolytic action of prolylendopeptidase (PEP), prolylcarboxypeptidase (PCP) (Welches et 
al. 1991) and the previously described neutralendopeptidase (NEP) (Yamamoto et al. 1992). 
Both ACE2 and NEP concurrently hydrolyse Ang II, thus fulfilling a counter-regulatory 
antihypertensive function within the RAS.  
Endogenous Ang (1-7) levels are extremely low under pathophysiological conditions in the 
absence of ACE inhibition (Iyer et al. 1998; Ferrario et al. 2005)  and this was clearly 
demonstrated in the present study whereby the highly sensitive RAS fingerprinting 
methodology was unable to quantify plasma peptide levels in the untreated MI group at 
either one or seven days post-MI.  
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Ang (1-7) is associated with a number of cardioprotective effects as previously described 
(section 1.5.1.1) and upregulation of this peptide is desirable following an MI event. The 
upregulatory effect of ACE inhibition on Ang (1-7) levels is well-documented, and this was 
observed in both the MI/lisinopril and MI/lisW-S-treated groups. It has been shown that the 
augmentation of circulatory levels of Ang (1-7) that occurs in conjunction with ACE inhibition 
is most likely a consequence of decreased ACE-mediated peptide metabolism both in vitro 
(Chappell et al. 1998) and in vivo, where ACE inhibitor administration was found to 
significantly extend the half-life of Ang (1-7) and thus endogenous levels in both 
normotensive and hypertensive rats (Kazuo et al. 1998). In addition, Allred et al. showed that 
ACE was primarily responsible for Ang (1-7) metabolism in the pulmonary tissues in 
normotensive rats (Allred et al. 2000) 
Studies have shown that NEP appears to be largely responsible for the presence of 
circulatory Ang (1-7) in vivo. In a study by Yamamomoto et al (1992), both spontaneously 
hypertensive and control rats were administered the ACE inhibitor enalapril, resulting in 
elevated levels of Ang I and Ang (1-7) (Yamamoto et al. 1992). However, when enalapril was 
administered in conjunction with an NEP inhibitor, upregulation of circulatory Ang (1-7) levels 
was blocked.  
It has been previously stated that Ang (1-7) was found to be primarily hydrolysed by the N-
domain of human ACE (P. Deddish et al. 1998) and there is evidence to suggest that the 
opposite may be true for rat ACE. Allred et al. (2000) studied the kinetic efficiency of both rat 
somatic ACE (equipped with both the C- and N-domain active sites) and rat testis ACE 
(equipped with only one active site equivalent to the C-domain) at metabolizing Ang (1-7) in 
vitro and found them to be identical, suggesting that the C-domain could be primarily 
responsible for the hydrolytic breakdown of this peptide. In vitro studies in the canine model 
by Chappell et al. further suggested that the C-domain of ACE might be predominantly 
responsible for the metabolism of Ang (1-7) (Chappell et al. 1998). However, a study by 
Andrade et al. delivered conflicting results suggesting that an N-domain fragment of rat ACE 
was hydrolytically more efficient at metabolizing Ang (1-7) than the full ACE peptide 
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(Andrade et al. 1998). The concept of species-specific domain-selectivity in both inhibitors 
and substrates was first introduced in Chapter 2 (Sections 2.1 and 2.2.1) and the domain-
specificity of rat ACE remains undetermined. 
In the present study, Ang (1-7) levels were clearly upregulated by ACE inhibition and the 
values obtained by RAS-fingerprinting were identical for both the MI/lisinopril and the 
Mi/LisW-S-treated groups. However, at both one and seven days post-MI, a significant 
elevation of Ang (1-5) levels was observed in the MI/lisW-S-treated group relative to the 
sham, MI and MI/lisinopril-treated groups. As previously described, Ang (1-5) is an ACE-
dependent metabolic breakdown product of Ang (1-7) (Yamada et al. 1998). A case could 
therefore be made for predominantly N-domain ACE-mediated metabolism of Ang (1-7) in 
the rat, as the C-domain specificity of lisW-S should accede efficient N-domain-mediated 
hydrolysis of this peptide under ACE inhibitory conditions.  
Simultaneously, a lack of conclusive evidence with regards to domain-specificity of the Ang 
(1-7) substrate in the rat model calls for the exploration of alternative explanations. Elevated 
levels of Ang II, Ang (2-10), Ang III (2-8), Ang IV (3-8) and Ang (1-5) could be a 
consequence of peptide ‘flow through’ in the RAS cascade as a result of the large increase 
in Ang I substrate in the MI/lisW-S-treated group. The results obtained by RAS-fingerprinting 
clearly showed significant increases in all of these peptide levels at both one and seven days 
post-MI following administration of lisW-S. Elevated levels of Ang (2-10) and Ang IV (3-8) 
could potentially have positive vasodilatory (Swanson et al. 1992; Yoshida et al. 1996), anti-
hypertrophic (Sim et al. 1998) and anti-inflammatory (Rufaihah et al. 2006) effects on the 
cardiovascular system following MI. Ang III (2-8) and Ang II, however, are associated with 
vasoconstrictive (Hall et al. 1981), profibrotic (Lijnen et al. 2001; Wang et al. 2010) and 
proinflammatory (Ruiz-Ortega et al. 2000) effects, which are likely to contribute towards the 
pathology of heart failure following MI. 
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4.6.6 BRADYKININ 
The non-selective ACE inhibitor lisinopril is a known and potent inhibitor of BK (1-9) 
metabolism and results in an elevation of this kinin in the plasma (Tom et al, 2003). As 
reviewed in section 1.6.2, the negative side-effects of non-selective ACE inhibitors are 
attributed to this accumulation of BK (1-9). Thus, it was hypothesized that BK (1-9) plasma 
levels in the MI/lisW-S-treated group would be approximately 50% lower than those of the 
MI/lisinopril-treated group due to inhibition of only one ACE domain. Despite the high 
sensitivity of the RAS fingerprinting technique, BK (1-9) levels could not be quantified in the 
samples provided by this study. However, it was possible to quantify BK (1-7) and BK (1-5), 
two principal breakdown products of ACE-mediated BK (1-9) metabolism.  
A significant and closely comparable increase in BK (1-7) levels was observed in both ACE 
inhibitor-treated groups at seven days post-MI, possibly suggesting a similar degree of ACE 
inhibition. However, analysis of angiotensin peptide quantification by RAS fingerprinting 
clearly shows that lisW-S is a less effective inhibitor of ACE than lisinopril, and so inhibition 
of ACE-mediated BK (1-9) metabolism would not be expected to be so closely related 
between these two treatment groups. However, in previous studies the Campbell group has 
demonstrated a ‘plateau effect’ of the ACE inhibitor perindopril on BK (1-9) degradation (D J 
Campbell et al. 1994) at much lower concentrations of perindopril than those needed to 
reach a plateau in ACE degradation of Ang I.  Thus both inhibitors used in this study may be 
working at maximal levels for inhibition of BK (1-9) hydrolysis. 
However, plasma levels of the terminal degradation product BK (1-5) presented a different 
picture of BK (1-9) metabolism in all groups in this study. These levels were significantly 
elevated by almost 2-fold in the MI/LisW-S-treated group relative to that in the MI/lisinopril-
treated group. This suggests that despite inhibition of the C-domain, BK (1-9) degradation 
may still be occurring via the N-domain in the lisW-S treated animals. Clearly data needs to 
be obtained on the actual levels of BK (1-9) to gain true clarity on this issue. 
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4.6.7 DOES LISW-S INHIBIT ACE? 
The work presented in this chapter offers a large amount of data and permits a thorough 
investigation of the interplay between the RAS system, myocardial infarction and the ACE 
inhibitory agents lisinopril and lisW-S. In particular, the results provided by the RAS-
fingerprinting technique provide unique insight into the complex mechanisms and reactions 
of the many counter-regulatory components of the RAS in response to both non-selective 
and C-domain-selective ACE inhibition under pathophysiological conditions in the rat model.  
Activation of the RAS system after an MI event leads to upregulation of renin synthesis and 
release (Duncan et al. 1997; Ocaranza et al. 2006) – the effects of which are seen 
throughout the RAS cascade in this group. Although renin plasma levels were not measured 
in this study, the relationship between the activated RAS and upregulation of renin activity is 
sound. Upregulation of Ang I is reflected in the elevated levels of peptides further down the 
cascade – in particular Ang II, Ang (2-10) and Ang III (2-8). RAS activation following MI had 
no effect on the ‘alternative’ Ang (1-9)/ Ang (1-7)/ Ang (1-5) axis and did not upregulate the 
cardioprotective peptide Ang (1-7). 
The RAS fingerprint of the clinical ACE inhibitor lisinopril provides entirely novel data on the 
effects of ACE inhibition on the full RAS cascade in a rat model of myocardial infarction. As 
expected, a dramatic reduction in Ang II plasma concentrations was observed with ACE 
inhibition. Due to inhibition of ACE-mediated pathways, the elevation of Ang I is reflected by 
the NEP-mediated generation of Ang (1-7) and the AP-mediated formation of Ang (2-10). 
The significant upregulation of Ang (1-7) and Ang (2-10) observed in this group enhances 
the effects of Ang II inhibition, as both of these peptides display cardioprotective properties 
that are antagonistic towards those of Ang II. 
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The main objective of this work was to assess both the C-domain-selectivity and the 
inhibitory efficacy of the ACE inhibitor lisW-S. To that end, the AcSDKP assay provided 
confirmation of the C-domain specificity of lisW-S in vivo. Furthermore, the 2-fold elevation of 
bradykinin metabolite (BK (1-5)) measured in this group relative to the MI/lisinopril-treated 
group suggests that the C-domain of ACE is being effectively inhibited whilst the N-domain is 
not. In the RAS fingerprint of the MI/lisW-S-treated group at the seven day timepoint, the 
most striking observation is the extraordinary 5- to 6-fold elevation of Ang I relative to the MI 
group. Ang II levels in this group are also significantly increased by almost 50% relative to 
the MI control. However, analysis of the conversion ratios of Ang I to Ang II generation 
presents strong evidence for a degree of inhibition by this ACE inhibitor.  
There is also a possibility that the organ-specific effects of ACE inhibition are far more 
relevant than those on the circulatory system. The tissue RAS is not dependent on the 
systemic system and peptide quantification of heart and kidney homogenates in addition to 
plasma should contribute to our understanding. In support of this, the Campbell group has 
shown that low doses of the ACE inhibitor perindopril have a much more profound effect on 
Ang II levels in the renal system than that observed in plasma (Campbell et al. 1994). 
Interestingly, in their study, the lowest dose of perindopril to elicit an effect on Ang II levels in 
the kidney also resulted in an increase in plasma Ang I levels. This implies that renal levels 
of Ang II may be responsible for stimulating systemic renin activity and thus driving 
circulatory Ang I production. Other studies have indicated that the plasma levels of Ang II 
may remain unchanged following ACE inhibition despite functional and structural cardiac 
improvement. The Campbell group showed that while plasma Ang II levels remained 
unchanged following administration of perindopril in rats, both cardiac Ang II and blood 
pressure was significantly decreased (Duncan et al. 1996). Yamagishi et al. demonstrated 
similar results in rats with administration of the ACE inhibitor delapril (Yamagishi et al. 1993). 
Based on the entirety of the results in the present study, it is tempting to speculate that the 
C-domain-selective ACE inhibitor lisW-S may have a far more profound effect on renal Ang II 
levels than that of the non-selective ACE inhibitor lisinopril. However, future studies on the 
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organ-specific effects of this ACE inhibitor are required before any such conclusions can be 
drawn.
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Chapter 5 CONCLUSIONS 
This study described the characterization of a novel C domain-selective ACE inhibitor 
by means of in vitro enzyme kinetics assays, in vivo pharmacokinetic studies and in 
vivo peptide quantification. This approach allowed us to examine the effects of C-
domain-specific ACE inhibition in a controlled in vitro environment as well as in a 
physiological animal model. In addition, the pharmacokinetics of the novel ACE 
inhibitor lisW-S was modeled as an initial step towards rational drug design.  
The novel ACE inhibitor was previously shown to be highly C domain-selective in 
both inhibition assays (Nchinda et al. 2006) and analysis of co-crystalization 
structures with tACE (a germinal form of ACE equivalent to the C-domain of somatic 
ACE) (Watermeyer et al. 2008). In the present study, the domain-selectivity of lisW-S 
in both rat plasma and human serum was confirmed using the C-domain selective 
FRET substrate Abz-LFK(Dnp)-OH and the non-selective FRET substrate Abz-
FRK(Dnp)P-OH. The inhibition profiles obtained confirmed domain selectivity, and 
though C-domain selectivity was not absolutely confirmed, the findings were highly 
suggestive that C-domain specificity was preserved in rat plasma.  
The in vitro studies also found that a lisW-S plasma concentration of 50 ng/ml was 
required to achieve 70% ACE inhibition in the rat. In order to achieve a higher 
percentage inhibition, the plasma concentration of the novel ACE inhibitor would 
need to be increased substantially. This would have been logistically difficult to do, 
owing to the method of lisW-S synthesis which produces a diastereomeric mixture 
requiring HPLC purification with resultant poor yields. Thus, it was decided that a 
plasma concentration of 50 ng/ml would produce an acceptable level of inhibition 
warranting further exploration in vivo. 
The chief aim of the pharmacokinetic studies was to assess the bioavailability of 
lisW-S, as well as establishing the administered dosage required to achieve 50 ng/ml 
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in plasma in vivo. The bioavailability of lisW-S was found to be 3.1%, significantly 
lower than that of the clinical ACE inhibitor lisinopril. Efforts to increase bioavailability 
by utilizing a maleate salt preparation of lisW-S did not yield any significant 
improvement despite the general high efficacy of pharmaceutical salts at improving 
pharmacokinetic profile of pharmaceutical compounds. However, as discussed in 
section 3.5, there is a possibility that the bioavailability estimate presented in this 
study has been underestimated and future studies should include a second 
bioavailability assessment including earlier timpoints following IV administration. 
Furthermore, lisW-S plasma concentrations in the desired therapeutic range of 50 
ng/ml could not be maintained for longer than 1 hour following oral administration. 
Thus, an alternative route of infusion by miniosmotic pump was chosen to effectively 
and continuously deliver the required dosage of the novel ACE inhibitor. 
Pharmacokinetic studies over a period of four weeks successfully demonstrated the 
stability of the lisW-S compound in vivo, as well as determining that a 30 mg/ml 
solution delivered by infusion was the most effective dose for ACE inhibition in vivo. 
Once the inhibitory potential, domain-selectivity and bioavailability of lisW-S had 
been successfully established, the effect of the novel ACE inhibitor on the RAS 
cascade was evaluated by enzyme-linked immunosorbent assay (EIA) and the 
recently developed LC-MS/MS-based RAS-fingerprinting technology. These studies 
were conducted in a rat model of MI, as MI-induced heart failure is a major 
therapeutic target for a C-domain selective ACE inhibitor. 
Peptide quantification by EIA confirmed the C-domain-specificity of the novel ACE 
inhibitor in vivo by assessing the plasma concentrations of the haemetopoietic factor 
AcSDKP, which is metabolised exclusively by the N-domain of ACE. In the case of 
non-selective ACE inhibition with lisinopril, AcSDKP levels were significantly raised 
due to suppression of N-domain-mediated hydrolysis. The results of this study 
showed that AcSDKP levels are unaffected by ACE inhibition with lisW-S, thus 
indicating the C-domain-specificity of this compound in vivo in a rat model. 
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Unfortunately the implications of withdrawing the positive anti-inflammatory and 
antifibrotic effects associated with elevated AcSDKP must be considered in future 
studies. 
The RAS-fingerprinting technique successfully quantified ten Ang peptides in the 
RAS cascade and two bradykinin breakdown products at one and seven days 
following acute MI in a rat model. Analysis of plasma peptide levels provided a 
detailed view of the RAS cascade under conditions of both C-domain-selective and 
non-selective ACE inhibition. Lisinopril was confirmed to be a highly effective inhibitor 
of ACE, eliciting an 8.8-fold reduction in Ang II levels and a 21.6-fold reduction in the 
Ang II/Ang I ratio relative to the untreated MI group at seven days post-infarction.  
Peptide quantification following administration of lisW-S was conducted at both one 
and seven days post-MI. A significant 2.1-fold decrease in Ang II levels and an 8-fold 
decrease in Ang II/Ang I relative to MI was observed twenty-four hours following 
acute MI. However, at the seven day timepoint, this inhibitory efficacy appeared to be 
lost as Ang II levels were increased by 1.6-fold relative to MI. The Ang II/Ang I ratio 
was reduced to 3.4-fold that of MI. These results certainly indicate a degree of ACE 
inhibition by the C-domain-selective inhibitor, although the efficacy of lisW-S does not 
appear to be comparable to that of lisinopril. It is surmised that these observations 
are a result of both significantly elevated Ang I substrate levels by seven days post-
MI, as well as a possible decrease in lisW-S plasma levels which was observed one 
week after miniosmotic pump implant in the pharmacokinetic studies.  
Physical limitations in this study included the low product yield of the lisW-S 
synthesising and purification process as well as the low bioavailability of lisW-S in 
vivo. A principal component of future work therefore needs to address these issues, 
as such limited bioavailability does not put lisW-S in a therapeutically superior 
position over any clinically available ACE inhibitors currently in use. The preliminary 
pharmacokinetic studies presented in this work provide an excellent basis for 
 Chapter 5  
  156 
 
additional studies to assess the bioavailability of further lisW-S analogues as the 
synthesis process is improved. The route of administration chosen in this work has 
been shown to be superior in the context of animal studies to either oral or 
intravenous routes and should therefore be maintained. However, in a clinical setting 
an oral agent would be optimal, thus further emphasising the need to enhance the 
current bioavailability profile of the C-domain selective ACE inhibitor.  
While it has been shown that lisW-S behaves as a C-domain selective ACE inhibitor 
both in vitro and in vivo, the significance of this to the RAS response has not been 
fully explored and requires further investigation. Based on the results obtained in this 
study, a number of suggestions can be made with regards to recommended aims for 
future studies.  
A dramatic upregulation of the Ang I substrate was observed after treatment with 
lisW-S, and a thorough review of the literature has not provided a clear reason for 
this extreme response to domain-selective ACE inhibition. Concurrently, several ACE 
inhibitor studies have reported a positive therapeutic effect on cardiac function and 
blood pressure in the absence of quantifiable changes in plasma angiotensin peptide 
concentrations. Assessment of the therapeutic benefits of lisW-S independent of 
peptide quantification is thus highly recommended. As the animal model for in vivo 
work has now been established, future studies should aim to evaluate the effects of 
domain-specific ACE inhibition on systolic blood pressure, cardiac function and 
myocardial remodeling. Dose response studies and a critical evaluation of peptide 
levels at further time points throughout the development of heart failure would 
provide critical insight into the effects of lisW-S on the RAS.  
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Additionally, the elevation of Ang (1-5) observed following administration of lisW-S is 
suggestive of N-domain ACE-mediated metabolism of its precursor Ang (1-7). While 
not conclusive, this provides further evidence of the C-domain specificity of this ACE 
inhibitor in vivo, and warrants further exploration. 
The theoretical basis for the rational drug design of the C-domain selective ACE 
inhibitor does appear to be sound, and prior to disregarding this compound and its 
potential efficacy as a therapeutic option in the context of MI, the physiological 
effects of the in vivo peptide results presented in this work must be thoroughly 
investigated. Of particular interest is the influence of endogenous AcSDKP levels in 
the presence of ACE inhibition on cardiac remodeling and the inflammatory process 
post-MI. Also of interest is the upregulation of the cardioprotective petide Ang (1-7) in 
conjunction with the vasodilatory, anti-inflammatory and anti-hypertrophic peptides 
Ang (2-10) and Ang (3-8). Conversely, the elevation of these peptides was observed 
to occur in conjunction with an unexpected increase in both Ang I and Ang II, and a 
physiological profile of this rare imbalance in the RAS will provide greater insight into 
the counter-regulatory mechanisms involved in the cascade. Peptide levels in renal 
and cardiac tissues must also be explored and their impact on the systemic RAS 
independently evaluated. 
Importantly, the results of BK (1-5) quantification demonstrated a significant increase 
in the presence of lisW-S relative to lisinopril, a novel result that suggests BK (1-9) 
degradation may be mediated by the N-domain of ACE. Future studies should 
prioritize the effective quantification of BK (1-9) under conditions of C-domain specific 
ACE inhibition in order to validate these findings.  
In conclusion, the thorough in vitro and in vivo characterisation of the C-domain 
selective ACE inhibitor reported in this study provides an excellent basis for future 
studies and establishes lisW-S as a promising alternative to current ACE inhibitor 
therapy.  
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